TWIST1 SUPPRESSES APOPTOSIS AND MEDIATES THERAPEUTIC RESISTANCE IN NON-SMALL CELL LUNG CANCER

by

ZACHARY ALAN YOCHUM

B.S., UNIVERSITY OF NOTRE DAME, 2012

Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of PhD in Molecular Pharmacology

University of Pittsburgh

2018
This dissertation was presented

by

Zachary Alan Yochum

It was defended on

May 25, 2018

and approved by

Donald DeFranco, Ph.D., Professor, Pharmacology and Chemical Biology

Steffi Oesterreich, Ph.D., Professor, Pharmacology and Chemical Biology

Lin Zhang, Ph.D., Professor, Pharmacology and Chemical Biology

James Herman, MD., Professor, Department of Medicine

Dissertation Advisor: Timothy Burns, MD., Ph.D., Assistant Professor, Pharmacology and Chemical Biology
Patients with non-small cell lung cancer (NSCLC) are classified into molecular subgroups based on the presence of oncogenic drivers. Patients with targetable oncogenic drivers, such as mutant EGFR, have benefited from tyrosine kinase inhibitors (TKIs) targeting these oncogenes. However, de-novo and acquired resistance to TKIs limits their efficacy. Studies investigating mechanisms of resistance to TKIs in NSCLC have demonstrated that epithelial-mesenchymal transition (EMT) is associated with resistance. TWIST1 is an EMT-transcription factor that is required for oncogene-driven NSCLC. Utilizing a chemical-bioinformatic screen, we identified the harmala alkaloid, harmine, as a first-in-class TWIST1 inhibitor. Harmine inhibited multiple TWIST1 functions, promoted TWIST1 degradation, and had activity in oncogene driver-defined NSCLC cell lines. Additionally, harmine cytotoxicity required degradation of the TWIST1-E2A heterodimer. Harmine also had activity in murine models of KRAS mutant NSCLC. Following identification of this novel TWIST1 inhibitor, we explored TWIST1 as potential target to overcome EGFR TKI resistance in EGFR mutant NSCLC. We demonstrated that TWIST1 expression is sufficient to mediate resistance to EGFR TKIs in vitro and in vivo. Genetic and pharmacological inhibition of TWIST1 in EGFR TKI resistant EGFR mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic gene, BCL2L11 (BIM), by directly binding to
**BCL2L11** intronic regions and promoter. In MET-driven NSCLC, TWIST1 overexpression mediated resistance to MET TKIs. Targeting TWIST1 with harmine increased crizotinib sensitivity in *MET* altered NSCLC cells. We also demonstrated that hepatocyte growth factor (HGF), a known mediator of EGFR and MET TKI resistance, induced TWIST1 expression. Harmine treatment overcame HGF-mediated resistance to MET and EGFR TKIs in MET- and EGFR-driven NSCLC. We also explored the role of TWIST1 in mediating resistance to other targeted agents in NSCLC. We demonstrated that TWIST1 negatively regulates death receptor signaling by directly upregulating transcription of *CFLAR* (CFLIP), an inhibitor of death receptor 4 and 5. TWIST1 upregulation of cFLIP was associated with resistance to TRAIL-based agents in NSCLC. Overall, these studies demonstrate that targeting TWIST1 is viable therapeutic strategy to overcome resistance to TKIs and TRAIL-based therapies in NSCLC.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PREFACE</strong></td>
<td>XVII</td>
</tr>
<tr>
<td><strong>1.0 INTRODUCTION</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>1.1 LUNG CANCER</strong></td>
<td>1</td>
</tr>
<tr>
<td>1.1.1 Lung cancer histological and genetic subtypes</td>
<td>2</td>
</tr>
<tr>
<td>1.1.2 Lung cancer treatment modalities</td>
<td>5</td>
</tr>
<tr>
<td>1.1.2.1 Definitive local treatment: Surgery and Radiation</td>
<td>7</td>
</tr>
<tr>
<td>1.1.2.2 Chemotherapy</td>
<td>8</td>
</tr>
<tr>
<td>1.1.2.3 Immunotherapy</td>
<td>9</td>
</tr>
<tr>
<td>1.1.2.4 EGFR targeted therapy</td>
<td>11</td>
</tr>
<tr>
<td>1.1.2.5 ALK targeted therapy</td>
<td>14</td>
</tr>
<tr>
<td>1.1.2.6 MET targeted therapy</td>
<td>17</td>
</tr>
<tr>
<td>1.1.3 Driver independent resistance mechanisms to targeted therapies in lung cancer</td>
<td>21</td>
</tr>
<tr>
<td>1.1.3.1 Bypass signaling pathway activation</td>
<td>21</td>
</tr>
<tr>
<td>1.1.3.2 HGF-MET Pathway Alterations</td>
<td>23</td>
</tr>
<tr>
<td>1.1.3.3 Histological Transformation</td>
<td>24</td>
</tr>
<tr>
<td>1.1.3.4 Epithelial-Mesenchymal Transition</td>
<td>25</td>
</tr>
<tr>
<td><strong>1.2 APOPTOSIS AND CANCER</strong></td>
<td>26</td>
</tr>
</tbody>
</table>
1.2.1 Apoptotic pathways ........................................................................................................... 27
1.2.2 Aberrations in apoptotic pathways and proteins in cancer .................................. 30
1.2.3 Apoptosis and response to targeted therapy in lung cancer .............................. 32

1.3 TWIST1 .............................................................................................................................. 33
1.3.1 TWIST1 and development ......................................................................................... 33
1.3.2 Regulation of TWIST1 expression ............................................................................... 35
  1.3.2.1 Transcriptional control of TWIST1 ....................................................................... 36
  1.3.2.2 Post-transcriptional control of TWIST1 ................................................................. 37
1.3.3 TWIST1 and cancer ...................................................................................................... 39
  1.3.3.1 EMT ....................................................................................................................... 40
  1.3.3.2 Apoptosis ................................................................................................................ 41
  1.3.3.3 Senescence .............................................................................................................. 42
  1.3.3.4 Therapeutic resistance ............................................................................................ 43

2.0 IDENTIFICATION OF A FIRST-IN-CLASS TWIST1 INHIBITOR WITH
ACTIVITY IN ONCOGENE-DRIVEN LUNG CANCER .................................................. 45

2.1 ABSTRACT ......................................................................................................................... 45
2.2 INTRODUCTION ............................................................................................................... 47
2.3 MATERIAL AND METHODS .......................................................................................... 49
  2.3.1 Cell lines and reagents ............................................................................................... 49
  2.3.2 Cell viability assays ..................................................................................................... 49
  2.3.3 SA-β-galactosidase staining ........................................................................................ 50
  2.3.4 Colony formation assay ............................................................................................. 50
  2.3.5 Quantitative RT-PCR .................................................................................................. 51
2.3.6 Immunoblot analysis ........................................................................................................ 51
2.3.7 Connectivity MAP analysis.......................................................................................... 52
2.3.8 3D organoid assay ...................................................................................................... 52
2.3.9 FGF2-branching experiments .................................................................................... 52
2.3.10 Lentiviral shRNA and cDNA overexpression experiments ........................................... 52
2.3.11 Pulse-Chase experiments .......................................................................................... 53
2.3.12 Quantification of caspase-3/7 activity ....................................................................... 53
2.3.13 Luciferase promoter reporter assay ............................................................................ 54
2.3.14 Transgenic Mice ....................................................................................................... 54
2.3.15 Patient-derived xenograft experiments .................................................................... 54
2.3.16 Histology and immunohistochemistry ...................................................................... 55
2.3.17 Statistics .................................................................................................................. 55
2.4 RESULTS ....................................................................................................................... 56
2.4.1 Identification of novel TWIST1 inhibitors with a Connectivity MAP analysis ........................................................................................................ 56
2.4.2 Harmine inhibits growth in oncogene driver-defined NSCLC cell lines and phenocopies loss of TWIST1 .............................................................................. 60
2.4.3 Harmine treatment results in TWIST1 protein degradation ........................................ 68
2.4.4 TWIST1 and the E2A proteins reciprocally stabilize each other and harmine leads to degradation of both components of this dimer ........................................... 73
2.4.5 The TWIST1/E2A heterodimer is critical for TWIST1 function and therapeutic response to harmine .............................................................................................. 79
2.4.6 Harmine has *in vivo* activity in both transgenic and patient-derived xenograft mouse models of *KRAS* mutant lung cancer.......................... 83

2.5 DISCUSSION.......................................................................................................................... 87

3.0 TARGETING THE EMT-TRANSCRIPTION FACTOR TWIST1 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN *EGFR* MUTANT NON-SMALL CELL LUNG CANCER........................................................................................................ 90

3.1 ABSTRACT.............................................................................................................................. 90

3.2 INTRODUCTION ...................................................................................................................... 92

3.3 MATERIAL AND METHODS .................................................................................................... 94

3.3.1 Cell lines and reagents...................................................................................................... 94

3.3.2 Quantification of caspase-3/7 activity .............................................................................. 95

3.3.3 Quantitative RT-PCR...................................................................................................... 95

3.3.4 Cell proliferation assays.................................................................................................. 96

3.3.5 Western blot and antibodies........................................................................................... 96

3.3.6 Chromatin immunoprecipitation...................................................................................... 96

3.3.7 Lentiviral shRNA and cDNA overexpression.................................................................. 97

3.3.8 Transgenic mice............................................................................................................... 97

3.3.9 Histology and immunohistochemistry............................................................................ 98

3.4 RESULTS............................................................................................................................... 98

3.4.1 Genetic or pharmacologic inhibition of TWIST1 results in growth inhibition and apoptosis in *EGFR* mutant NSCLC .................................................. 98

3.4.2 TWIST1 is necessary and sufficient for EGFR TKI resistance in a subset of *EGFR* mutant NSCLC cell lines................................................................. 102
3.4.3 TWIST1 suppresses BIM expression .......................................................... 109

3.4.4 Creation and characterization of an autochthonous EGFR mutant Twist1 overexpression lung tumor mouse model ............................................................... 113

3.4.5 Twist1 expression induces erlotinib resistance in vivo ............................. 118

3.5 DISCUSSION ................................................................................................. 122

4.0 TWIST1 IS A KEY MEDIATOR OF HGF-MET DRIVEN RESISTANCE TO TARGETED THERAPIES IN EGFR MUTANT AND MET-DRIVEN LUNG CANCER

4.1 ABSTRACT .................................................................................................. 126

4.2 INTRODUCTION ......................................................................................... 128

4.3 METHODS .................................................................................................. 130

  4.3.1 Cell lines and reagents .......................................................................... 130

  4.3.2 Cell proliferation assays ....................................................................... 131

  4.3.3 Western blot and antibodies .................................................................. 131

  4.3.4 Lentiviral shRNA and cDNA overexpression ....................................... 131

  4.3.5 Pulse-Chase experiments ...................................................................... 132

  4.3.6 Xenograft experiments ........................................................................ 132

  4.3.7 Transgenic Mice .................................................................................. 133

4.4 RESULTS ..................................................................................................... 133

  4.4.1 Pharmacologic inhibition of TWIST1 overcomes HGF-mediated resistance to MET and EGFR TKIs in EGFR mutant and MET amplified NSCLC .......................................................... 133

  4.4.2 TWIST1 mediates resistance to MET TKIs in MET altered NSCLC .... 136
4.4.3 Twist1 cooperates with Hgf to promote tumorigenesis in a mouse model of Hgf-driven lung cancer

4.5 DISCUSSION

5.0 TWIST1 MEDIATES RESISTANCE TO TRAIL-BASED THERAPIES THROUGH DIRECT UPREGULATION OF C-FLIP

5.1 ABSTRACT

5.2 INTRODUCTION

5.3 METHODS

5.3.1 Cell lines and reagents

5.3.2 Cell proliferation assays

5.3.3 Western blot and antibodies

5.3.4 Luciferase reporter assay

5.3.5 Chromatin immunoprecipitation

5.3.6 Lentiviral shRNA and cDNA overexpression

5.4 RESULTS

5.4.1 Apoptosis following loss of TWIST1 expression requires both the intrinsic and extrinsic apoptotic pathways

5.4.2 TWIST1 directly upregulates cFLIP

5.4.3 TWIST1 mediates resistance to TRAIL-based therapies

5.5 DISCUSSION

6.0 CONCLUSIONS

APPENDIX A

BIBLIOGRAPHY
LIST OF TABLES

Table 1. List of primers used for SYBR Green qRT-PCR ......................................................... 174
Table 2. List of Primers used for Taqman qRT-PCR ................................................................. 175
Table 3. List of antibodies used for western blotting and immunohistochemistry............... 175
Table 4. Sequences for TWIST1/BCL2L11/TCF3 shRNA (5’-3’) in pKLO.1 ......................... 176
Table 5. ORFs obtained from Johns Hopkins University HiT Center ................................. 177
Table 6. Source of plasmids utilized ....................................................................................... 177
Table 7: ChIP Primers for BCL2L11 Promoter ..................................................................... 178
Table 8: ChIP Primers for CFLAR Promoter ......................................................................... 179
LIST OF FIGURES

Figure 1: Distribution of histological subtypes of lung cancer ....................................................... 3
Figure 2: Targetable molecular drivers in NSCLC with adenocarcinoma and squamous histology ......................................................................................................................................................... 5
Figure 3: Treatment paradigm for patients with metastatic Non-Small Cell Lung Cancer ............ 6
Figure 4: Mechanisms of resistance to EGFR and ALK TKIs in NSCLC ................................. 20
Figure 5: Intrinsic and extrinsic apoptotic pathways ................................................................. 28
Figure 6: Illustration of the TWIST1 protein and key domains.................................................. 37
Figure 7: Connectivity MAP (CMAP) analysis identifies compounds which inhibit NSCLC proliferation, TWIST1-dependent dissemination and TWIST1-suppression of organoid branching ........................................................................................................................................ 58
Figure 8: FGF2 treatment induces branching morphogenesis of primary epithelial cells in 3D culture ........................................................................................................................................................................ 60
Figure 9: Harmine inhibits growth through the induction of oncogene-induced senescence (OIS) in oncogene driver-defined NSCLC cell lines ...................................................................................... 63
Figure 10: Basal expression levels of TWIST1 in KRAS mutant and MET amplified/mutant NSCLC cell lines .................................................................................................................................................. 64
Figure 11: Harmine treatment induces Oncogene-Induced Senescence (OIS) in EGFR and MET mutant NSCLC cell lines ................................................................................................................................. 65

Figure 12: TWIST1 suppresses oncogene-induced apoptosis in MET amplified NSCLC .......... 66

Figure 13: Harmine induces apoptosis in oncogene-driven NSCLC cell lines ....................... 67

Figure 14: Harmine treatment leads to TWIST1 protein degradation ..................................... 70

Figure 15: Harmine treatment promotes TWIST1 degradation and decreases TWIST1 protein stability ........................................................................................................................................... 72

Figure 16: The E2A proteins and TWIST1 reciprocally stabilize each other ............................ 76

Figure 17: Harmine leads to degradation of the E2A proteins which are required for suppression of OIS ........................................................................................................................................ 77

Figure 18: Silencing of $E2A$ induces apoptosis and phenocopies silencing of $TWIST1$ .......... 78

Figure 19: The TWIST1/E2A heterodimer is critical for TWIST1 function and therapeutic response to harmine ......................................................................................................................................... 81

Figure 20: Overexpression of TWIST1 or its binding partner, E2A, rescues harmine induced growth inhibition ........................................................................................................................................ 82

Figure 21: Harmine has activity in $Kras^{G12D}/Twist1$ mouse model of autochthonous lung adenocarcinoma ............................................................................................................................................. 85

Figure 22: Treatment with harmine decrease tumor growth in a $KRAS$ mutant Patient-Derived Xenograph (PDX) model and degrades Twist1 and induces apoptosis in a transgenic mouse model of $Kras$ mutant lung cancer ........................................................................................................................................... 86

Figure 23: TWIST1 is required for $EGFR$ mutant NSCLC ....................................................... 100

Figure 24: Inhibition of TWIST1 induces apoptosis in a subset of $EGFR$ mutant NSCLC cell lines ................................................................................................................................................. 101
Figure 25: TWIST1 overexpression is sufficient to mediate resistance to EGFR TKIs............. 104
Figure 26: TWIST1 overexpression suppresses EGFR TKI-induced apoptosis in EGFR mutant NSCLC cell lines ........................................................................................................................................... 105
Figure 27: Inhibition of TWIST1 is sufficient to overcome EGFR TKI resistance ............. 106
Figure 28: Inhibition of TWIST1 can overcome acquired resistance to erlotinib ............... 108
Figure 29: TWIST1 suppresses BIM expression by directly suppressing its transcription....... 111
Figure 30: TWIST1 overexpression does not decrease BIM protein half-life.................... 113
Figure 31: Generation and characterization of a novel Twist1 overexpressing, mutant EGFR autochthonous lung tumor mouse model ................................................................. 116
Figure 32: Twist1 overexpression in vivo is sufficient to cause erlotinib resistance............ 120
Figure 33: Characterization of Twist1-mediated erlotinib resistance in vivo ...................... 121
Figure 34: HGF treatment increases TWIST1 protein stability ........................................... 135
Figure 35: Pharmacologic inhibition of TWIST1 overcomes HGF-mediated resistance to MET and EGFR TKIs in EGFR mutant and MET amplified NSCLC ......................................................... 135
Figure 36: TWIST1 modulates sensitivity to crizotinib in MET altered NSCLC................. 137
Figure 37: Harmine has activity in a PDX mouse model of EGFR mutant MET amplified lung cancer ........................................................................................................................................ 137
Figure 38: Twist1 overexpression leads to increased tumor size in a mouse model of Hgf-driven lung cancer ........................................................................................................................................ 139
Figure 39: Silencing of TWIST leads to apoptosis in NSCLC cell lines............................. 151
Figure 40: Growth inhibition following genetic inhibition of TWIST1 requires apoptosis.... 152
Figure 41: Overexpression of c-FLIPs or BCL-2 partially rescues apoptosis and growth inhibition following silencing of TWIST1 .................................................................................................. 153
Figure 42: Knockdown of BIM partially rescues growth inhibition following pharmacologic and genetic inhibition of TWIST1 ................................................................. 154

Figure 43: Modulation of TWIST1 expression results in altered expression of extrinsic apoptotic pathway members ................................................................. 158

Figure 44: The TWIST1 homodimer and heterodimer transactivates the CFLAR promoter ..... 159

Figure 45: TWIST1 directly binds to the CFLAR promoter ............................................. 160

Figure 46: TWIST1 mediates resistance to TRAIL-based therapies ............................... 162
I would like to thank Dr. Burns for his incredible mentorship during my time in graduate school. To members of the Burns and Stabile lab, specifically Lucia, Suman, Eric, Natalie, and Susheel, it has been a great experience working alongside all of you. I would also like to thank our collaborators Drs. Phuoc Tran, Jessica Cades, and Charles Rudin, who were instrumental in the mouse studies in Chapters 2-3. I thank my committee and Dr. Steinman for their helpful feedback and support over the past 4 years. To my friends, specifically Joe and Erik, our friendship means to the world to me. Finally, I would like to thank my parents. Without their support, sacrifice, and love, I would have never been able to complete this journey.
1.0 INTRODUCTION

1.1 LUNG CANCER

Lung cancer is the leading cause of cancer-related death in the United States and worldwide (1). In 2018, it is estimated that 234,030 patients will be diagnosed with lung cancer and approximately 154,050 deaths will occur due to lung cancer (2). While survival rates have marginally improved over the past few decades (1), 5-year survival rates for lung cancer patients remain a dismal 18% (2). 5-year survival rates for lung cancer patients diagnosed with local disease are 56%, however, only 15% of patients are diagnosed with local disease (1,2). For those patients diagnosed with metastatic disease, the 5-year survival rate is 5% (2). While targeted therapies and immunotherapies have improved outcomes for distinct subsets of patients with metastatic lung cancer, most systemic therapies remain marginally effective in the metastatic setting and few patients are cured in the metastatic setting.

There are numerous behavioral risk factors and environmental exposures that are known to increase lung cancer risk. The leading cause of lung cancer is cigarette smoking. It is estimated that approximately lung cancer deaths in 90% of men and 75-80% of women can be attributed to cigarette smoking (1). Smoking leads to lung cancer through exposure to polycyclic aromatic hydrocarbons and N-nitro compounds both of which are potent carcinogenic compounds found in cigarette smoke (1,3,4). The second leading cause of lung cancer is
exposure to radon (5). Occupational exposures to high levels of radon have been linked to increased risk of lung cancer (1,6). Radon is hypothesized to be carcinogenic when it is inhaled, as the decay of radon causes release of high energy $\alpha$-particles in the lung (1,7,8). Occupational exposures account for approximately 5% of lung cancers, the most important of these exposures being asbestos. Studies have demonstrated that asbestos functions as carcinogen by promoting chronic inflammation in the lung (9).

### 1.1.1 Lung cancer histological and genetic subtypes

Lung cancer is not just a single disease but rather a collection of distinct neoplasms with distinct histologies, biologies and clinical outcomes (10). Lung cancer is classified by both histology and/or molecular drivers. Histologically, there are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC, which accounts for approximately 15% of all lung cancers, is a neuroendocrine tumor that is initially responsive to chemotherapy (11). However, resistance to chemotherapy inevitably occurs and median survival for patients with advanced disease is approximately one year (11). Beyond mutations in $TP53$ (75-90%) and $RB1$ (60-90%), few molecular drivers have been identified in SCLC and few patients with SCLC benefit from molecularly targeted therapies (11).
NSCLC accounts for approximately 85% of lung cancers and has multiple major histological subtypes including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (Figure 1). Studies investigating genomic alterations in NSCLC with adenocarcinoma histology have identified a number of potentially targetable molecular drivers (Figure 2) (12-14). These molecular drivers are actionable as they have targeted therapies that are FDA approved or in clinical trials. Currently, patients with mutations in EGFR, ALK translocations, BRAF mutations and ROS1 translocations are treated with FDA approved targeted therapies (15). Other putative oncogenic drivers such as MET mutations/amplifications, RET translocations, NRTK translocations and HER2 mutations have been identified and targeting these oncogenic drivers is currently being explored both pre-clinically and in clinical trials (15).

Importantly, KRAS mutations are found to be oncogenic drivers in approximately 25% of patients with NSCLC with adenocarcinoma histology. Attempts to inhibit this oncogenic driver both directly and indirectly have failed (16). Direct inhibition of mutant KRAS has proven to be difficult due to the affinity of mutant KRAS for GTP and limited availability of binding sites (17). However, covalent inhibitors have been recently identified that specifically inhibit the G12C mutant form of KRAS by covalently binding to the allosteric switch II pocket of the GDP
bound form of KRAS (18,19). These covalent inhibitors have pre-clinical activity in mutant KRAS \textit{G12C}-driven cancers, however, resistance to these agents has already been observed pre-clinically and clinical efficacy of these compounds needs to be explored (18,19). Indirect strategies to target mutant \textit{KRAS} have included interrupting key post-translational modifications and inhibiting key downstream pathways. For example, KRAS requires prenylation and subsequent localization to the cell membrane in order activate downstream signaling pathways and enzymes such as farnesyltransferase are important for this process (17). Use of farnesyltransferase inhibitors had promising preclinical efficacy but failed clinically. A potential reason for this poor clinical efficacy is that KRAS can be alternatively prenylated by enzymes such as geranylgeranyltransferase (17). In addition, salirasib (S-trans,trans-farnesylthiosalicylic acid), which is a small molecule farnesylcysteine mimetic that inhibits RAS function by interfering with RAS plasma membrane docking, also failed to have clinical efficacy in KRAS-driven tumors despite preclinical activity (17,20,21).

Targeting downstream effector pathways of KRAS has been largely unsuccessful as well. There have been efforts to target signaling molecules within the PI3K and MAPK signaling pathways, which are two key downstream effector pathways of KRAS. However, given the complexity of KRAS signaling and redundancy within the multiple signaling pathways that mutant \textit{KRAS} activates, efforts to target individual signaling molecules, such as PI3K, BRAF, and MEK, have failed despite promising preclinical studies (17). Current efforts are aimed at determining if genetic subgroups within \textit{KRAS} mutant tumors may respond to targeted therapy and if combinations of targeted agents may have superior outcomes in \textit{KRAS} mutant tumors (17). Targeted therapies in NSCLC are discussed in detail in Section 1.1.2.
Within NSCLC with squamous histology, putative oncogenic drivers, specifically actionable oncogenic drivers, are less frequent compared to NSCLC with adenocarcinoma histology (Figure 2). Early efforts to determine genetic aberrations in NSCLC with squamous histology revealed frequent TP53 mutations (81%) as well as mutations in MLL2 (20%), PI3K (16%), CDKN2A (15%) (10,22). Unlike adenocarcinoma, NSCLC with squamous histology rarely has mutations in EGFR and KRAS (10). Potential actionable oncogenic drivers in patients with squamous histology include amplifications in FGFR1, mutations in DDR2, and PIK3CA mutations (Figure 2) (10,12,23). Clinical trials are currently investigating the efficacy of targeting of potential oncogenic drivers in NSCLC with squamous histology including a SWOG cooperative study called the LUNG-MAP study (24).

1.1.2 Lung cancer treatment modalities

Patients with NSCLC have a number of therapeutic options including: definitive surgery or radiation, chemotherapy, targeted therapy, or immunotherapy. Patients with early stage disease,
which is typically identified as an incidental finding on imaging (chest X-Ray or computed tomography (CT) scan) or on a screening CT scan for heavy smokers, are commonly candidates for definitive local treatment which includes surgery, radiation, and/or perioperative chemotherapy followed by surgery. Diagnosis of metastatic disease typically precludes patients from surgical intervention. Choice of first-line systemic therapy is contingent on the presence or absence of “targetable” molecular drivers. Those patients with actionable molecular drivers typically receive first-line targeted therapy. Those patients without targetable molecular drivers with tumors positive for Programmed death-ligand 1 (PD-L1) expression are offered immunotherapy. Chemotherapy with and without immunotherapy remains the mainstay of therapy for patients with advanced lung cancer that do not qualify for targeted agents or immunotherapies.

Figure 3: Treatment paradigm for patients with metastatic Non-Small Cell Lung Cancer
1.1.2.1 Definitive local treatment: Surgery and Radiation

The mainstay of treatment for patients with early stage NSCLC (Stage I-II) or a subset of locally advanced NSCLC (Stage IIIa) is surgical resection of the tumor (25,26). The types of surgical procedures recommended for NSCLC differ between stage and histological subtypes but segmentectomy or lobectomy is generally reported to have superior outcomes to wedge resections (26). Adjuvant or postoperative chemotherapy has been investigated extensively in patients with local disease. Currently, it is recommended that patients with Stage II-III disease post-resection receive a cisplatin-based chemotherapy regiment, given that chemotherapy for these patients provides an approximate 5% increase in 5-year survival (25,27). Additionally, chemotherapy may be considered for patients with Stage 1B disease as it has been shown to provide a small increase in survival (27). Several studies have also demonstrated that neoadjuvant therapy is equivalent to adjuvant therapy and is used by some centers across the country (28).

For those patients with Stage I-II local disease, who either do not qualify or refuse surgical resection, radiation therapy is recommended. For patients with Stage I disease, disease control rates for patients receiving high-dose stereotactic radiation therapy have disease control rates are between 85-90% (25,29-33). For patients with larger tumors (Stage II), conventional radiation is recommended rather than stereotactic radiation (25). However, outcomes for patients with inoperable Stage II disease receiving radiation therapy is worse than those that can receive surgery (34). Additionally, there is no evidence to support the addition of chemotherapy to radiation for Stage I-II.

For those patients with Stage III unresectable disease, 5- year survival is poor at 15-20% (33). The standard of care for these patients is definitive chemotherapy and radiotherapy (25,33).
Early studies demonstrated that the addition of sequential chemotherapy plus radiation provided a survival benefit to radiotherapy alone (35,36). Subsequent studies demonstrated concurrent chemotherapy plus radiation provided a greater survival advantage to sequential chemotherapy plus radiation (35,37). The most commonly used chemotherapy regiments include cisplatin-etoposide or carboplatin-paclitaxel (35,38). Cisplatin-based regiments have been shown to have better response versus carboplatin-based regiments, while cisplatin-based regiments have higher rates of side effects (35,38,39). Of note, there was preclinical evidence that resistance to chemotherapy and radiation therapy may occur through upregulation of PD-L1 expression within tumors (35,40,41). Based on this evidence, the recent PACIFIC trial (NCT02125461) investigated whether patients with unresectable Stage III disease previously treated with chemoradiation would benefit from the PD-L1 inhibitor, durvalumab. The results of the trial revealed that there was significant increase in progression free survival (PFS) for those patients that received the PD-L1 inhibitor, durvalumab (16.8 months) versus those that received placebo (5.6 months) with median survival not reached in the durvalumab group at the time of the publication (42). Additionally, the quality of life for those patients receiving durvalumab was not significantly different than those patients receiving placebo (43).

1.1.2.2 Chemotherapy

For those patients with advanced or metastatic NSCLC without a targetable molecular driver or elevated levels of PD-L1 expression (>50%), the standard of care treatment remains systemic chemotherapy with or without immunotherapy (Figure 3) (44). Currently, the recommended chemotherapy regiments include a platinum-based chemotherapy, such as cisplatin or carboplatin, plus another chemotherapy agent (44). Other chemotherapies that can be utilized include taxanes (docetaxel), antimetabolites such as gemcitabine and pemetrexed, and vinca
alkaloids such as vinorelbine. The current recommended platinum-based chemotherapy doublet therapy in non-squamous histologies is cisplatin plus pemetrexed as it provides a greater survival benefit compared to other regimens (Figure 3) (44-46). For patients with nonsquamous histology, the addition of a monoclonal antibody against vascular endothelial growth factor (VEGF) to chemotherapy results in increased survival and PFS (Figure 3) (44,47). Additionally, as discussed in Section 1.1.2.3, pembrolizumab plus chemotherapy (carboplatin and pemetrexed) is another option for patients with advanced NSCLC as this regiment was recently shown to be superior to chemotherapy alone in patients with advanced nonsquamous NSCLC (48). However, overall survival (OS) remains poor for patients without molecular drivers or PD-L1 expression, as systemic chemotherapies remain marginally beneficial (44).

1.1.2.3 Immunotherapy

For those patients with metastatic NSCLC in the absence of targetable molecular drivers, survival remains poor, with most patients who receive chemotherapy succumbing to the disease within a year (49-51). However, immunotherapies have emerged as a new class of agents for patients with advanced or metastatic NSCLC. Due to initial poor success of immunotherapies, lung cancer was largely considered to be nonimmunogenic (52). In lung cancer, specifically advanced lung cancer, there is an immunosuppressive tumor microenvironment that results from secretion of immunosuppressive cytokines, loss of antigen expression for major histocompatibility complex, decreased presence of intratumoral lymphocytes, and increased intratumoral T regulatory cells (52-56).

Current successful immunotherapies have focused on targeting checkpoint pathways that negatively regulate T cell activation. One such molecule is cytotoxic T-lymphocyte antigen-4 (CTLA-4), which functions as a T-cell checkpoint inhibitor. T-cells express a co-stimulatory
protein, CD28, which binds to CD80/86 proteins on antigen-presenting cells (APCs) and increases T-cell activation (52,57). CTLA-4 is also expressed on T-cells and binds to CD80/86 on APCs, resulting in suppression of T-cell activation (52,57). Interestingly, CTLA-4 binds with greater affinity to CD80/86 and the relative abundance of CTLA-4 versus CD28 determines whether a T-cell will proliferate or become anergic (57). Currently, ipilimumab, a monoclonal anti-CTLA antibody, has shown activity in solid tumors and is currently FDA approved for metastatic and unresectable melanoma but failed to show activity in combination with chemotherapy in NSCLC (57-59). Another pathway that has been the focus of immunotherapy is the programmed death-1 (PD-1) pathway. Programmed death-ligand 1 (PD-L1) is expressed on APCs and aberrantly expressed on tumor cells and binds to PD-1 which is expressed on the surface of T-cells (57). The binding of PD-L1 to PD-1 on T-cells results in decreased T-cells activation (57). There are a number of FDA approved monoclonal antibody therapies targeting PD-1 (Nivolumab and Pembrolizumab) and PD-L1 (Durvalumab and Atezolizumab) that have activity in both melanoma and NSCLC.

Currently, pembrolizumab is the first-line treatment for patients with metastatic NSCLC with ≥50% of tumor cells positive for PD-L1 expression (Figure 3). This first-line designation was a result of the KEYNOTE-024 trial that demonstrated in patients with metastatic NSCLC and ≥50% PD-L1 expression that pembrolizumab significantly increased overall survival and PFS compared to platinum-based chemotherapy (51,60). Additionally, pembrolizumab is approved as a first-line therapy for metastatic NSCLC patients (with and without PD-L1 expression) with nonsquamous histology in combination with chemotherapy, as a result of the KEYNOTE-021 and KEYNOTE-189 trials that demonstrated pembrolizumab plus chemotherapy resulted in superior response rates, PFS, and OS compared to chemotherapy alone.
In the second-line setting, pembrolizumab is approved in the PD-L1 positive population while both nivolumab and atezolizumab are approved regardless of PD-L1 status as all three agents have shown superiority in overall response rates (ORR), PFS, and OS compared to docetaxel (51,62). Interestingly, the combination of CTLA-4 and PD-1 inhibitors in patients with metastatic melanoma has impressive activity and has demonstrated a marked survival benefit for these patients. In NSCLC, a recent Phase I trial demonstrated that the combination of ipilimumab and nivolumab resulted in a high response rate and durable responses in patients with advanced NSCLC (63). A recent study has suggested that this combination may be beneficial in the first-line setting in patients with high tumor mutational burden (64). Given the early success of combinations of immunotherapies, there are numerous trials investigating combination of CTLA-4 and PD-1/PD-L1 inhibitors in NSCLC as well as other novel immunotherapy agents.

1.1.2.4 EGFR targeted therapy

Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases (RTKs) (65). EGFR can bind to multiple ligands including epidermal growth factor (EGF), amphiregulin, and transforming growth factor α (TGFα) (65). EGFR binding these ligands results in homodimerization or heterodimerization with other members of ErbB family of receptors (65). EGFR dimerization results in transphosphorylation of EGFR and provides docking sites for proteins involved in activation of downstream pathways including the PI3K-mTOR pathway, RAS/RAF/MEK pathway, and JAK-STAT pathway (65). These pathways regulate cell proliferation, angiogenesis, apoptosis, migration, and cell motility (10). Aberrations in EGFR signaling can result from protein overexpression, gene amplification, or mutations
within the receptor (66). These all can result in aberrant activation of EGFR and its downstream signaling pathways and can promote tumorigenesis.

In patients with NSCLC, the most frequent actionable EGFR aberrations are mutations within the tyrosine kinase domain (10). Mutations in the EGFR gene occur in approximately 30-50% of patients of East Asian descent and 15% of patients of non-East Asian descent (10,33). Of note, East Asian patients who are never smokers this proportion of EGFR mutations is greater than 50% (10). The majority of EGFR mutations (~90%) found in NSCLC patients are exon 19 deletions and L858R point mutations within exon 21 (10). Both mutations result in ligand-independent constitutively active receptors (67,68). Structural studies of L858R mutated EGFR have demonstrated that the L858R mutation prevents the activation loop of EGFR from adopting an inactive confirmation resulting in a constitutively active protein (67). Interestingly, these EGFR mutations (exon 19 deletions and L858R mutations) are termed “sensitizing mutations” because these mutated receptors display an increased binding affinity for 1st generation EGFR TKIs such as erlotinib and gefinitib (67,69). Additionally, these sensitizing mutations display a reduced binding affinity for adenosine triphosphate (ATP) which may account for their increased sensitivity to competitive ATP inhibitors such as erlotinib and gefinitib (67,69).

EGFR TKIs were initially established as first-line therapy for patients with late stage (IIIB or IV) EGFR mutated NSCLC based of the results of the phase III Iressa Pan-Asia Study (IPASS) (70). This trial was the first to establish that the EGFR TKI, gefinitib, was superior to chemotherapy for patients with EGFR mutations. Patients with EGFR mutations, the majority (~90%) of whom had exon 19 deletions or L858R mutations, who received gefinitib displayed a significantly increased response rate, relative risk reduction, and PFS compared to patients that received chemotherapy (70). Interestingly, this study also demonstrated that in patients with
wild-type \textit{EGFR} gefinitib resulted in worse clinical outcomes than chemotherapy (70). Since IPASS, there have been numerous phase III trials that have also demonstrated that EGFR TKIs are a superior first-line treatment for patients with \textit{EGFR} mutations over chemotherapy (33,71-74).

A major hurdle for EGFR targeted therapy is acquired resistance. Resistance can occur through EGFR-dependent mechanisms (amplification or 2\textsuperscript{nd} site mutations) or through EGFR-independent mechanisms or bypass signaling pathways which will be discussed in Section 1.1.3. The most frequent mechanism of resistance (~49\%) is secondary to \textit{T790M} mutations in \textit{EGFR} (75). The \textit{T790M} mutation introduces a hydrophobic, bulky methionine amino acid for the hydrophilic threonine into the ATP binding pocket of EGFR (76,77). Mutant \textit{EGFR} with secondary \textit{T790M} mutations retains affinity for gefinitib or erlotinib, however, this mutation significantly increases affinity of EGFR for ATP, thus reducing the potency of first generation EGFR TKIs (76,77). 3\textsuperscript{rd} generation EGFR TKIs are irreversible inhibitors that covalently bind to cysteine 797 within the ATP binding pocket (77,78). As opposed to 2\textsuperscript{nd} generation EGFR TKIs which inhibited both wild type and mutant \textit{EGFR}, 3\textsuperscript{rd} generation EGFR TKIs are more selective for mutant forms of \textit{EGFR} (77,78). Previously, osimertinib had been established as the mainstay of treatment for patients with \textit{EGFR} mutant NSCLC that had progressed on 1\textsuperscript{st} generation EGFR TKIs (79-81). Recently, osimertinib was established as the first-line therapy for patients with \textit{EGFR} mutant NSCLC (\textbf{Figure 3}). The recent Phase III FLAURA study, demonstrated that use of first-line osimertinib resulted in a significantly longer PFS (18.9 months) compared to FDA approved first-line EGFR TKIs (10.2 months) (82). Additionally, first-line osimertinib resulted in a significantly longer duration of response compared to 1\textsuperscript{st} generation EGFR TKIs (17.2 months for osimertinib versus 8.5 months for erlotinib/gefinitib) (82). Similar to 1\textsuperscript{st} generation
EGFR TKIs, acquired resistance to osimertinib has limited its long-term efficacy (82). Additional mutations in EGFR are the most common mechanisms of osimertinib resistance (83,84). Initial studies have demonstrated that approximately 25% of osimertinib resistant patients develop the C797S mutation, which prevents osimertinib from covalently binding to EGFR (83,84). Currently, there are efforts to develop fourth-generation EGFR TKIs to target the C797S EGFR mutation (85,86).

1.1.2.5 ALK targeted therapy

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is a member of the insulin receptor family (87). The function of wild type ALK is not fully understood, as it is rarely expressed postnatally in humans and mice (87). In mouse models, Alk has shown to play role in the development of the nervous system and following nervous system development Alk expression is drastically reduced (87). Additionally, mouse Alk knockout models develop normally except for minor behavioral abnormalities (87). However, in zebrafish models, Alk expression is required for survival and differentiation of neural progenitors in the developing central nervous system (88). There are case reports in humans in which germline mutations in ALK are associated with a neuroblastoma accompanied by encephalopathy and abnormal brainstem development (89). Interestingly, ALK was shown to play a role in cancer when ALK fusion genes with nucleophosmin (NPM) were identified in anaplastic large-cell lymphoma (ALCL) (87,90). The NPM-ALK fusion gene in ALCL results in constitutively active ALK protein that drives ALCL tumorigenesis (87,90). Recently, an ALK fusion gene with echinoderm microtubule-associated protein-like 4 (EML4) was identified in patients with NSCLC (87,90). Both ALK and EML4 are located on chromosome 2 and the EML4-ALK fusion occurs via an inversion event at this chromosome (90). Since discovery of the EML4-ALK fusion, in patients
with NSCLC, a number of *EML4-ALK* variants have been identified, as well as, additional ALK fusions such as *KIF5B-ALK*, *TFG-ALK*, and *KLC1-ALK* (10). With the *EML4-ALK* fusion being the most common, *ALK* translocations have been identified in approximately 3-7% of NSCLC (87,90,91). Importantly, these *ALK* translocations appear to be mutually exclusive from other potential molecular drivers such as mutant *KRAS* or *EGFR* (92).

Despite having different fusion partners, all *ALK* translocations share a number of common characteristics. First, the fusion gene includes the full tyrosine kinase domain of *ALK* (90). Additionally, the promoter of the fusion gene originates from the fusion partner as the promoter of the *ALK* gene is inactive postnatally and is unable to drive transcription of the fusion gene (87,90). Lastly, the fusion gene includes an oligomerization domain from the fusion partner that is capable of inducing ligand-independent dimerization (90). Importantly, the *EML4-ALK* translocation in NSCLC has the aforementioned characteristics. In a number of pre-clinical models, *EML4-ALK* was confirmed as a potential oncogenic driver in lung cancer as its expression was sufficient for development of lung tumors (87). Additionally, in these models *EML4-ALK*-driven tumors were sensitive to ALK inhibition (87). Similar to EGFR, ALK promotes tumorigenesis via activating a number of downstream pathways that play important roles in regulating proliferation, apoptosis, angiogenesis and migration including the PI3K-mTOR pathway, RAS/RAF/MEK pathway, and JAK-STAT pathway (87).

Four years following identification of the *ALK* translocation in NSCLC, crizotinib was approved by the FDA for the treatment of ALK-driven NSCLC. Crizotinib is an ALK ATP competitive inhibitor that was originally developed as a MET inhibitor. Crizotinib eventually became a first-line therapy for *ALK* rearranged advanced NSCLC as a Phase III study (PROFILE 1014) demonstrated that patients that received crizotinib had a significantly longer PFS (10.9
months) compared to patients receiving chemotherapy (7.0 months) (93). However, similar to erlotinib/gefinitib in EGFR mutant NSCLC, patients with ALK-driven NSCLC inevitably develop resistance to crizotinib. The most common mechanism of resistance are secondary aberrations in ALK. In approximately 20-36% of patients develop mutations within the tyrosine kinase domain of ALK that results in decreased sensitivity to crizotinib (92,94,95). The most common mutation secondary mutation in ALK is the “gatekeeper” L1196M mutation, which introduces a bulky methionine group into the active site and sterically hinders crizotinib from accessing the hydrophobic active site (87,96). Another common mutation is G1269A which near the N-terminus of the activation loop and introduces an alanine for a glycine. Substitution of an alanine for glycine sterically hinders crizotinib from accessing the active site of ALK (90,97). Interestingly, other secondary ALK mutations have been identified including the C1156Y mutation near the αC-Helix, which stabilize the active confirmation of ALK and promotes increased ATP binding, thus decreasing the potency of crizotinib (87,97). Additionally, approximately 9% of patients develop ALK amplification as a mechanism of resistance to crizotinib (90,94). Interestingly, patients can have concurrent ALK mutations and amplifications as a mechanisms of resistance to crizotinib (90).

Interestingly, second generation ATP competitive inhibitors of ALK such as alectinib and ceritinib are potent ALK inhibitors that have activity against multiple ALK mutations including the L1196M “gatekeeper” mutation. Additionally, ceritinib has been shown to have activity in EML4-ALK-driven NSCLC with amplification of the EML4-ALK allele, suggesting that second generation ALK TKIs can overcome multiple mechanisms of resistance to crizotinib (97). Multiple Phase III trials have demonstrated that ceritinib was more efficacious than chemotherapy and was subsequently approved as first-line therapy for ALK rearranged NSCLC
in 2017 (87). However, crizotinib and ceritinib have limited activity in the central nervous system (CNS) given that they are both substrates for and removed from the CNS via the p-glycoprotein (87). The poor penetration into the CNS results in frequent brain recurrence for patients that have progressed on crizotinib. Alectinib has marked CNS penetrance as it is not a target of the p-glycoprotein and is highly effective in patients with CNS disease (98). The recent ALEX trial demonstrated that alectinib was more efficacious than crizotinib in ALK-driven NSCLC and resulted in fewer CNS recurrences than crizotinib (99). As a result, alectinib was approved as a first-line therapy for ALK-positive NSCLC and is the current standard of care treatment for ALK-positive NSCLC (Figure 3).

Over 50% of patients become resistant to alectinib and ceritinib via secondary mutations in ALK, the most common being the G1202R mutation which sterically blocks these second generation drugs from accessing the kinase domain (87). Lorlatinib, a third generation ALK inhibitor has efficacy against G1202R ALK mutation (87,100). A recent Phase I trial revealed that lortatinib has efficacy in patients resistant to second generation drugs (101). Additionally, there is currently a Phase III trial comparing the efficacy of lorlatinib versus crizotinib (NCT03052608).

1.1.2.6 MET targeted therapy

The c-MET (MET) protein is a receptor tyrosine kinase which upon binding its only known ligand, hepatocyte growth factor (HGF), mediates tumor cell proliferation, epithelial-mesenchymal transition (EMT), motility, invasion and angiogenesis all of which contribute to its role in tumorigenesis (102). The MET signaling pathway is often dysregulated in lung cancer as a result of several mechanisms including MET or HGF protein overexpression, MET amplification and MET mutations (103). MET overexpression occurs in up to 61% of NSCLC.
and is correlated with poor prognosis (104,105). Likewise, HGF overexpression is also linked to poor survival (106). HGF/MET receptor pathway alterations, such as MET amplification and mutations, specifically exon 14 skipping mutations which result in increased MET stability, have recently been recognized as potential targetable oncogenic drivers in NSCLC. MET amplification is found in approximately 5-6% of NSCLC tumors (107) and is associated with poor prognosis and mediastinal lymph node metastases (105,108). In both gastric adenocarcinoma and lung cancer, preclinical studies have demonstrated that MET amplification can predict response to MET TKIs (109-111). In multiple Phase I trials, patients with MET amplified advanced NSCLC had dramatic responses to MET TKIs (112,113). Additionally, the results of these trials suggest that patients with higher levels of MET amplification are more likely to respond to MET inhibition (112). Currently, there are numerous clinical trials such as NCT02750215, NCT00585195, and NCT02132598, further investigating the role of MET inhibitors in MET amplification NSCLC.

MET mutations have been identified in 3-8% of lung tumors (49,114). These mutations reside in the extracellular semaphorin domain as well as the intracellular juxtamembrane domain which affect ligand binding and receptor downregulation, respectively (104,115,116). In particular, MET Exon 14 skipping mutations have been investigated as potential drivers of NSCLC. Exon 14 contains the juxtamembrane domain of MET. Mutations around the splicing junction of Exon 14 cause aberrant splicing of the MET transcript and loss of Exon 14 (111,117). Importantly, the juxtamembrane domain contains a binding site for the E3 ubiquitin ligase, casitas B-lineage lymphoma (CBL) (111,117). Loss of this site (Y1003) results in increased MET half-life, protein stability and prolonged PI3K-AKT and MAPK pathway activation (117). Preclinical studies have demonstrated that MET Exon 14 skipping mutations were sufficient to
induce adenocarcinoma in mouse models, confer anchorage independent growth in cell lines, and markedly increase sensitivity to MET TKIs (117,118). Additionally, dramatic responses have been observed in patients with MET mutant tumors treated with the MET TKIs, crizotinib or capmatinib (117-120). Similar to EGFR and ALK TKIs in EGFR mutant and ALK-positive NSCLC, patients MET mutations inevitably develop resistance to MET TKIs. Initial studies investigating mechanisms of resistance to MET TKIs have identified secondary mutations in MET (117,121). Interestingly, these secondary mutations in MET prevent binding of type I MET TKIs, which preferentially bind active confirmation of MET, such as crizotinib or capmatinib, but are still sensitive to type II MET TKIs, which bind to the inactivation form of MET, such as cabozantinib (121,122). A case report has demonstrated that a patient that developed resistance to type I MET TKIs responded to a type II MET TKI, cabozantinib (122).
Figure 4: Mechanisms of resistance to EGFR and ALK TKIs in NSCLC
Despite impressive responses to EGFR and ALK TKIs, patients with EGFR- and ALK-driven NSCLC inevitably develop acquired resistance to these therapies. The most common mechanism of acquired resistance to EGFR and ALK TKIs are second site mutations within EGFR and ALK, respectively. These mutations, such as the T790M EGFR mutation and the L1196 ALK mutation, lead to TKI resistance by preventing drug binding or increasing affinity for ATP over the TKI. Alternatively, activation of bypass signaling pathways has been identified as a mechanism of resistance. Commonly, TKI resistant tumors increase activity of alternative receptor tyrosine kinases (RTKs) such as MET, HER2, HER3, and IGFR1, through genetic mutation/amplification or through increased expression of ligands, such as HGF for the MET receptor. Additionally, mutations in individual genes (PIK3CA, PTEN, RAF, MEK) within important signaling pathways can also confer TKI resistance. Independent of bypass signaling, epithelial-mesenchymal transition and histological transformation have been associated with resistance to EGFR and ALK TKIs. Decreased expression of the pro-apoptotic BCL-2 protein, BIM, and polymorphisms in the BIM gene, BCL2L11, have also been linked to resistance to TKIs in NSCLC. * denotes genes mutated in TKI resistant setting
1.1.3 Driver independent resistance mechanisms to targeted therapies in lung cancer

In molecularly defined subpopulations of patients with NSCLC, use of targeted therapies typically result in marked response rates and improved clinical outcomes (123). However, the efficacy of targeted therapies is significantly limited due to the frequency of de-novo resistance and the almost universality of acquired resistance in patients that initially respond to these therapies (123). As mentioned in Sections 1.1.2.4-1.1.2.6, the most frequent mechanisms of acquired resistance are “on-target resistance” mechanisms such as secondary site mutations or gene amplification of the molecular target. Alternatively, patients can develop resistance to targeted therapies via mechanisms that are independent of the molecular driver. These mechanisms include activation of bypass signaling pathways, histological transformation, or EMT, all of which render the original tumor no longer dependent on the initial molecular driver.

1.1.3.1 Bypass signaling pathway activation

By directly inhibiting EGFR and ALK, EGFR and ALK TKIs suppress activity through key signaling pathways required for tumorigenesis. Patients with resistance to EGFR and ALK TKIs frequently have genetic aberrations or increased autocrine signaling that activates bypass signaling pathways required for tumor growth, proliferation, and survival (124,125). A common mechanism of resistance occurs via increased signaling through alternative receptor tyrosine kinases (RTKs) such as MET (discussed in the following Section), HER2, HER3, and IGF1R (Figure 4) (124,125). Activation of these RTKs can occur with gene amplification or mutations as found with HER2 or MET or increased ligand expression as found with HER3 and IGF1R (124-128). While activation of alternative RTKs has been observed as a mechanism to 1st generation EGFR and ALK TKIs, these mechanisms appear to be relevant in resistance to later
generation TKIs as well, as patients with osimertinib and alectinib/ceritinib resistance commonly have aberrations in RTK signaling (124,125,129,130).

KRAS is a GTPase protein that activates numerous of signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR (131). Mutations in KRAS are oncogenic drivers in approximately 25% of NSCLC (131). While KRAS mutations are rarely seen in treatment naïve EGFR mutant or ALK translocation positive NSCLC, they have been observed in patients with acquired resistance to EGFR and ALK TKIs (Figure 4) (95,124,129,130,132,133). Importantly, in EGFR mutant NSCLC, KRAS mutations have been identified as a mechanism of resistance to osimertinib (129,130,132).

An additional mechanism of bypass signaling-mediated resistance to TKIs in NSCLC is mutations in individual signaling molecules within key mitogenic pathways. Two commonly mutated genes within the PI3K signaling pathway include, PIK3CA which is the gene that encodes the catalytically active subunit of the PI3K protein, and PTEN which is a negative regulator of PI3K signaling (Figure 4) (124). Activating mutations in PIK3CA and inactivating mutations in PTEN lead to aberrant activity of PI3K-AKT-mTOR signaling. In vitro, these mutations have been demonstrated to be sufficient to mediate resistance to TKIs (134). Interestingly, approximately 5% NSCLC patients with acquired resistance to erlotinib have PIK3CA mutations (75). PIK3CA mutations are also found in patients with acquired resistance to osimertinib and approximately 4% of patients with acquired resistance to alectinib (100,130). PTEN mutations have been identified in patients with both acquired and de-novo resistance to ALK and EGFR TKIs (135-137). Additionally, aberrations in the MAPK pathway have been identified in patients with acquired resistance. Specifically, activating mutations in BRAF and
MAP2K1 (gene encoding MEK1), which both lead to constitutive MAPK signaling, are seen in patients with acquired resistance to EGFR and ALK TKIs (Figure 4) (130,138,139).

1.1.3.2 HGF-MET Pathway Alterations

A frequent mechanism of resistance to targeted therapy in NSCLC is activation of the HGF-MET pathway. Activation of this signaling pathway serves as a bypass mechanism to targeted therapy as it results in activation of pathways such as MAPK and PI3K/AKT/mTOR, which are required for cell survival and proliferation in ALK- or EGFR-driven NSCLC (140,141). There are typically two aberrations of this pathway that are seen in resistance to targeted therapy: MET amplification and HGF overexpression (Figure 4). Importantly, these aberrations are seen across genetic subtypes of NSCLC in the resistance setting, which suggests that there is a conservation of HGF-MET function across genetic subtypes (141).

MET amplification promotes resistance to targeted therapy in lung cancer cells via HGF-independent activation of PI3K signaling by directly interacting with ERBB3 (142). MET amplification serves as mechanism of resistance in 5-20% of EGFR mutant patients that develop acquired resistance to erlotinib (75,142). Importantly, MET amplification has also been observed as a mediator of resistance to the third-generation EGFR TKI, osimertinib (143,144). In regards to ALK-driven NSCLC, MET amplification can mediate resistance to second generation ALK TKIs, alectinib and ceritinib (144,145). Additionally, there is clinical evidence that the MET/ALK TKI, crizotinib has activity in EGFR- and ALK-driven NSCLC with concurrent MET amplification (140,144,146). Currently, there are clinical trials investigating the efficacy of MET inhibitors in EGFR mutant NSCLC patients with MET-mediated resistance to EGFR inhibitors (140).
Similar to MET amplification, HGF overexpression promotes resistance to targeted therapies in lung cancer by reactivating MAPK and PI3K signaling (147,148). HGF overexpression can result in autocrine activation of MET signaling via direct release from cancer cells or paracrine activation of MET signaling via release from stromal cells, specifically fibroblasts (147). HGF overexpression has been observed as a mechanism of resistance to both EGFR and ALK TKIs (147-151). In EGFR mutant patients, HGF overexpression has been observed in as many as 60% of patients with resistance to erlotinib (151). HGF overexpression can also result in de-novo resistance to EGFR TKIs (149). In addition, HGF has been shown to mediate resistance to alectinib in ALK-driven NSCLC and use of crizotinib has been shown to overcome this HGF-mediated resistance (150).

1.1.3.3 Histological Transformation

A fundamental change in histology from NSCLC to SCLC is observed in patients with EGFR- and ALK-driven NSCLC resistant to EGFR and ALK TKIs, respectively (Figure 4) (141). In EGFR mutant NSCLC, this histological switch is observed in approximately 5-15% of patients resistant to 1st generation EGFR TKIs (152). Importantly, this transformation to SCLC has been observed following resistance to the 3rd generation TKI, osimertinib, which is currently the first-line treatment for patients with EGFR mutations (136). While histological transformation is more frequently observed in resistance to EGFR TKIs, it has also been identified as mechanism of resistance to ALK TKIs in NSCLC patients with ALK translocations (153,154). Mechanistic investigation into this histological change has revealed that these tumors both clinically and genetically resemble neuroendocrine SCLC. Clinically, these tumors grow rapidly, respond initially to chemotherapy, and invariably develop chemoresistance. Genetically, these tumors universally have genetic loss of RB1, which is a hallmark genetic event for patients with SCLC.
These tumors also have low or absent EGFR expression, potentially accounting for the fact that these tumors are no longer responsive to EGFR TKIs (152). Additionally, a hallmark of SCLC in pre-clinical studies is sensitivity to BCL-2 inhibition as approximately 65% of SCLC overexpress BCL-2 and a subset of these tumors are sensitive to BCL-2 inhibitors (155). Interestingly, EGFR mutant tumors that have undergone a switch to SCLC are sensitive to BCL-2 inhibition, providing a potential avenue to treat this mechanism of EGFR TKI resistance (152).

1.1.3.4 Epithelial-Mesenchymal Transition

Epithelial-mesenchymal transition (EMT) is a process in which epithelial cells transdifferentiate and adopt a mesenchymal phenotype (156,157). EMT results in loss of epithelial cell polarity and cell-cell interactions (156,157). In the setting of tumorigenesis, EMT is associated with cell invasion, migration, and metastasis (156,157). EMT can also lead to suppression of apoptosis and senescence (156,157). Interestingly, the presence of an EMT or mesenchymal phenotype has been observed in patients with acquired and \textit{de-novo} resistance to targeted therapies in EGFR- and ALK-driven NSCLC (\textbf{Figure 4}) (75,100,158-161). In the acquired resistance setting, EMT, defined by morphology and changes in E-cadherin, Vimentin, or AXL expression, is seen in as many as 20% of patients resistant to EGFR TKIs and 40% of patients resistant to ALK TKIs (100,161). The mechanisms by which an EMT phenotype is associated with resistance to targeted therapies remains unclear. Previous studies have demonstrated that expression of EMT-transcription factors, ZEB1 and SNAI2, can lead to EGFR TKI resistance by suppressing EGFR TKI-induced apoptosis (160,162-164). Additionally, increased expression of AXL, SRC, TGF-β and IGF1R have been shown to lead to EMT and mediate resistance to TKIs in lung cancer (90,161,165-167). In \textit{EGFR} mutant NSCLC, there are numerous clinical trials investigating if targeting these aforementioned upstream mediators of EMT can overcome \textit{de-novo} and acquired
resistance to EGFR TKIs, however, EMT-transcription factors have not been targeted to date (141).

1.2 APOPTOSIS AND CANCER

Apoptosis is a form of programmed cell death that plays a pivotal role in development and homeostasis by removing unneeded or damaged cells (168,169). Apoptosis occurs in response to extracellular or intracellular stress signals that lead to cellular shrinkage, condensation of chromatin, fragmentation of DNA, plasma membrane blebbing, and formation of apoptotic bodies which are small vesicles that are subsequently engulfed by neighboring phagocytes (168,169). Unlike other forms of programmed cell death, apoptosis is unique in that it does not result in an inflammatory response (168).

There are two main pathways of apoptosis: intrinsic and extrinsic apoptosis. Mitochondrial or intrinsic apoptosis is activated in response to internal cell stress signaling, while the extrinsic apoptotic pathway is activated in response to death receptor signaling. The cellular mediators of apoptosis are caspases (cysteine aspartic-specific proteases). There are two forms of caspases: “initiator” and “executioner” caspases. In response to stress signals, initiator caspases (caspase-2, -8, -9, and -10) cleave and activate executioner caspases (caspase-3 or -7), which when activated cleave a variety of cellular substrates such as cytoskeletal and nuclear proteins (170). Interestingly, aberrations in these apoptotic pathways and proteins within these pathways are an almost universal feature in cancers. The ability to suppress apoptosis in the presence of cellular stresses is a “hallmark of cancer” and the goal of most systemic therapies is to overcome this suppression of apoptosis (170,171).
1.2.1 Apoptotic pathways

Intrinsic apoptosis is a form of apoptosis that occurs in response to internal cellular stresses such as DNA damage, hypoxia, metabolic stress, withdrawal of growth factors, replicative stress, and microtubular/mitotic defects (169,170). The initiating step of intrinsic apoptosis is mitochondrial outer membrane permeabilization (MOMP). Members of the BCL-2 family of proteins regulate this fundamental step of intrinsic apoptosis (172). In response to apoptotic signals, BAX and BAK, which are pro-apoptotic effectors of the BCL-2 family of proteins, induce MOMP by oligimerizing and forming pores on the outer mitochondrial membrane. Anti-apoptotic members of the BCL-2 family, such as BCL-2, BCL-xL, MCL-1, and BCL-W, antagonize the function of BAX/BAK by directly binding to BAX/BAK and preventing their oligimerization (168). Anti-apoptotic BCL-2 family members are counteracted by pro-apoptotic BCL-2 family members, such BIM, PUMA, BAD, which complex with anti-apoptotic BCL-2 proteins and free BAX/BAK (168). Pro-apoptotic members, such as BIM, BID, and PUMA, can also directly activate BAX/BAK and promote their oligimerization (169).

Once a pore is formed by BAX/BAK on the outer mitochondrial membrane, cytochrome c and second mitochondria-derived activator of caspases (SMAC) are released from the mitochondria into the cytosol. Once in the cytosol, cytochrome c complexes with adaptor protein apoptotic protease-activating factor 1 (APAF-1), pro-caspase-9, and ATP (172). This complex, referred to as the apoptosome, results in activation of caspase-9 (172). Activated caspase-9 then subsequently cleaves and activates the executioner caspases-3/7. In addition, upon release from the mitochondria SMAC promotes apoptosis by inhibiting X-linked inhibitor of apoptosis protein (XIAP), which is an inhibitor of caspase-3, -7, and -9.
Figure 5: Intrinsic and extrinsic apoptotic pathways
Intrinsic or mitochondrial-mediated apoptosis is mediated by BAX/BAK oligimerization at the outer mitochondrial membrane (OMM). BAX/BAK form a pore on the OMM, which leads to cytochrome c release and subsequent caspase-9 activation. Caspase-9 then activates “executioner” caspases-3/7 which cleave a variety of cellular substrates that ultimately induce apoptosis. BAX/BAK activation is modulated by expression of anti-apoptotic and pro-apoptotic BCL-2 family members. During extrinsic apoptosis, death ligands bind to corresponding death receptors, which results in death receptor trimerization and recruitment of caspase-8. Once bound to death receptors in a complex called the DISC, caspase-8 is activated and subsequently activates downstream executioner caspases-3/7. Additionally, caspase-8 can activate intrinsic apoptotic by cleaving BID, which can translocate to the mitochondria and directly activate BAX/BAK and/or inhibit anti-apoptotic BCL-2 proteins. Extrinsic apoptosis is antagonized by cFLIP which is a negative regulator of caspase-8 activation at the DISC.
Extrinsic apoptosis is a form of apoptosis that involves activation of death receptors (TNFR1, FAS, DR4/5) via binding of cognate death ligands (FASL, TNF-α, TRAIL). Following binding death ligands, death receptors trimerize, which allows for formation of the essential mediator of extrinsic apoptosis, the death-inducing signaling complex (DISC) (173). At the DISC, Fas associated via death domain (FADD) binds to the trimerized death receptor via homotypic interactions between death domain (DD) regions of both proteins. Once bound to a death receptor, FADD undergoes a conformational change which exposes its death effector domain (DED). Procaspase-8 has two DED on its N-terminus. DED1 of procaspase-8 binds to the DED of TRADD, while DED2 of procaspase-8 interactions with DED1 of another procaspase-8 molecule (173-175). This DED interaction between procaspase-8 molecules results in oligimerization and procaspase-8 filament formation. After approximately six procaspase-8 molecules form a filament, procaspase-8 undergoes autoproteolytic cleavage, which results in activation of caspase-8 (173,175). In type I cells, activation of caspase-8 is sufficient to activate executioner caspases-3/7 and induce apoptosis. In type II cells, the presence of XIAP prevents caspase-8 from inducing apoptosis. In these cells in order to induce apoptosis, caspase-8 must cleave and activate the pro-apoptotic BCL-2 protein, BID, which results in BID translocation to the mitochondria and activation of mitochondria-mediated apoptosis.

FLICE-like inhibitory protein (cFLIP) is the major modulator of extrinsic apoptosis. There are two functional isoforms of cFLIP: cFLIP short (cFLIPs) and cFLIP long (cFLIPL). cFLIPs is a truncated form of procaspase-8, which contains two DEDs and a truncated C-terminal domain (173). The short isoform of cFLIP blocks extrinsic apoptosis by blocking procaspase-8 filament formation (173). cFLIPL resembles full length procaspase-8, however, lacks autocatalytic function of procaspase-8. Interestingly, the function of cFLIPL is complex, as the
levels of cFLIP_L determine its regulation of apoptosis. At low levels, cFLIP_L promotes apoptosis by enhancing caspase-8 activation at the DISC, while at high levels cFLIP_L inhibits apoptosis by reducing procaspase-8 activity at the DISC (173). The exact mechanism by which cFLIP_L has these dichotomous function is not understood. The current paradigm is that at low levels, cFLIP_L heterodimerizes with procaspase-8 and promotes its activation, while at higher levels, cFLIP_L blocks procaspase-8 filament formation (173).

1.2.2 Aberrations in apoptotic pathways and proteins in cancer

Evasion of apoptosis despite high levels of both internal and external stress signaling is a hallmark of malignant cells (171). The main mechanisms by which cancer cells evade apoptosis is via modulating expression of apoptotic proteins within both the intrinsic and extrinsic pathway. Within the intrinsic apoptotic pathway, cancer cells evade apoptosis by increasing the expression of anti-apoptotic BCL-2 family proteins. Approximately one half of all hematological and solid malignancies, including lung cancers, overexpress BCL-2 (176). Additionally, many solid tumors, including lung and breast cancers, have gene amplification of BCL-xL or MCL-1 (172). Increased expression of these proteins anti-apoptotic BCL-2 family members is associated with therapeutic resistance, poor prognosis, and tumor recurrence (172).

Another strategy employed by cancer cells to evade apoptosis is to decrease the expression of pro-apoptotic BCL-2 family members. One of the main mechanism by which cancer cells decrease pro-apoptotic protein expression is via genetic loss or mutation of TP53, which occurs in approximately 50% of cancers (172). Numerous pro-apoptotic genes, including BAX, PUMA, NOXA, and APAF-1, are upregulated by p53 (172). Subsequently, loss of p53 increases the threshold for mitochondrial mediated-apoptosis (172). Pro-apoptotic BCL-2
proteins are also subject to post-translational regulation. In cancers, these proteins are frequently phosphorylated and/or ubiquitinated which results in their inactivation and/or degradation. An example of this post-translational regulation of pro-apoptotic BCL-2 proteins is extracellular signal-regulated kinase (ERK)-mediated phosphorylation of BIM. This phosphorylation event leads to downregulation of BIM expression by increasing its ubiquitination and proteasomal degradation (172,177).

In addition to evading mitochondrial-mediated cell death, cancer cells frequently suppress death receptor signaling. One common mechanism that cancers evade extrinsic apoptosis is via mutations in death receptors. Several malignancies, including NSCLC, have mutations the death domains of FAS and DR5, which results in an impaired ability to activate caspase-8 at the DISC (178). Additionally, decoy death receptors are frequently overexpressed and/or amplified in cancers (178,179). These decoy receptors share homology with functional death receptors but typically lack a functional death domain, which allows decoy receptors to bind ligand without activating caspase-8 (180). The ability of cancer cells to undergo extrinsic apoptosis is influenced by the relative expression of functional death receptor versus decoy receptor.

The main regulator of death receptor signaling, cFLIP, is frequently overexpressed in solid tumors and v-FLIPs serves as a viral oncogene in herpesviruses (179,181). cFLIP overexpression, both cFLIPs and cFLIPL, is associated with resistance to TRAIL-based therapies and chemotherapy as well as poor clinical prognosis (179,182-184). Another important mechanism by which cancers evade extrinsic apoptosis is via mutations in caspase-8 and epigenetic silencing of caspase-8 (179). Mutations in caspase-8 have been shown to not only
suppress death receptor-mediated cell death but can also confer therapeutic resistance and enhance tumorigenesis (185).

1.2.3 Apoptosis and response to targeted therapy in lung cancer

Apoptosis has been shown to the main mechanism by which targeted therapies lead to tumor regression. (186). Robust apoptotic responses to targeted therapies have been linked to improved clinical outcomes (186). The main mediator of apoptosis in response to targeted therapies in oncogene-driven NSCLC, including MET amplified, EGFR mutant, and EML4-ALK positive NSCLC, and other oncogene-driven cancers is the pro-apoptotic protein, BIM (186-191). Previous studies have demonstrated that BIM expression predicts response to targeted therapies in EGFR mutant NSCLC and HER amplified breast cancers (186). Additionally, those EGFR mutant NSCLC patients with high levels of BCL2L11 (gene encoding BIM) mRNA expression have increased response rates and PFS (186). Interestingly, a subset of patients have a polymorphism in the BCL2L11 gene, which results in preferential splicing of exon 3 over exon 4, which contains the functional BH-3 domain (192). This splicing results increased expression of a non-functional BIM protein (192). The BCL2L11 polymorphism have been associated with decreased response, decreased PFS, and de-novo resistance to EGFR and ALK TKIs in EGFR mutant and ALK-driven NSCLC (Figure 4) (135,192,193).

Other BCL2- family members have been implicated in response to targeted therapies. The pro-apoptotic protein, PUMA, has been shown to be required for apoptotic responses to targeted therapies in oncogene-driven NSCLC and breast cancer (194). A previous study has demonstrated an impaired response to erlotinib in a Puma deficient mouse model of Egfr mutant NSCLC (194). Additionally, the anti-apoptotic protein, MCL-1, has been implicated in resistance
to targeted therapies in NSCLC. Previous studies have demonstrated that the EGFR TKIs, erlotinib and osimertinib, require MCL-1 degradation in order to induce apoptosis (191,195). Impaired MCL-1 degradation in these models is associated with resistance to EGFR TKIs (191,195).

1.3 TWIST1

TWIST1 is a basic-helix-loop-helix (bHLH) transcription factor that binds to canonical E-box response elements and regulates the expression of numerous target genes (196-198). Depending on the target gene, TWIST1 can activate gene transcription via recruiting coactivators such as p300 or inhibit gene transcription via inhibiting acetyl-transferases or recruiting histone deacetylases (198,199). TWIST1 expression is essential for proper development and organogenesis. As TWIST1 is rarely expressed post-natally, its physiological function in adults is not well understood (200,201). However, TWIST1 expression is frequently reactivated in cancers. TWIST1 promotes tumorigenesis by inducing EMT, invasion, and metastasis. Additionally, TWIST1 overexpression can lead to suppression of the failsafe programs of senescence and apoptosis. Given its pleotropic role in cancer and its restricted expression post-natally, TWIST1 is a potential therapeutic target in cancer.

1.3.1 TWIST1 and development

*Twist1* was first identified in *Drosophila* as a gene required for ventral furrow development (198,202). During *Drosophila* development, Twist1 is highly expressed in cells of the mesoderm
in early development and is essential for mesodermal specification and differentiation into distinct tissue types (203). Lack of Twist1 expression in *Drosophila* results in abnormal development (lack of a mesoderm and abnormal gastrulation) and death before completion of embryogenesis (203,204).

Similar to its function in *Drosophila*, Twist1 expression is essential for mesoderm-derived tissue differentiation in mice. Unlike *Drosophila* lacking *Twist1* expression, *Twist1*−/− mice undergo normal gastrulation, but die at E10.5-11 due to lack of closure of the neural tube and marked defects in the cranial mesoderm, branchial arches, facial primordium, and limb bud (198). These defects suggest that Twist1 in vertebrates functions after mesodermal specification but remains important for mesodermal differentiation (198). Importantly, Twist1 is not required postnatally as mice with conditional *Twist1* knockout postnatally do not exhibit a phenotype (205).

Interestingly, TWIST1 can form both homodimers and heterodimers with the E2A proteins or HAND2. During development, Twist1 homodimers display distinct functions and often antagonist functions when compared to Twist1 heterodimers (198,206,207). The levels of Twist1 homodimers versus heterodimers are critically important in proper limb development and cranial suture formation and closure (198,206,207). The formation of Twist1 homodimers versus heterodimers is determined by the expression levels of other bHLH transcription factors and inhibitor helix loop helix proteins, such as the Id proteins (208). For example, expression of Id proteins, which resemble bHLH transcription factors without a functional DNA binding domain, promotes formation of Twist1 homodimers as the Id proteins avidly bind and sequester the E2A proteins (208). In addition, phosphorylation of Twist1 can influence the composition of Twist1 dimers (208). Specially, phosphorylation of Twist1 at threonine 125 and serine 127 favors the
formation of Twist1 homodimers and reduces formation of Twist1-E2A and Twist1-Hand2 heterodimers (208,209).

Twist1 haploinsufficiency in mice does not result in lethality, however, results in marked craniofacial abnormalities and polydactyl (198). In humans, TWIST1 mutations lead to Saethre-Chotzen syndrome, which is characterized by craniofacial and limb defects similar to those found in Twist1 haploinsufficient mice (198). Twist1 expression maintains chondrocyte and osteoblasts in an immature state. Twist1 haploinsufficiency in mice or TWIST1 mutations in humans results in premature osteoblastic differentiation and close of sutures (198). This premature osteoblastic differentiation has also been tied to alterations in Twist1 homodimer and Twist1-E2A heterodimer formation (198).

1.3.2 Regulation of TWIST1 expression

TWIST1 expression in adult humans is restricted to precursor cells in mesodermal tissues such as the heart, skeletal muscle, and placental (198,210). While the physiological role of TWIST1 in adult humans is not well understood, previous studies have demonstrated that TWIST1 is expressed in white and brown adipose tissue and may play a role in adaptive thermogenesis and energy homeostasis (198,200). As mentioned in Section 1.3, TWIST1 is frequently overexpressed in cancers including carcinomas, sarcomas, melanomas, and neuroblastomas (198). While TWIST1 overexpression via gene amplification is seen in approximately 20% of osteosarcomas, in most cancers it is likely that TWIST1 overexpression is the result of a confluence of aberrations in multiple signaling pathways (211,212). In both physiologic and pathologic settings, TWIST1 is regulated both at the transcriptional and post-transcriptional levels.
1.3.2.1 Transcriptional control of TWIST1

TWIST1 is regulated on the transcriptional level by a number of different signaling pathways and transcription factors. These pathways play a role in both the physiologic and pathologic transcriptional regulation of TWIST1. Firstly, previous studies have demonstrated that in the setting of hypoxia and HIF-1α stabilization, TWIST1 levels are increased (198). HIF-1α was found to upregulate TWIST1 transcription by directly binding to a hypoxia-response element in the TWIST1 promoter region (198). STAT3 has also been shown to directly upregulate TWIST1 transcription via direct binding of the TWIST1 promoter (213,214). Interestingly, a previous study has demonstrated that in addition to direct upregulation of TWIST1, STAT3 can indirectly upregulate TWIST1 mRNA via increasing HIF-1α stabilization (215). Furthermore, TWIST1 has been identified as direct target gene of NF-κB (213). In the setting of inflammation, specifically TNF-α-mediated inflammation, TWIST1 expression is induced in a NF-κB-dependent manner (213,216). However, TWIST1 has anti-inflammatory effects as it negatively regulates NF-κB activity by directly binding to RelA and inhibiting its ability to active pro-inflammatory target genes (213,217). Lastly, the RAS and TGF-β signaling pathways have been shown to directly upregulate TWIST1 expression via upregulation of the downstream transcription factors, Msh homeobox protein (MSX2) and high mobility group A2 (HMGA2), respectively (213,218,219). Interestingly, the promoter of TWIST1 has been found to be highly methylated in some cancers. However, numerous studies have demonstrated that TWIST1 promoter methylation does not correlate with TWIST1 mRNA or protein expression (198,220,221).
Figure 6: Illustration of the TWIST1 protein and key domains
TWIST1 function and stability is regulated by multiple post-translational modifications such as phosphorylation, ubiquitination, and acetylation. TWIST1 is phosphorylated by casein kinase 2 (CK2), AKT, and MAPKs (ERK1/2, JNK, and p38) at key residues (red) that regulate both TWIST1 function and stability. The TWIST1 box region is required not only for TWIST1 target gene regulation and interaction with other proteins such as p53 but also TWIST1 polyubiquitination and proteasomal degradation. TWIST1 is also regulated by polyubiquitination and acetylation at certain lysine residues (purple). K175, K137, K76, K77, and K73 have all been implicated in TWIST1 polyubiquitination, while K76 and K73 are acetylated. NLS=Nuclear Localization Signal, CBP=CREB binding protein.

1.3.2.2 Post-transcriptional control of TWIST1
Post-transcriptional control of TWIST1 is critically important for regulation of TWIST1 expression and function. One of the main post-translational modifications that effects TWIST1 expression and function is phosphorylation. Previous studies have demonstrated that multiple mitogen activated protein kinases (MAPKs), including p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) can increase TWIST1 protein accumulation (203,213). MAPKs phosphorylate TWIST1 on serine 68 (S68), which increases TWIST1 by preventing TWIST1 ubiquitination and proteasomal degradation (Figure 6) (203,213). This phosphorylation event is required for TWIST1-mediated invasion and EMT in the setting of RAS activation and TGF-β/TGF-β receptor signaling (203,213). Similarly, casein kinase 2 (CK2) phosphorylation of TWIST1 on serine 18 and 20 results in increased protein stability and increased TWIST1-mediated motility (Figure 6) (213). Additionally, TWIST1 is phosphorylated...
on serine 42 (S42) by AKT/protein kinase B (PKB) (Figure 6) (222). This phosphorylation event has been shown to be required for TWIST1-mediated metastasis in breast cancer models (222). Interestingly, studies have demonstrated that different isoforms of AKT have differential effects on TWIST1 stability and activity (213,223). AKT1 specifically has been shown to negatively regulate TWIST1 expression and EMT. AKT1/PKB phosphorylates TWIST1 on S42, T121, and S123, resulting in increased TrCP-ß-mediated ubiquitination and proteasomal degradation of TWIST1 (Figure 6) (213,223). However, these negative regulatory effects are not seen with AKT2/3 (213,223). Beyond TrCP-ß, additional other E3 ligases, such as F-box and leucine-rich repeat protein 14 (FBXL14), have been shown to negatively regulate TWIST1 expression (224). A previous study demonstrated the small molecule imipramine blue, can decrease TWIST1 expression by increasing FBXL14-mediated poly-ubiquitination of TWIST1 (224).

Specific domains of TWIST1 have been implicated in polyubiquitination and proteasomal degradation of TWIST1. The TWIST1 box is a domain of TWIST1 essential for its function in development and tumorigenesis, as it is required for target gene regulation and binding of other transcription factors such as Runx2 and p53 (Figure 6) (225-227). Despite the absence of lysines in the TWIST1 box, it is required for polyubiquitination and degradation of TWIST1 (228,229). Outside of the TWIST1 box, lysine 175 (K175) has been shown to be essential for TWIST1 polyubiquitination, as point mutations in K175 increase TWIST1 stability and inhibit ubiquitination (Figure 6) (228). Other lysines such K73, 76, 77, and K137 have been implicated in polyubiquitination and stability of TWIST1 (Figure 6) (228).

A previous report has demonstrated that TWIST1 acetylation may be required for target gene induction. In basal-like breast cancer (BLBC), Tip60-mediated diacetylation of TWIST1 at lysines 73 and 76 was required for induction of WNT5A (Figure 6) (213,230). Diacetylated
TWIST1 binds to the bromodomain and extra terminal domain (BET) family member, BRD4 (213,230). The TWIST1-BRD4 complex binds to acetylated histones and subsequently recruits P-TEFb/RNA-POL II to the promoter of \textit{WNT5A} (213,230). Disruption of TWIST1 acetylation in BLBC prevents \textit{WNT5A} activation and suppresses EMT and invasion (213,230).

Independent of its post-translational modification, one of the most important factors in determining TWIST1 stability is expression of the helix-loop-helix ID proteins, which lack the ability to bind DNA but can avidly bind and sequester the E2A proteins, E12/47 (198,203). Studies have demonstrated that the TWIST1-E2A heterodimer is more stable than the TWIST1-TWIST1 homodimer (231). Increased expression of ID proteins can result in decreased TWIST1 stability by promoting TWIST1 homodimerization (231,232). In addition to the difference in stability between TWIST1 homo- and heterodimer, the different TWIST1 dimers induce distinct transcriptional target genes and distinct phenotypes (198,203).

1.3.3 TWIST1 and cancer

TWIST1 is overexpressed in a variety of cancers including breast, colon, pancreatic, prostate, head and neck, melanoma, and lung cancers (198). Overexpression of TWIST1 is associated with aggressive, high grade cancers, increased risk of metastasis, tumor recurrence and poor patient prognosis (213). We and others have demonstrated that TWIST1 is overexpressed in a significant fraction of NSCLC (198,233). Given its role as a pleiotropic gene regulator, TWIST1 mediates multiple phenotypes that promote tumorigenesis such as EMT, metastasis, and cancer stemness (198,213). Independent of its ability to induce EMT, TWIST1 also suppresses the failsafe programs of oncogene-induced senescence and apoptosis, a critical step in tumor progression.
(234). In addition to promoting tumorigenesis, TWIST1 overexpression confers chemoresistance in many cancer types (213).

1.3.3.1 EMT

As mentioned in Section 1.1.3.3, EMT is a transdifferentiation process in which epithelial cells adopt a mesenchymal phenotype, loose cell-cell contacts, and polarity (156,157). Additionally, EMT is associated with invasion, migration, and cancer cell metastasis (156,157). As a EMT-transcription factor, TWIST1 activates a transcriptional network that leads to EMT changes. Previous studies have demonstrated that E-cadherin is a main mediator of epithelial cell phenotype and loss of E-cadherin expression is a pivotal event in the process of EMT (156,157). One mechanism by which TWIST1 induces EMT is via direct repression of E-cadherin expression (213,235). TWIST1 directly binds to E-boxes in the promoter of CDH1 (E-cadherin gene) and represses transcriptional activity (213,235). TWIST1 can also indirectly inhibit E-cadherin expression by directly upregulating other EMT-transcription factors that repress CDH1 promoter activity, such as SNAI2 (236). Additionally, TWIST1 has been shown to upregulate mesenchymal genes such as CDH2 (gene encoding N-cadherin) (237). TWIST1 binds to an E-box in the CDH2 promoter and increases mRNA CHD2 expression (237).

Numerous studies have demonstrated that TWIST1-induced EMT is associated with its ability to promote metastasis. An early study investigating the role of Twist1 and metastasis demonstrated that expression of Twist1 decreased E-cadherin expression, increased expression of mesenchymal genes, and increased breast cancer cell motility (238). While knockout of Twist1 in breast cancer cells suppressed their ability to form lung metastasis without affecting primary tumor growth (238). Additional studies in lung and head and neck cancers, demonstrated that knockdown of TWIST1 reversed EMT and suppressed metastasis (239). In patients,
TWIST1 expression is associated with EMT and distant metastasis (213). The pro-metastatic function of TWIST1 may be connected with its ability to promote invadopodia formation, migration, and invasion (213). Additionally, TWIST1-induced EMT is associated with acquisition of stem-cell like properties in cancer cells. TWIST1 confers stem-cell like properties by directly upregulating BMI-1, a polycomb-group protein that promotes EMT and stemness (213,240). However, other studies have demonstrated that TWIST1 expression can confer stem-cell like properties independently of EMT (213). Additional studies are needed to determine whether TWIST1-induced EMT is required for TWIST1-mediated phenotypes or is simply a marker of TWIST1 expression.

1.3.3.2 Apoptosis

TWIST1 was initially identified as an oncogene that could suppress MYC-induced apoptosis (198,241). One main mechanism by which TWIST1 suppresses apoptosis is via direct and indirect inhibition of p53. Initial studies revealed that the N-terminus of TWIST1 can directly bind to the C-terminus of p53 (227,242). This interaction inhibits not only p53 DNA binding but also key post-translational modifications of p53 important for p53 stability (227). TWIST1 expression also enhances MDM2-mediated degradation of p53 (227,242). Interestingly, the p53-TWIST1 interaction inhibits both proteins from activating known target genes (242). Other studies suggest that TWIST1 can inhibit p53 through indirect mechanisms. TWIST1 can suppress transcription of TP53, by directly binding and inhibiting a p53 transactivator, HOXA5 (213,243). TWIST1 also decreases transcription of TP53 by downregulation of a p53-activator, p14ARF (213,244). Additionally, TWIST1 can decrease p53 access to target genes by binding and inactivating histone acetyltransferase p300, which is required for opening of chromatin at p53
target genes (245). These mechanisms of indirect inhibition of p53 have been linked to the ability of TWIST1 to suppress DNA damage-induced apoptosis (246).

TWIST1 can also suppress apoptosis independent of p53. One p53-independent mechanism includes TWIST1 modulating the expression of BCL-2 family members. In NSCLC cell lines, inhibition of TWIST1 results in decreased MCL-1 protein expression (247). Additionally, TWIST1 expression can also decrease BAX expression and increase the BCL-2/BAX ratio (198). In oncogene-driver defined NSCLC cell lines, we have demonstrated that inhibition of TWIST1 results in apoptosis in p53 mutant NSCLC cell lines, suggesting that TWIST1 suppresses apoptosis in NSCLC independently of p53 (234). However, the mechanism(s) by which TWIST1 suppresses apoptosis and modulates expression of BCL-2 family members remains poorly elucidated.

1.3.3.3 Senescence

A known barrier to oncogenic transformation is the failsafe program of oncogene-induced senescence (OIS), which is a form of irreversible cell arrest characterized by a flattened and enlarged cell body, condensed chromatin, and senescence-associated β-galactosidase activity (234). Oncogenic activation in early lesions can result in OIS and in order to progress into malignant lesions, pre-malignant lesions must overcome OIS (234). Activation of the p53 and/or RB pathways can lead to induction of OIS. TWIST1 has been shown to inhibit OIS in many cancers including breast, prostate, and lung cancers (198). In breast cancers, TWIST1 expression suppresses OIS following RAS and ERBB2 activation (248,249). TWIST1 suppresses OIS in breast cancer by inhibiting transcriptional activation of p21\(^{WAF1}\) and p16\(^{INK4A}\) and in prostate cancer via inhibition of p14\(^{ARF}\) (244,249). In NSCLC, TWIST1 cooperates with mutant Kras in murine models of lung cancer by suppressing OIS (233). Genetic inhibition of TWIST1 in
oncogene driver-defined NSCLC including those tumors with \textit{KRAS} mutations, \textit{MET} amplification/mutants, and \textit{EGFR} mutations, results in OIS (234). Interestingly, in NSCLC, OIS following genetic silencing of \textit{TWIST1} does not require p53 and/or RB expression, suggesting that TWIST1 regulates additional mediators of OIS outside the p53 and Rb-pathway (234).

1.3.3.4 Therapeutic resistance

Systemic chemotherapies remain an important treatment modality for cancers, especially in the advanced setting. However, chemoresistance remains a major barrier to long-term efficacy of chemotherapy. TWIST1 has been identified as a mediator of chemoresistance in solid tumors including lung, breast, and prostate cancers (213). Given its role as a pleiotropic gene regulator, TWIST1 can mediate chemoresistance through a variety of mechanisms (198).

One mechanism by which TWIST1 mediates chemoresistance is by increasing expression of transport proteins. TWIST1 can confer multi-drug resistance (MDR) to chemotherapies by directly upregulating ATP binding cassette transporters (ABC transporters), which directly efflux a variety of chemotherapeutic agents (213,250,251). In colon cancer cells, TWIST1 mediates chemoresistance by directly upregulating the expression of \textit{ABCB1} and \textit{ABCC1} (251). In breast cancer, TWIST1 increases promoter activity and expression of \textit{ABCC4} and \textit{ABCC5} (250). TWIST1 also mediates chemoresistance in breast, bladder, and colon cancers by upregulating the ABC transporter, P-glycoprotein (P-gp) (213). Multiple pre-clinical studies have demonstrated that targeting TWIST1 can reverse MDR by decreasing the expression of ABC transporters (213).

Additional mechanisms of TWIST1-mediated chemoresistance involve increasing expression of proteins within oncogenic signaling pathways and/or modulating apoptotic
proteins. In breast cancer, TWIST1 overexpression confers paclitaxel resistance by increasing AKT2 expression (252). TWIST1 binds to E-box binding sites within the AKT2 promoter and directly upregulates AKT2 expression (252). In head and neck cancer, TWIST1 mediates chemoresistance by directly increasing Jagged1 expression and activating Notch signaling (253). Jagged1/Notch signaling increases KLF4 activity, which confers chemoresistance by inducing a stem-cell like phenotype (253). TWIST1 is also a key mediator of NF-κB-mediated chemoresistance in prostate cancer (254). NF-κB directly upregulates TWIST1 in response to chemotherapy (254). In prostate cancer cells, TWIST1 suppresses chemotherapy-induced apoptosis by suppressing inhibitory phosphorylation of BCL-2 (254).

TWIST1 has also been linked to chemoresistance to SCLC and NSCLC (213,255). In NSCLC, TWIST1 mediates cisplatin resistance through multiple mechanisms. Inhibition of TWIST1 in NSCLC cell lines resistant to cisplatin, restored cisplatin sensitivity by decreasing MCL-1 expression by increasing AMP-activated protein kinases (AMPK)-mediated inhibition of mTOR and ribosome protein S6 kinase 1 (S6K1) (247). Another study demonstrated that inhibition of TWIST1 increases cisplatin sensitivity via increasing the BCL-2/BAX ratio and mitochondrial-mediated apoptosis (198). Recent studies have demonstrated that EMT-transcription factors including ZEB1, SNAI2, and TWIST1 may lead to resistance to targeted therapies in EGFR mutant NSCLC (160,162-164). Overall, these previous studies suggest that TWIST1 may mediate therapeutic resistance to multiple modalities of systemic therapies in lung cancer.
2.0 IDENTIFICATION OF A FIRST-IN-CLASS TWIST1 INHIBITOR WITH ACTIVITY IN ONCOGENE-DRIVEN LUNG CANCER

2.1 ABSTRACT

TWIST1, an epithelial-mesenchymal transition (EMT) transcription factor, is critical for oncogene-driven non-small cell lung cancer (NSCLC) tumorigenesis. Given the potential of TWIST1 as a therapeutic target, a chemical-bioinformatic approach using connectivity mapping (CMAP) analysis was used to identify TWIST1 inhibitors. Characterization of the top ranked candidates from the unbiased screen revealed that harmine, a harmala alkaloid, inhibited multiple TWIST1 functions including single-cell dissemination, suppression of normal branching in 3D epithelial culture, and proliferation of oncogene driver-defined NSCLC cells. Harmine treatment phenocopied genetic loss of TWIST1 by inducing oncogene-induced senescence or apoptosis. Mechanistic investigation revealed that harmine targeted the TWIST1 pathway through its promotion of TWIST1 protein degradation. As dimerization is critical for TWIST1 function and stability, the effect of harmine on specific TWIST1 dimers was examined. TWIST1 and its dimer partners, the E2A proteins, which were found to be required for TWIST1-mediated functions, regulated the stability of the other heterodimeric partner post-translationally. Harmine preferentially promoted degradation of the TWIST1-E2A heterodimer compared to the TWIST1-TWIST1 homodimer and targeting the TWIST1-E2A heterodimer was required for harmine
cytotoxicity. Finally, harmine had activity in both transgenic and patient-derived xenograft (PDX) mouse models of KRAS mutant NSCLC. These studies identified harmine as a first-in-class TWIST1 inhibitor with marked antitumor activity in oncogene-driven NSCLC including EGFR mutant, KRAS mutant and MET altered NSCLC.

**IMPLICATIONS:** TWIST1 is required for oncogene-driven NSCLC tumorigenesis and EMT, thus harmine and its analogues/derivatives represent a novel therapeutic strategy to treat oncogene-driven NSCLC as well as other solid tumor malignancies.

**Contributors to study:** Zachary A. Yochum, 1-2*, Jessica Cades, 3-5*, Lucia Mazzacurati, 2, Neil M. Neumann, 6, Susheel K. Khetarpal, 2, Suman Chatterjee, 2, Hailun Wang, 4, Myriam A. Attar, 2, Eric H.-B. Huang, 2, Sarah N. Chatley, 2#, Katriana Nugent, 4, Ashwin Somasundaram, 2, Johnathan A. Engh, 7, Andrew J. Ewald, 6, Yoon-Jae Cho, 8, Charles M. Rudin, 9, Phuoc T. Tran, 4-5, 10, Timothy F. Burns 1-2

1Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA
2Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA.
3Department of Pharmacology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
4Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
5Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
6Department of Cell Biology, Center for Cell Dynamics, Johns Hopkins University School of Medicine, Baltimore, MD.

7Department of Neurological Surgery University of Pittsburgh Medical Center, Pittsburgh, PA

8Division of Pediatric Neurology, Oregon Health & Science University, Portland, OR.

9Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY.

10Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD

This work is published in Molecular Cancer Research:


* -- denotes these authors contributed equally to the work

2.2 INTRODUCTION

As the leading cause of cancer deaths in the U.S. and worldwide, lung cancer remains a major public health problem. Recent advances in classifying non-small cell lung cancer (NSCLC) into molecularly-defined subgroups that respond to targeted therapies have shifted the treatment paradigm in NSCLC from standard chemotherapy to a personalized therapeutic approach. While initial response rates to these targeted therapies are high, resistance is all but inevitable (75,94,256). Additionally, patients with the most frequent molecular driver, mutant KRAS, lack effective targeted therapies (257). New strategies are needed to effectively and durably target oncogene-driven NSCLC.
Epithelial-mesenchymal transition (EMT) is a reversible biological process that allows for the transdifferentiation of epithelial cells to adopt a mesenchymal phenotype, resulting in an increase in motility and a loss of epithelial polarity (156). EMT-transcription factors (EMT-TF) such as the TWIST, SNAIL and ZEB proteins are drivers of the EMT transcriptional program. Expression of EMT-TFs and subsequent induction of EMT is associated with invasion, dissemination, metastasis, suppression of oncogene-induced senescence (OIS) and apoptosis, and promotion of a cancer stem cell phenotype (156,258). Additionally, induction of EMT and expression of EMT-TF have also been implicated in resistance to chemotherapy, radiation and targeted therapies (75,259,260). Developing molecules that can effectively inhibit the activity of EMT-TFs would have significant therapeutic implications given the diverse role of EMT-TFs in tumorigenesis, metastasis and therapeutic resistance.

We previously demonstrated that TWIST1 is required for tumorigenesis in NSCLC characterized by defined oncogenic drivers including \textit{Kras} mutant, \textit{EGFR} mutant and \textit{MET} amplified/mutant tumors (233,234). We have also demonstrated that Twist1 cooperates with mutant \textit{Kras} to induce lung adenocarcinoma \textit{in vivo} and that suppression of Twist1 expression can lead to OIS and oncogene-induced apoptosis (OIA) (233,234). TWIST1 has been shown to promote tumorigenesis in breast and prostate carcinomas through induction of EMT, invasion, and metastasis as well as suppression of OIS and apoptosis (214,238,239,249,252,254,261). While TWIST1 has been implicated in tumorigenesis through its ability to promote EMT and metastasis, we have demonstrated that TWIST1 in oncogene-driven NSCLC functions to primarily suppress OIS and OIA (233,234). Taken together, data from these previous studies suggests that pharmacological inhibition of TWIST1 may be a valuable therapeutic strategy across multiple solid tumors. In the current study, we identified and characterized harmine as the
first pharmacologic inhibitor of TWIST1 with significant antitumor activity in oncogene-driven lung cancer.

2.3 MATERIAL AND METHODS

2.3.1 Cell lines and reagents

All human non-small cell lung cancer cell lines, (A549, H460, H358, H23, H727, H23, Calu-1, Calu-6, PC-9, H1975, H3255, Hcc827, H1650, H1437, H596, H1648, and H1993) and embryonic kidney cell line HEK 293T were obtained from the American Type Culture Collection (ATCC) and grown in media as recommended by ATCC. Cell lines were authenticated using a short tandem repeat (STR) DNA profiling from the cell bank from which they were acquired. Cell lines were tested for mycoplasma every six months using MycoAlert Detection Kit (Lonza). Harmine (286044-1G) and cyclohexamide (C4859) was purchased from Sigma-Aldrich and Q-VD-oPH (A1901) was purchased from ApexBio Technology.

2.3.2 Cell viability assays

For all harmine experiments, NSCLC cell lines were seeded in 96 well plates at an appropriate cell density based on their optimal growth rates. Following a 24-hour incubation, cells were treated with harmine for 24, 48, and 72 hours. For all E2A knockdown and Twist1-E2A harmine rescue experiments, NSCLC cell lines were seeded in 96 well plates at an appropriate cell density and were infected with lentivirus for 24 hours. Following 24 hours of infection, lentivirus
was replaced with normal growth media or media with harmine. Cell viability was assessed at 24 and 48 hours following harmine treatment or at Day 4, 5 and 6 after lentiviral infection. Cell viability was assessed using CellTiter96® Aqueous One Solution Cell Proliferation Assay kit (Promega) or CellTiter-Glo (Promega) according to manufacturer’s protocol. For all viability experiments, experimental treatment groups were performed in quadruplet and experiments were performed at least twice to ensure consistent results. All viability data was normalized to its appropriate non-treated control. IC50 values were calculated using Prism V6 software.

2.3.3 SA-β-galactosidase staining

SA-β-galactosidase staining was performed as previously described utilizing the Senescence β-Galactosidase Staining Kit (Catalogue #9860) from Cell Signaling (234).

2.3.4 Colony formation assay

On day 4 or 6 after infection with the indicated shRNA lentiviruses, cells were plated in 12-well plates at a density of 5,000-10,000 cells/well. On day 12, the cells were stained with crystal violet (0.5% in 95% ethanol) as previously described (234). For all colony forming experiments, experimental treatment groups were performed in triplicate and experiments were repeated at least twice to ensure consistent results.
2.3.5 **Quantitative RT-PCR**

Total RNA was isolated from cells using the QIAprep RNeasy Kit (Qiagen) according to manufacturer’s protocol. Using 1µg of RNA, cDNA was generated using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 34 ng equivalents of cDNA were applied for amplification of the transcripts described below using an Applied Biosystems StepOne RT-PCR system (Perkin Elmer Applied Biosystems) for 40 cycles using the PowerUp™ SYBR® Green Master Mix (Perkin Elmer Applied Biosystems) or TaqMan® Universal PCR Master Mix (Perkin Elmer Applied Biosystems) according to manufacturer’s protocol. Taqman was used for determining baseline *TWIST1* and *TCF3* mRNA levels in Figure 14B, while SYBR Green was used in Figure 16E. Following amplification, data was analyzed using the Applied Biosystems StepOne Real-Time PCR Software (Perkin Elmer Applied Biosystems). For each sample, the RNA levels of genes of interest were standardized using a housekeeping gene (18s) within that sample. The level of the gene of interest was normalized to the expression of that gene from the appropriate comparator sample. Primer list is available in Table 1-2 (Appendix A).

2.3.6 **Immunoblot analysis**

After treatment with harmine or infection with lentivirus, cells were lysed and protein was quantified, prepared, and western blots were performed as previously described (234). Table 3 (Appendix A) contains details of primary antibodies used. The antigen-antibody complexes were visualized by chemiluminescence (ECL and ECL-plus reagent by GE Healthcare). Western blot experiments were performed at least twice unless otherwise stated.
2.3.7 Connectivity MAP analysis

A gene signature after silencing of TWIST1 was generated based on our previous published data (234) and used to query against publically available gene expression profiles for a panel of drugs (http://www.broad.mit.edu/cmap). Connectivity analysis was performed as previously described (262).

2.3.8 3D organoid assay

Generation of the 3D organoid system, activation of TWIST1, and subsequent analysis of dissemination and branching was performed as previously described (263). Mammary organoids were isolated from the previously described, CMV::rtTA;TRE-Twist1 mice (233,263).

2.3.9 FGF2-branching experiments

Generation of the 3D organoid system, treatment with FGF2, and subsequent analysis of mammary epithelial organoid branching was performed as previously described (263).

2.3.10 Lentiviral shRNA and cDNA overexpression experiments

293T cells were seeded (4 × 10⁶ cells) in T-25 flasks and lentiviral particles were generated using a four-plasmid system and infected as according to the TRC Library Production and Performance Protocols, RNAi Consortium, Broad Institute (264), and as previously described (234). A full list
of constructs used is available in Tables 4-6 (Appendix A). The sequence of these constructs and any primers used are available upon request.

2.3.11 Pulse-Chase experiments

For harmine pulse-chase experiments, PC9 TRE3G-TWIST1 cells were treated with doxycycline (500 ng/ml) for 24 hours and subsequently treated with doxycycline (500ng/ml) and harmine (10 µM) or vehicle (DMSO) for an additional 48 hours. Cells were then treated with cyclohexamide (50 µg/ml) and harvested at the indicated time points. For E2A pulse-chase experiments, PC9 TRE3G-TWIST1 and H1975 TRE3G-TWIST1 cells were treated with doxycycline (500 ng/ml) for 24 hours and 72 hours, respectively. Cells were then treated with cyclohexamide (25 µg/ml) and harvested at the indicated time points.

2.3.12 Quantification of caspase-3/7 activity

For quantification of caspase-3/7 activity, NSCLC cells were seeded in T-25 flask at an optimal cell density based on growth rate and treated with harmine or infected with lentivirus (shTCF3 or shScram). After treatment period, cells were harvested and washed once with phosphate buffered saline (PBS). CellEvent® Caspase-3/7 Green Detection Reagent was added to cells at a concentration of 500nM and incubated at 37°C for 25 min. Following incubation, SYTOX™ AADvanced™ stain was added at a concentration of 1 µM and incubated for 5 min. at 37°C. A total of 50,000 events per replicate were analyzed using Accuri C6 Cytometer (BD Biosciences) and corresponding Accuri C6 software.
2.3.13 Luciferase promoter reporter assay

Luciferase promoter reporter assays were performed as previously described (265). Cell extracts were prepared 48 hours after transfection in passive lysis buffer, and the reporter activity was measured using the Dual-Luciferase Reporter Assay System (Promega).

2.3.14 Transgenic Mice

All mice were housed in pathogen free facilities and all experimental procedures were approved by the Institutional Animal Care and Use Committee of The Johns Hopkins University. Inducible Twist1/Kras\textsuperscript{G12D} transgenic mice in the FVB/N inbred background were of the genotype: CCSP-rtTA/tetO-Kras\textsuperscript{G12D}/Twist1-tetO-luc (CRT). All the mice were weaned 3–4 weeks of age and then placed on doxycycline at 4–6 weeks of age. The CRT mice treated had similar levels of tumor burden per CT. Micro-CT imaging and quantification of tumor burden was performed as previously described (233). For \textit{in vivo} experiments, harmine was dissolved in normal saline by heating and sonication. The mice received 10 mg/kg harmine or saline via intraperitoneal injection daily, 5 days a week for 3 weeks.

2.3.15 Patient-derived xenograft experiments

All mice were maintained in pathogen-free animal facilities and experiments were conducted under an approved Institutional Animal Care and Use Committee protocol at the University of Pittsburgh (Pittsburgh, PA). For the PDX experiments, we used a \textit{KRAS} mutant PDX established from the brain metastasis (BM012-15 M3VF) of a patient with \textit{KRAS} mutant (G12C mutation)
lungs. 2 mm² tumor tissues cut with sterile blade were implanted subcutaneously into 6-8 week old Athymic Nude Mice [Crl:NU (Ncr)-F] (Charles Rivers). Once reaching ≥150 mm³, animals were randomized into 2 arms and i.v. dosed with saline, or harmine (10 mg/kg) via intraperitoneal injection daily, 5 days a week for 16 days. Tumor sizes \(\frac{1}{2}(\text{length} \times \text{width}^2)\) were measured by digital caliper twice a week until they reached ~ 2000 mm³. When this size was reached, animals were sacrificed and tumors were collected for further analysis.

### 2.3.16 Histology and immunohistochemistry

Histology and immunohistochemistry and were performed as previously described (266). Primary antibodies were used at the following dilutions: Ki-67 at 1:2000 and cleaved caspase-3 at 1:500.

### 2.3.17 Statistics

Student’s t-test was performed where indicated. For dissemination experiments (Figure 7C-J), data did not follow a normal distribution, therefore non-parametric comparison testing was performed (Kruskal-Wallis). For the PDX experiment, a Student t-test was performed on the finalized tumor volumes between the harmine and vehicle treated groups.
2.4 RESULTS

2.4.1 Identification of novel TWIST1 inhibitors with a Connectivity MAP analysis

Transcription factors, such as TWIST1, have long been considered a potential therapeutic target for cancer, given their essential role in modulating transcriptional networks that drive tumorigenesis. Beyond therapies targeting ligand-activated nuclear receptors, such as selective estrogen receptor modulators (SERMs) targeting the estrogen receptor, effective small molecule therapies that inhibit the majority of transcription factors without ligand binding pockets remain elusive (267). Therefore, the identification of inhibitors of oncogenic EMT-transcription factors would be a significant advance in cancer therapeutics and potentially lead to therapies which would not only inhibit tumor growth but metastatic potential as well. Connectivity mapping (CMAP) is a tool that compares gene signature changes associated with biological manipulation or disease to corresponding changes produced by potential drugs (262). In order to identify potential TWIST1 targeting chemical compounds, we utilized our previously published TWIST1 knockdown expression profile (234) as the query signature for CMAP analysis. CMAP analysis generated a rank list of the 6100 compounds based on statistical correlation between changes in global gene expression signature induced by drug versus that induced by TWIST1 knockdown (Figure 7A, Data Supplement 1). We selected eight of the top thirty ranked compounds based on a review of the literature suggesting that these compounds inhibited pathways important in tumorigenesis or anti-cancer activity. These compounds were evaluated for their respective cytotoxic activity in vitro in KRAS mutant NSCLC cell lines (Figure 7A). Of these compounds, only four demonstrated anti-proliferative effects in NSCLC (Figure 7B). To identify inhibitors of TWIST1 that suppress TWIST1-dependent processes that are independent of proliferation...
such as single-cell dissemination, we utilized our previously published 3D organoid assay with primary breast epithelial cells derived from our doxycycline inducible CMV:rtTA;TRE-Twist1 mouse model (233,263). We have previously shown that expression of Twist1 inhibits normal branching morphogenesis and leads to rapid and widespread dissemination of primary breast epithelial cells from the 3D organoid (Figure 7C) which can be reversed by removing doxycycline from the medium (263). We therefore examined whether selected candidate compounds could inhibit the Twist1-dependent dissemination in this model. Remarkably, all of seven compounds tested resulted in a significant decrease in Twist1-mediated dissemination (Figure 7D-J) compared to the vehicle control (Figure 7C). In this 3D organoid system, FGF2 treatment induces normal branching morphogenesis of primary breast epithelial cells (Figure 8A-C) (263). We next examined the ability of these compounds to restore FGF2-induced branching which we have previously shown is inhibited by Twist1 expression in this model (263). Two compounds, meteneprost and the harmala alkaloid, harmine were able to restore FGF2-induced branching in a dose dependent manner (Figure 7D, 7H) compared to the vehicle control (Figure 7C). Interestingly, three harmine analogues were in the top 80 compounds identified in the CMAP analysis, with two of the compounds being in the top 40 (Data Supplement 1). Previous studies have reported that harmine and its analogues have marked antitumor activity (268-270). While two compounds screened, harmine and meteneprost, inhibited TWIST1-dependent single epithelial cell dissemination and TWIST1-suppresion of epithelial organoid branching (Figure 7D, 7H), harmine was the only compound screened that inhibited growth in lung cancer cell lines as well as the aforementioned TWIST1-dependent functions in our mammary 3D organoid system. Given these factors, we decided to further characterize the biological activities of harmine as a TWIST1 inhibitor.
Figure 7: Connectivity MAP (CMAP) analysis identifies compounds which inhibit NSCLC proliferation, TWIST1-dependent dissemination and TWIST1-suppression of organoid branching.
(A) CMAP Analysis Schematic. A gene signature for TWIST1 knockdown was utilized to query the Connectivity Map (Broad Institute). (B) Chart depicting eight of the top 30 ranked compounds which were selected for further analysis. IC$_{50}$ was determined in two KRAS mutant NSCLC cell lines (A549 and H460) at 72 hours using MTS assays. (C) TWIST1 induction with doxycycline results in profound dissemination of cells and prevents branching (DMSO, upper left panel). Primary Twist1 inducible breast epithelial cells are implanted as organoids in 3D culture. Red arrowheads indicate disseminated cells. (D-J) Candidate compounds inhibit Twist1-induced 3D dissemination and/or restore FGF2-induced branching of primary breast epithelial cells in vitro. Values within the graph indicate the number of organoids quantified per treatment condition. Dissemination data is normalized to the median of each experimental replicate. Error bars, 95% Confidence Intervals. Treatment with small molecules listed at the indicated doses induced statistically significant (Kruskal-Wallis test, P<.05) reductions in dissemination. (D) Branching data is presented as mean of each experimental replicate. See Figure 8A-C for representative images of unbranched versus branched organoids. Error bars, ±SD. Treatment with harmine at the indicated doses induced statistically significant (One-way ANOVA, P<.05) increases in branching. Scale bar, 50µm.
2.4.2 Harmine inhibits growth in oncogene driver-defined NSCLC cell lines and phenocopies loss of TWIST1

Harmine was originally identified as an active β-carbolin alkaloid found in the herb *Peganum harmala* (*P. harmala*), which has long been used in traditional medicine as a sedative and for treating conditions like hypertension and depression (271). Studies investigating the activity of harmine and other active β-carbolins found in *P. harmala* in the nervous system have demonstrated that these compounds inhibit monoamine oxidase-A (271). Additionally, in traditional medicine, *P. harmala* has been used to treat malignancy. Previous studies have demonstrated that harmine has antitumor activity, which has been linked to its ability to inhibit DYRK1A, topoisomerase I, and suppress homologous recombination (272-276). However, the mechanism(s) by which harmine inhibits tumor growth remain poorly described and its activity in lung cancer has not been explored. Here, we first characterized the growth inhibitory effects of
harmine (Figure 9A) across a panel of oncogene driver-defined NSCLC lines which we had previously reported as dependent on TWIST1 expression (234). Similar to genetic silencing of TWIST1, we found harmine treatment to be cytotoxic across the panel of oncogene driver-defined NSCLC lines (KRAS mutant, MET amplified/mutant, and EGFR mutant) (Figure 9B). While harmine was more potent in cell lines with high TWIST1 levels (Figure 9B), harmine also had activity in cell lines with low TWIST1 expression (Figure 10) (277). Additionally, harmine had activity in NSCLC cell lines with primarily epithelial or mesenchymal phenotypes, suggesting that the activity of harmine is independent of EMT status (277-279). We had previously demonstrated that inhibition of TWIST1 leads to oncogene-induced senescence (OIS) in KRAS mutant NSCLC lines (233). Similar to silencing of TWIST1, treatment of the KRAS mutant NSCLC lines A549, H460, and H358 with harmine induced changes characteristic of OIS, including positive Senescence-Associated Beta-galactosidase (SA-β-Gal) staining and induction of p21 and p27 (Figure 9C). We also found that harmine treatment induced OIS in NSCLC cell lines with EGFR and MET mutations (Figure 11A-B). While an increase in SA-β-Gal staining was observed in both EGFR and MET mutant NSCLC cells lines, an increase in p21/p27 expression was only observed in the EGFR mutant cell line. Importantly, we have previously demonstrated that OIS following genetic inhibition of TWIST1 does not require p21 or p27 (234).

We have also previously shown that TWIST1 is required for suppression of OIA in a subset of KRAS mutant lung cancer cells including Calu-6 and H23 (234). We expanded upon these studies and demonstrated that knockdown of TWIST in the MET amplified NSCLC cell line, H1648, results in growth inhibition and in induction of apoptosis (Figure 12A). Of note, H1648 cells have high levels of TWIST1 and therefore may be more dependent on TWIST1 for
survival (Figure 10). Consistent with a TWIST1-suppressive effect, after harmine treatment, we observed a significant induction of apoptosis, in a dose-dependent manner in all three cell lines (Figure 12B, 13A). Of note, in the H1648 cell line, a more robust apoptotic response was observed following harmine treatment as compared to genetic inhibition of TWIST1. Given that rapid apoptosis occurs in this cell line, the increased apoptotic response observed with harmine could be due to the fact that apoptosis was analyzed at an earlier timepoint in the harmine treatment group than the TWIST1 knockdown group. The growth inhibition by harmine in these cells was dependent on apoptosis as co-treatment with the pan caspase inhibitor, Q-VD-oPH, prevented the cytotoxic effects of harmine (Figure 13B). Furthermore, BCL-2 overexpression partially prevented harmine-induced apoptosis, suggesting that the intrinsic apoptotic pathway is required for the growth inhibitory effects of harmine in these lines (Figure 13C).
Figure 9: Harmine inhibits growth through the induction of oncogene-induced senescence (OIS) in oncogene driver-defined NSCLC cell lines

(A) Chemical structure of the harmala alkaloid, harmine. (B) MTS assays demonstrating growth inhibition in the indicated KRAS mutant, EGFR mutant, and MET mutant/amplified NSCLC cells following harmine treatment at 72 hours. Data represent mean ±SD (n=4 technical replicates). (C) UPPER: Senescence-Associated Beta-galactosidase (SA-β-Gal) staining demonstrating that harmine (Har) treatment leads to oncogene-induced senescence (OIS) in KRAS mutant NSCLC cell lines. Cells were treated at the indicated doses for 72 hours and stained 7 days following treatment. Images were obtained with bright field objective at 40X magnification. LOWER: Western blot demonstrating a marked increase in p21 and p27 expression 48 hours after harmine treatment at the indicated doses.
Figure 10: Basal expression levels of TWIST1 in *KRAS* mutant and *MET* amplified/mutant NSCLC cell lines.

Western blot demonstrating baseline levels of TWIST1 in *KRAS* mutant and *MET* altered NSCLC cell lines.
Figure 11: Harmine treatment induces Oncogene-Induced Senescence (OIS) in EGFR and MET mutant NSCLC cell lines

(A) Senescence-Associated Beta-galactosidase (SA-β-Gal) staining demonstrating that harmine treatment leads to OIS in EGFR mutant and MET mutant cell lines, H1650 and H596. Cells were treated with the indicated doses of harmine for 72 hours and stained 7 days following harmine treatment. Images were obtained with bright field objective at 40X magnification.

(B) Western blot demonstrating that harmine treatment leads to increased p27 and/or p21 expression in a cell line specific manner, as induction of p21 and p27 was observed in H1650 cells but not H596 cells. Cells were treated with the indicated doses of harmine for 48 hours.
Figure 12: TWIST1 suppresses oncogene-induced apoptosis in MET amplified NSCLC

(A) Silencing of TWIST1 with two distinct shRNAs resulted in growth inhibition and apoptosis in a MET amplified cell line (H1648) as shown by colony formation assay (UPPER) and western blot (LOWER). H1648 cells were harvested 10 days following lentiviral infection for colony formation assay and 4 days following lentiviral infection for western blot analysis.

(B) Western blot demonstrating an increase in cleaved PARP, a maker of apoptosis, following harmine treatment. H1648 cells were treated with the indicated doses of harmine for 48 hours and harvested for western analysis.
Figure 13: Harmine induces apoptosis in oncogene-driven NSCLC cell lines

A) UPPER: Western blot demonstrating PARP cleavage 48 hours after harmine treatment at the indicated doses of harmine in two KRAS mutant cell lines (Calu-6 and H23). LOWER: Active Caspase 3/7 staining demonstrating the induction of apoptosis after harmine treatment at the indicated doses. Calu-6 cells were treated for 36 hours while H23 cells were treated for 24 hours. Data represent mean ±SD (n=3 biological replicates). **, p<.01, 2-tailed Student’s t-test.

B) UPPER: Western blot demonstrated that co-treatment with pan-caspase inhibitor Q-VD-oPH prevents harmine-induced apoptosis. LOWER: MTS proliferation assay demonstrating that growth inhibition following harmine treatment can be prevented by treatment with Q-VD-oPH, a pan caspase inhibitor. Cells were pre-treated with Q-VD-oPH for 4 hours and were subsequently co-treated with Q-VD-oPH and harmine for 24 hours. Data represent mean ±SD (n=4 technical replicates).

C) UPPER: Western Blot demonstrating that BCL-2 overexpression prevents PARP cleavage 24 hours following harmine treatment at the indicated doses. LOWER: MTS proliferation assay demonstrating that growth inhibition following harmine treatment can be partially prevented by BCL-2 overexpression. Data represent mean ±SD (n=4 technical replicates). *, p<.05, 2-tailed Student’s t-test.
2.4.3 Harmine treatment results in TWIST1 protein degradation

Previous studies have demonstrated that modulation of TWIST1 protein stability is a critical regulatory mechanism of TWIST1 function (231,280-282). To determine whether harmine directly targets TWIST1 or the TWIST1 pathway, we first examined the effect of harmine on TWIST1 protein stability. Harmine treatment reduced the levels of TWIST1 protein in a dose and time dependent manner as shown by western blotting and this was accompanied by a reciprocal induction of p21 (Figure 14A, 15A), a known TWIST1 repressed transcriptional target gene (242,283). The effect of harmine on TWIST1 expression appears to occur through a post-translational mechanism as harmine treatment did not decrease TWIST1 mRNA levels (Figure 14B) but did decrease the half-life of the TWIST1 protein (Figure 14C, Figure 15B).

In addition to harmine, several other harmala alkaloid compounds were identified in our CMAP analysis. To determine if particular structural features of harmala alkaloids were important for the induction of TWIST1 degradation, we selected three related compounds that differed from harmine in key structural positions (Figure 14D, left panel). We were interested in both the 7-methoxy structural moiety which has previously been shown to effect cytotoxicity and neurotoxicity and the saturation level of the pyridine ring, which has been demonstrated to affect the biological activity of beta-carbolines (268-270,284). Of note, harmine and harmaline have a methoxy group, whereas harmol and harmalol have hydroxyl groups at the position R7. Conversely, harmine and harmol contain pyridine rings with three versus two double bonds found in harmaline and harmalol. The compounds (harmine and harmol) which contained pyridine rings with three double bonds exhibited the most cytotoxicity suggesting that this
feature was critical for tumor growth inhibition and TWIST1 degradation (Figure 14D-E). However, the presence of a methoxy or hydroxyl group, at the position R7 did not correlate with increased cytotoxicity and the ability to degrade TWIST1. Notably, the relatively potency of these compound directly correlated with their ability to lead to TWIST1 degradation (Figure 14D-E).
Figure 14: Harmine treatment leads to TWIST1 protein degradation

(A) LEFT: Western blot demonstrating 72 hours of harmine treatment promotes TWIST1 degradation and subsequent oncogene-induced senescence (p27 and/or p21) and apoptosis (Cl-Parp) in a dose-dependent manner in the EGFR mutant NSCLC cell line, PC-9. RIGHT: Western blot demonstrating reduction of exogenous TWIST1 protein expression as well as induction of p21 after 72 hours of harmine treatment in the KRAS mutant NSCLC cell line, H460. (B) Quantitative RT-PCR analysis of TWIST1 and TCF3 mRNA transcripts following 72 hours of harmine treatment in A549 and H460 cells which failed to detect a decrease in mRNA levels of TWIST1 or TCF3. All harmine treatment groups are normalized to untreated group. Data represent mean ±SD (n=3 technical
replicates). (C) Harmine treatment decreases the half-life of TWIST1 protein. Protein concentration was quantified using densitometry and protein half-lives were estimated using linear regression analysis. (D) LEFT: Chemical structures of Harmala Alkaloid compounds identified as potential TWIST1 inhibitors from CMAP analysis. RIGHT: MTS assays demonstrating growth inhibition of a H460 TWIST1 NSCLC cell line in a dose dependent manner following treatment with indicated harmala alkaloids at 72 hours. Data represent mean ±SD (n=4 technical replicates). (E) Western blot demonstrating reduction of exogenous TWIST1 protein expression by harmine and harmol in H460 TWIST1 overexpressing cells 72 hours after treatment with the indicated doses.
Figure 15: Harmine treatment promotes TWIST1 degradation and decreases TWIST1 protein stability

(A) Western blots demonstrating harmine treatment promotes TWIST1 degradation and subsequent oncogene-induced senescence (p27 and/or p21) and apoptosis (Cl-PARP) in a dose and time dependent manner. PC9 TRE3G-TWIST1 cells were treated with doxycycline (500 ng/ml) for 24 hours and subsequently treated with doxycycline and the indicated doses of harmine. Cells were harvested at 24 and 48 hours following harmine treatment. (B) Western blot demonstrating that harmine treatment decreases the half-life of TWIST1 protein. PC9 TRE3G-TWIST1 cells were treated with doxycycline (500 ng/ml) for 24 hours, subsequently treated with doxycycline (500 ng/ml) and harmine (10 µM) or vehicle (DMSO) for an additional 48 hours. Cells were then treated with cyclohexamide (50 mg/ml) and harvested at the indicated time points. (C) Western blot demonstrating that TWIST1 overexpression increases the half-life of the E2A proteins. PC9 TRE3G-TWIST1 cells were treated with doxycycline (500 ng/ml) for 24 hours. Cells were then treated with cyclohexamide (25 µg/ml) and harvested at the indicated time points. (D) TWIST1 overexpression in H1975 TRE3G-TWIST1 cells increases the half-life of E2A proteins. Protein concentration was quantified using densitometry and protein half-lives were estimated using linear regression analysis.
2.4.4 TWIST1 and the E2A proteins reciprocally stabilize each other and harmine leads to degradation of both components of this dimer

The TWIST1 protein forms both homo- and hetero-dimers and its functions are dependent on its respective dimer partner (208). We and others have previously shown that heterodimerization with the proteins encoded by the TCF3 gene, here after referred to as the E2A proteins (E12 and E47), are critical for TWIST1 function in tumorigenesis and EMT (248,265,285) and TWIST1 protein stability in osteoblasts (231). Therefore, we decided to examine the role of the E2A proteins in regulating both TWIST1 protein stability in NSCLC and response to harmine. To examine the effect of modulating the levels of TWIST1 and E2A proteins on the stability of the other dimer partner, we knocked down and overexpressed each of the proteins and examined the effect on the protein level of its dimer partner. Silencing of TCF3 in the Kras mutant NSCLC cell line A549 induced modest downregulation of TWIST1 (Figure 16A) and conversely overexpression of the E12 or E47 induced upregulation of TWIST1 (Figure 16B). In both Kras mutant (A549, H460), MET-amplified (H1648, H1993) NSCLC cell lines, silencing of TWIST1 induced downregulation of E2A proteins (Figure 16C). Conversely, overexpression of TWIST1 in Kras mutant H460 cells and an EGFR mutant NSCLC cell line (PC9) increased E2A protein expression (Figure 16D). To explore the mechanism of TWIST1 regulation of E2A, we analyzed TCF3 mRNA levels following TWIST1 overexpression. We found that in H460 and PC9 cell lines, TWIST1 overexpression does not result in a marked increase in TCF3 mRNA levels, and in fact decreases TCF3 mRNA levels in PC9 cells, suggesting that it is unlikely that TWIST1 regulates TCF3 transcriptionally. Also, we found that TWIST1 overexpression in multiple cell
lines leads to an increase in E2A protein half-life (Figure 15C-D, Figure 16E). These results suggest that TWIST1 regulates expression of the E2A proteins post-translationally.

Given the ability of the E2A proteins and TWIST1 to reciprocally stabilize each other, we examined the effect of harmine on the E2A proteins. Treatment with harmine resulted in a dose-dependent decrease of E2A protein expression in both KRAS mutant and MET-mutant/amplified NSCLC cell lines (Figure 17A). This decrease in E2A protein expression also appears to be post-transcriptional as harmine treatment does not decrease TCF3 RNA levels (Figure 17B). To further characterize the potential role of the E2A proteins in TWIST1-mediated lung tumorigenesis, we silenced TCF3 in KRAS mutant NSCLC cell lines. Silencing of TCF3 also resulted in OIS, phenocopying silencing of TWIST1. Similar to our previously published results (233,234), both growth inhibition in colony formation assays and OIS as evidenced by increased SA-β-Gal staining and p21/p27 levels were observed with silencing of TCF3 (Figure 17B). Of note, an increase in p21 expression was not observed following silencing of TCF3 in A549 cells. Similarly, in A549 cells, we have previously observed that p21 expression is not increased following knockdown of TWIST1. Importantly, we have also demonstrated that OIS following genetic inhibition of TWIST1 does not require p21 expression (234).

As discussed above, TWIST1 is required for suppression of OIA in a subset of lung cancer cells and we wanted to examine whether we could observe a similar phenotype after silencing of TCF3 (234). Genetic silencing of TCF3 in the KRAS mutant cell lines, Calu-6 and H23, resulted in significant growth inhibition and a corresponding increase in apoptosis (Figure 18A-C) phenocopying our previous studies with silencing of TWIST1 (234) and studies above with harmine (Figure 12-13). Furthermore, we demonstrated that the growth inhibition after
silencing of TCF3 was dependent on apoptosis as pre-treatment with the pan caspase inhibitor, Q-VD-oPh rescued cell viability (Figure 18C).
Figure 16: The E2A proteins and TWIST1 reciprocally stabilize each other
(A) Silencing of TCF3 leads to downregulation of TWIST1 in the KRAS mutant NSCLC cell line, A549. Cells were infected with the indicated shRNAs and were harvested for western blot analysis 96 hours following infection. (B) Overexpression of the E2A proteins, E12 or E47 induces upregulation of TWIST1 in 293T cells as well as in KRAS mutant NSCLC cells (A549, H460). 293T cells were harvested 72 hours following transfection. Experiments in A549 and H460 were performed in stable E12 or E47 overexpressing cell lines. (C) Silencing of TWIST1 induces downregulation of E2A proteins in KRAS mutant (A549, H460) as well as in MET amplified (H1648, H1993) NSCLC cell lines. Cells were infected with the indicated shRNAs and were harvested for western blot analysis 96 hours following infection. (D) Overexpression of TWIST1 induces the E2A proteins in KRAS mutant NSCLC cells (H460) and EGFR mutant NSCLC cells (PC-9). H460 cells were harvested once stable cell lines were established. PC9 TRE3G-TWIST1 cells were harvested following 500 ng/ml treatment of doxycycline for 24 hours. (E) LEFT: TWIST1 induction of E2A proteins is not accompanied by a robust upregulation of TCF3 mRNA in KRAS mutant (H460) and EGFR mutant NSCLC cells (PC-9). All TWIST1 overexpressing groups are normalized to untreated group (n=3 technical replicates). Data represent mean ±SD. RIGHT: TWIST1 overexpression increases the half-life of E2A proteins. Protein concentration was quantified using densitometry and protein half-lives were estimated using linear regression analysis.
Figure 17: Harmine leads to degradation of the E2A proteins which are required for suppression of OIS

(A) Western blot demonstrating dose-dependent downregulation of E2A proteins in KRAS mutant (H460, A549 and Calu-6) and MET mutant/amplified (H596 and H1993) NSCLC cell lines following 72 hours of harmine treatment.

(B) UPPER: shRNA silencing of TCF3 in KRAS mutant NSCLC cell lines (A549 and H460) leads to growth inhibition as demonstrated in triplicates of crystal violet staining. MIDDLE/LOWER: shRNA silencing of TCF3 induces OIS as shown by western blot demonstrating a marked increase in p21 and/or p27 expression and positive SA-β-Gal staining (LOWER). For western blotting, cells were infected with the indicated shRNAs for 96 hours and harvested. For SA-β-Gal staining cells were infected with the indicated shRNAs and stained for 10 days following infection. Images were obtained with bright field objective at 40X magnification.
Figure 18: Silencing of E2A induces apoptosis and phenocopies silencing of TWIST1

(A) TCF3 knockdown inhibits growth in KRAS mutant NSCLC cell lines. Calu-6 and H23 were infected with control shRNA (shSCRAM) or shRNA targeting TCF3 (shTCF3 #3, #4) for 6 days before cell viability was measured using Cell-Titer Glo. % Viability is normalized to shScram control. Data represent mean ±SD (n=4 technical replicates). *, p<.05, **, p< .01, 2-tailed Student's t-test.

(B) UPPER: Western blot showing PARP cleavage 72 hours after silencing of TCF3 in Calu-6 cells. LOWER: Active Caspase 3/7 staining demonstrating the induction of apoptosis after TCF3 knockdown in Calu-6 cells. Cells were infected with shSCRAM, shTCF3#3, or shTCF3#4 for 72 hours and stained for active caspase 3/7. Data represent mean ±SD (n=3 biological replicates). **, p<.01, 2-tailed Student’s t-test.

(C) UPPER: Western blot showing PARP cleavage 72 hours after silencing TCF3 in H23 cells. LOWER: Pre-treatment with pan-caspase inhibitor prevents growth inhibition following TCF3 knockdown. H23 cells were pre-treated with Q-VD-oPH for 4 hours and subsequently infected with control shRNA (shSCRAM) or shRNA targeting TCF3 (shTCF3 #3, #4) for 4 days before cell viability was measured using Cell-Titer Glo. % Viability is normalized to shScram control. Data represent mean ±SD (n=4 technical replicates).
2.4.5 The TWIST1/E2A heterodimer is critical for TWIST1 function and therapeutic response to harmine

The exact mechanism of how TWIST1 and E2A interact to promote lung tumorigenesis is unknown; however we propose two potential mechanisms for the cooperation between TWIST1 and the E2A proteins, E12 or E47, to promote their neoplastic phenotypes. In the first scenario (dimerization), the TWIST1-E12 heterodimer is directly required for the transcriptional activity of TWIST1 and induces tumorigenesis (Figure 19A). The second scenario (sequestration) suggests that E12/E47-mediated sequestration of Ids (Inhibitor of DNA-binding proteins) leads to TWIST1 transcriptional activity through allowing increased TWIST1 homodimer formation (Figure 19A). In order to determine which mechanism is important for TWIST1 transcriptional activity, we first performed a luciferase assay utilizing the promoters of SNAI2 and YBX1, known transcriptional targets of TWIST1 (286,287). As expected, increased induction of SNAI2 and YBX1 promoter activity was seen in cells transiently overexpressing Twist1. To determine the transcriptional function of the TWIST1 homo- and heterodimeric proteins, we expressed Twist1 tethered Twist1, Twist1 tethered E12 and Twist1 tethered E47 fusion proteins in these luciferase assays (288,289). The Twist1-E12 and Twist1-E47 had significantly increased transcriptional activity compared to the Twist1-Twist1 homodimer or Twist1 alone (Figure 19B). Since the Twist1-E2A heterodimers appeared to be the most potent inducer of transcription and harmine led to degradation of both TWIST1 and the E2A proteins we examined the relative effect of harmine on stability of the TWIST1 homo and heterodimers. We observed that harmine was most effective against the Twist1-E12 heterodimer following harmine treatment (Figure 19C). Further supporting a role for the TWIST1 heterodimer in TWIST1 function and therapeutic response, overexpression of TWIST1 or the E2A proteins, E12 and
E47, were able to rescue the harmine-induced growth inhibition in the KRAS mutant NSCLC cell lines A549 and H460 (Figure 20A-C). Furthermore, overexpression of the Twist1-E12 heterodimer similarly lead to a rescue of harmine-induced cytotoxicity, while overexpression of the Twist1-Twist1 heterodimer failed to lead to such rescue at most doses of harmine (Figure 19D). Together these data support the model that the E2A proteins are necessary for TWIST1 functions and that degradation of TWIST1-E2A heterodimer is critical for harmine-induced cytotoxicity.
Figure 19: The TWIST1/E2A heterodimer is critical for TWIST1 function and therapeutic response to harmine

(A) Proposed model of potential mechanism(s) of TWIST1/E2A cooperation in tumorigenesis. (B) Luciferase assay showing increased induction of SNAI2 and YBX1 promoter activity in cells transiently overexpressing either Twist1 alone, Twist1-Twist1 homodimer, or Twist1-E12 heterodimer compared to the reporter activity with the vector alone (fold induction = 1) after 48 hours. All luciferase values were normalized to the corresponding renilla luciferase value in each well. Differences were statistically different for each loci for Twist1-E12 or Twist1-E47 versus Twist1 or Twist1-Twist1, ***, p < 0.0005, 2-tailed Student’s t-test. (C) Western blot demonstrating preferential downregulation of the Twist1-E12 heterodimer in A549 KRAS mutant cell line following 48-hour treatment with harmine at the indicated doses. (D) Representative Cell-Titer Glo assay demonstrating that overexpression of Twist1-E12 heterodimer rescues harmine-induced growth inhibition in a KRAS mutant NSCLC cell line (H460), while the Twist1-Twist1 homodimer fails to prevent harmine-induced cytotoxicity. Data represent mean ±SD (n=4 technical replicates). *, p<.05, 2-tailed Student’s t-test.
Figure 20: Overexpression of TWIST1 or its binding partner, E2A, rescues harmine induced growth inhibition

(A) MTS assays demonstrating that constitutively or inducibly (B) overexpressing both E12 and E47 partially rescues harmine induced growth inhibition 24 hours following harmine treatment in KRAS mutant NSCLC cell lines (A549 and H460). % Viability is normalized to untreated control. Data represent mean ±SD (n=4 technical replicates). *, p<.05, 2-tailed Student’s t-test.

(C) Constitutively overexpressing TWIST1 partially rescues harmine induced growth inhibition following 24 hours of harmine treatment. Viability was measured by Cell-Titer Glo assay and percent viability was normalized to untreated control. Data represent mean ±SD (n=4 technical replicates). *, p<.05, 2-tailed Student’s t-test.
2.4.6 Harmine has *in vivo* activity in both transgenic and patient-derived xenograft mouse models of *KRAS* mutant lung cancer

Having observed *in vitro* activity in *KRAS* mutant NSCLC cell lines, we wanted to determine whether harmine would have *in vivo* efficacy in a *Kras*\(^{G12D}/Twist1\) mouse model of autochthonous lung adenocarcinoma. We treated the *CCSP-rtTA/tetO-Kras*\(^{G12D}/Twist1-tetO7-luc\) (CRT) mice, which overexpress mutant Kras and Twist1 predominantly in the type II cells of the mouse lung and form lung adenocarcinoma by 15 weeks (233), with harmine for 3 weeks and measured index lung tumor volumes in mice at baseline and weekly with serial micro-computed tomography (microCT). Micro-CT images, comparing tumor volume at baseline and at the end of treatment, revealed that treatment with harmine decreased tumor volume growth (*Figure 21A*). Of note, the antitumor activity of harmine in our *Kras/Twist1* transgenic was similar to the tumor stasis seen in the same mice following genetic suppression of Twist1 expression as we have previously published (233). Additionally, harmine significantly inhibited tumor growth in a patient-derived xenograft (PDX) mouse model of *KRAS* mutant lung cancer (*Figure 22A*). Treatment of the animals with harmine resulted in no change in body weight (data not shown) and no observable toxicity, which was accessed by changes in appetite, activity, coloration, waste elimination, and responsiveness.

We then examined the potential mechanisms of growth inhibition after harmine treatment *in vivo*. We first examined whether a decrease in proliferation was responsible for the observed growth inhibition, however, we observed no significant difference in proliferation rate as measured by Ki-67 staining after harmine treatment (*Figure 21C*). We next examined whether increased apoptosis contributed to the growth inhibitory effects of harmine and we did observe increased apoptosis as measured by cleaved caspase 3 and cleaved PARP with harmine (*Figure
Most notably, harmine treatment led to marked decrease in Twist1 protein in the mouse lung tumors (Figure 21C, Figure 22B). Thus, harmine has cytotoxic effects \textit{in vivo} on \textit{Kras} mutant, \textit{Twist1} overexpressing lung adenocarcinoma, which are accompanied by Twist1 degradation.
Figure 21: Harmine has activity in Kras^{G12D/Twist1} mouse model of autochthonous lung adenocarcinoma

(A) Representative microCT images of autochthonous lung tumors showing decreased lung tumor growth 3 weeks following treatment with harmine versus vehicle in the CCSP-rtTA/tetO-KrasG12D/Twist1-tetO7-luc (CRT) mice. Contoured lung tumors represent index lesions followed serially for tumor volume quantification. (B) Lung tumor volumes were quantified at baseline and weekly with serial micro-computed tomography (microCT) in the same CRT mice. MicroCT images were reviewed by a board certified radiation oncologist on multiple index tumors in a blinded fashion (n=18 tumors for vehicle from 6 mice and n=16 from 5 mice for harmine). Difference was statistically different using a Mann-Whitney test, P=0.0025. Volumes were normalized to the starting volume, t=0 before harmine treatment, and percent tumor volume growth was then calculated by (normalized tumor vol. X 100%) - 100%. (C) LEFT: Treatment with harmine results in similar proliferation levels as measured by Ki-67 staining, but increased apoptosis as measured by cleaved caspase 3 staining indicated by black arrows. RIGHT: Quantification and comparison of Ki-67 staining (n=12 tumors for vehicle and n=15 for harmine) (p=0.3621) and cleaved caspase 3 IHC (n=12 tumors for vehicle and n=16 for harmine) (p=0.0453). (D) Quantification of Twist1 and cleaved PARP protein levels in vehicle and harmine treated animals at 3 weeks. Proteins were normalized to luciferase protein levels to control for possible differences in tumor burden. Differences were statistically significant (using Student’s T-Test) for Twist1 (n=15 tumors for vehicle and n=20 tumors for harmine), P < 0.04 and c-PARP (n=9 tumors for vehicle and n=12 tumors for harmine), P < 0.005 respectively.
Figure 22: Treatment with harmine decrease tumor growth in a *KRAS* mutant Patient-Derived Xenograph (PDX) model and degrades Twist1 and induces apoptosis in a transgenic mouse model of *Kras* mutant lung cancer.

(A) Tumor growth is decreased after 13 days of harmine treatment in the *KRAS* mutant (G12C) PDX model (BM012). Tumor size was monitored twice a week until tumors were approximately 2000 mm$^3$. N = 7 mice in vehicle, and 5 in harmine arms in PDX model. Data represent mean ± SEM. *, *p* < .05, 2-tailed Student’s t-test. (B) Representative westerns from *CCSP-rtTA/tetO-KrasG12D/Twist1-tetO7-luc* (CRT) murine tumors demonstrating that harmine leads to decreased Twist1 and increased Cl-Parp expression. Tumors were harvested from CRT mice treated with vehicle or harmine for three weeks. Proteins were normalized to luciferase protein levels to control for possible differences in tumor burden.
2.5 DISCUSSION

Using a Connectivity MAP chemical-bioinformatic analysis, we identified multiple compounds that recapitulated the genetic signature of TWIST1 knockdown. We subsequently assayed seven of the top ranked candidates from this screen for their ability to inhibit multiple TWIST1-mediated in vitro phenotypes that included single-cell dissemination and suppression of FGF2-dependent branching of mammary epithelial cells in a 3D organoid system. All seven compounds tested were able to inhibit TWIST1-mediated dissemination, while the harmala alkaloid compound, harmine, was also able to restore FGF2-dependent mammary epithelial cell branching. We chose to further characterize harmine and demonstrated that it had significant growth inhibitory activity in multiple oncogene-driven NSCLC cell lines. We demonstrated that harmine not only leads to TWIST1 degradation but also phenocopied the loss of TWIST1 by inducing either OIS or OIA in previously defined subsets of NSCLC cell lines. Remarkably, in our mouse model of Kras mutant, Twist1 overexpressing lung cancer, harmine had significant antitumor activity, no overt toxicity, and led to decreased expression of Twist1 protein in vivo.

These studies also revealed that TWIST1 and its binding partners, the E2A proteins, reciprocally regulate the stability of each other. In addition, we demonstrated that genetic silencing of TCF3 in part phenocopies the loss of TWIST1, with loss of TCF3 expression reactivating latent senescence and apoptotic programs. Our data also suggests that the TWIST1-E2A heterodimer, rather than the TWIST1-TWIST1 homodimer, is critical for the transcriptional activation of TWIST1 target genes important for tumorigenesis. Interestingly, the TWIST1-E12 heterodimer has been previously shown to be critical for the ability of TWIST1 to cooperate with RAS to promote mammary tumorigenesis and suppress senescence (248). In addition, the metastatic ability of TWIST1 in prostate cancer cells requires the ability of TWIST1 to
heterodimerize with the E2A proteins (265). Our data demonstrated that harmine preferentially induces degradation of the TWIST1-E2A heterodimer rather than the TWIST1-TWIST1 homodimer and degradation of the heterodimer is required for the cytotoxic effects of harmine. Future studies will be aimed at determining the mechanism(s) by which harmine leads to TWIST1 degradation, specifically the TWIST1-E2A heterodimer.

Although harmine was not associated with overt toxicity in our in vivo model, harmine has been found to have potentially dose-limiting neurotoxicity in humans (269,276). Previous structure-activity studies have determined that harmine derivatives with substituents at position-2 and -9 can modulate the cytotoxic effects of harmine, while the addition of a bulky substituent at the -7 position can ameliorate the neurotoxicity associated with harmine (268-270,276). Although micromolar range doses were required for harmine-mediated cytotoxicity in vitro, it should be noted that we were able to achieve doses in vivo that both inhibited tumor growth and promoted TWIST1 degradation without noticeable side effects. Current efforts in our laboratory are ongoing to identify harmine analogues or related compounds that allow for more potent inhibition of TWIST1 transcriptional activity without associated neurotoxicity. Harmine readily crosses the blood brain barrier (BBB) given its small size and hydrophobicity. One strategy we are currently exploring is to limit the neurotoxicity of harmine is via limiting the permeability of harmine across the BBB through the addition of bulky hydrophilic substituents.

In summary, we identified harmine as a first-in-class inhibitor of TWIST1 with broad cytotoxic activity in the three major classes of oncogene-driven NSCLC, EGFR mutant, KRAS mutant, and c-MET amplified/mutant. Given that we have previously established the requirement of TWIST1 for tumorigenesis in oncogene-driven lung cancer with these genetic backgrounds (234), using harmine derivatives may be a viable therapeutic option to treat oncogene-driven
NSCLC both in the treatment-naïve and acquired resistance setting. In addition, as TWIST1 is rarely expressed post-natally (200,201), pharmacological inhibition of TWIST1 may be associated with minimal side-effects. TWIST1 has been implicated in oncogenesis, EMT, metastasis, therapeutic resistance, and tumor stem cell maintenance, across multiple solid tumors including head and neck, lung, breast, and prostate cancers (222,224,247,265,290,291). The use of harmine and potential analogues has far-reaching therapeutic implications given the diverse roles of TWIST1 in tumorigenesis, metastasis, and therapeutic response. For this reason, we are currently screening harmine derivatives that allow for more potent, specific inhibition of TWIST1, which we can bring to the clinic.
3.0 TARGETING THE EMT-TRANSCRIPTION FACTOR TWIST1 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN EGFR MUTANT NON-SMALL CELL LUNG CANCER

3.1 ABSTRACT

Patients with *EGFR* mutant non-small cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to *de novo* resistance (~30%) as well as acquired resistance. Epithelial-mesenchymal transition transcription factors (EMT-TFs), have been identified as drivers of EMT-mediated resistance to EGFR TKIs, however, strategies to target EMT-TFs are lacking. As the third-generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of *T790M* mutations will significantly decrease in the acquired resistance setting. Previously less common mechanisms of acquired resistance to 1st generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. Importantly, there are no other FDA approved targeted therapies after progression on osimertinib. Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeting the EMT-TF, TWIST1, in *EGFR* mutant NSCLC. We demonstrated that genetic silencing of *TWIST1* or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in *EGFR* mutant NSCLC. TWIST1 overexpression resulted in erlotinib and osimertinib resistance.
in EGFR mutant NSCLC cells. Conversely, genetic and pharmacological inhibition of TWIST1 in EGFR TKI resistant EGFR mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic BH3-only gene, BCL2L11 (BIM), by directly binding to BCL2L11 intronic regions and promoter. As such, pan-BCL2 inhibitor treatment overcame TWIST1-mediated EGFR TKI resistance and was more effective in the setting of TWIST1 overexpression. Finally, in a mouse model of autochthonous EGFR mutant lung cancer, Twist1 overexpression resulted in erlotinib resistance and suppression of erlotinib-induced apoptosis. These studies establish TWIST1 as a driver of resistance to EGFR TKIs and provide rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance to EGFR TKIs.


* -- denotes these authors contributed equally to the work

# -- denotes co-corresponding authors

1Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA

2Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.

3Department of Pharmacology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
3.2 INTRODUCTION

Lung cancer is the leading cause of cancer related death in the United States and worldwide. Despite a 15% five-year survival rate, there have been improvements in the treatment of subsets of non-small cell lung cancer (NSCLC) patients with known targetable molecular drivers such as mutations in EGFR, BRAF and MET, and translocations involving ALK, ROS1, RET and NTRK1/2 (33,107,114). Previous studies have demonstrated that patients with EGFR mutant tumors (~15%) can have a marked response to EGFR tyrosine kinase inhibitors (TKIs). While approximately 70% of patients demonstrate responses to such therapies, long-term efficacy of these therapies is limited due to the inevitability of acquired resistance and frequent...
de-novo resistance (~30%) (70,292,293). Efforts to identify drivers of acquired resistance to first generation EGFR TKIs have revealed multiple mechanisms of resistance including T790M gatekeeper EGFR mutations (~49%), MET amplification (~5%), conversion to small-cell lung cancer (~14%), and PIK3CA mutations (~5%) (75).

In as many as 20% of patients, epithelial-mesenchymal transition (EMT) or a mesenchymal phenotype is observed at time of resistance to EGFR TKIs including third generation inhibitors, such as osimertinib (75,160,161,294). EMT is a reversible process of transdifferentiation in which epithelial cells lose their polarity and cell-cell interactions and adopt a mesenchymal phenotype (156,157). This process is associated with a variety of protumorigenic functions such as with increased invasion, metastasis, and suppression of failsafe programs of apoptosis and senescence (156,157). Interestingly, the presence of an EMT or mesenchymal phenotype is associated with both de-novo as well as acquired resistance to EGFR TKIs (75,295-297). Previous studies have demonstrated that upregulation of AXL, TFG-β, and IGF1R signaling axes are drivers of EMT-mediated acquired resistance to EGFR TKIs (161,165-167). Recent studies have implicated EMT-transcription factors (EMT-TFs), which are drivers of global transcriptional changes that lead to EMT, in resistance to targeted therapies in EGFR mutant NSCLC (163). Specifically, upregulation of the EMT-TFs, SNAI2 and ZEB1, have been shown to can confer resistance to EGFR TKIs (162,164,298). However, the mechanism(s) by which these EMT-TFs mediate resistance and therapeutic strategies to target these EMT-TFs have been lacking.

We have previously demonstrated that the EMT-TF, TWIST1, is required for oncogene-driven NSCLC (Chapter 2) (234). In multiple oncogene-driver dependent settings, including tumors with EGFR mutations, TWIST1 functions to suppress oncogene-induced senescence and
apoptosis (232,234,299). In addition to suppressing failsafe programs, TWIST1 has also been shown to promote EMT, metastasis, and therapeutic resistance (238,249,252,254). We have also identified a first-in-class inhibitor of TWIST1, harmine that has marked antitumor activity in oncogene-driven NSCLC including EGFR mutant NSCLC (232). In the current study, we demonstrated genetic and pharmacological inhibition of TWIST1 resulted in growth inhibition and apoptosis in EGFR mutant NSCLC cell lines, including cells with acquired resistance T790M mutations. We also identified TWIST1 as a driver of resistance to EGFR TKIs in EGFR TKI naïve EGFR mutant NSCLC cell lines as well as in EGFR TKI acquired resistant cell lines with T790M mutations. We further demonstrated that TWIST1 induces EGFR TKI resistance in a transgenic mouse model of autochthonous EGFR mutant lung cancer. We have identified that one mechanism by which TWIST1 mediates resistance is through suppression of EGFR TKI-induced apoptosis by directly binding to the promoter and intronic regions of the pro-apoptotic BH3-only gene, BCL2L11 (BIM) and repressing BCL2L11 transcription. Additionally, we demonstrated that TWIST1-mediated EGFR TKI resistance can be overcome with either a BCL-2/BCL-XL inhibitor, or the TWIST1 inhibitor harmine, suggesting that targeting TWIST1 in the clinic may be a viable option to overcome EMT-mediated resistance to EGFR TKIs.

3.3 MATERIAL AND METHODS

3.3.1 Cell lines and reagents

PC9, H1975, H1650, Hcc4006, Hcc4011, Hcc2935, Hcc827, H3255, and embryonic kidney cell line HEK 293T were acquired from the American Type Culture Collection (ATCC) and were
cultured in the recommended ATCC media. Hcc827R2 and 11-18 cells were obtained from Dr. Christine Lovly (Vanderbilt University) and cultured in the recommended media. The identity of the aforementioned cell lines was verified by autosomal STR (short tandem repeat) profiling done at University of Arizona Genetics Core (UAGC). Cell lines were tested for mycoplasma every six months using MycoAlert Detection Kit (Lonza). Osimertinib and erlotinib were purchased from Selleck Chemicals (Houston, TX). Harmine was purchased from Sigma-Aldrich (St. Louis, MS). ABT-737 was purchased from ApexBio Technology (Houston, TX).

3.3.2 Quantification of caspase-3/7 activity

Cells were seeded at appropriate density in 25-cm² plates and incubated for 24 hours. Following incubation, cells were treated with harmine at 0, 20, 40µM for 48 hours. Apoptosis was analyzed as previously described in Chapter 2.3.12.

3.3.3 Quantitative RT-PCR

RNA isolation, cDNA generation, and cDNA amplification using PowerUp™ SYBR® Green Master Mix (Perkin Elmer Applied Biosystems) and TaqMan® Universal PCR Master Mix (Perkin Elmer Applied Biosystems) were carried out as previously described in Chapter 2.3.5. Primer list is available in Table 1-2 (Appendix A).
3.3.4 Cell proliferation assays

For all viability experiments, cells were seeded at an appropriate density in 96 well plates and incubated for 24 hours. Cells were subsequently treated with a range of doses of the appropriate inhibitor for 72 hours. Viability was determined using the CellTiter96® Aqueous One Solution Cell Proliferation Assay kit (Promega) or Cell-Titer Glo 2.0 Assay (Promega) according to manufacturer’s protocol. Data was analyzed as previously described in Chapter 2.3.2. All experiments were performed at least twice to ensure consistent results.

3.3.5 Western blot and antibodies

Following appropriate treatment, cells were harvested and lysed and subsequent protein was quantified and western blotting was performed as previously described (234). All information on antibodies is included in Table 3 (Appendix A). Western blot experiments were performed at least twice unless otherwise stated.

3.3.6 Chromatin immunoprecipitation

H1975 TRE3G-TWIST1 cells were seeded in 15cm dishes and incubated for 24 hours. Cells were treated with 50ng/ml of doxycycline. Following 24 hours of doxycycline treatment, cells were harvested and Chromatin Immunoprecipitation (ChIP) was performed using SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to manufacturer’s recommendations. ChIP primers that were used are included in Table 7 (Appendix A). For ChIP,
2µg of ChIP-grade TWIST1 antibody (Abcam, Ab5087) and 2µg Mouse IgG, Whole Molecule Control (Thermo Scientific, 31903) were used.

3.3.7 Lentiviral shRNA and cDNA overexpression

293T cells were seeded at a density of 4 X 10^6 in 25-cm² flasks. Following a 24 hour incubation period, cells were transfected to generate lentivirus using a four-plasmid system according to the TRC Library Production and Performance protocols, RNAi Consortium, Broad Institute (264) and as previously described (234). A complete list of the constructs used is in Supplementary Tables 4-6 (Appendix A) and sequences of these constructs and primers used are available upon request.

3.3.8 Transgenic mice

Mice were housed in groups of no more than five per cage with free access to food and water, under controlled light/dark cycles, in facilities with regulated temperature and humidity. Mice were randomly assigned to different experimental groups.

Inducible EGFR\textsuperscript{L858R} and Twist1/EGFR\textsuperscript{L858R} transgenic mice in the FVB/N inbred background were of the genotype: CCSP-rtTA/tetO-EGFR\textsuperscript{L858R} (CE) or CCSP-rtTA/tetO- EGFR\textsuperscript{L858R}/Twist1-tetO-luc (CET). The tetO-EGFR\textsuperscript{L858R} mice were obtained from Dr. Katerina Politi (Yale University). All the mice were weaned at 3–4 weeks of age and then placed on doxycycline (DOX) drinking water at 4–8 weeks of age as previously described (299,300). After three weeks of DOX treatment, mice were randomized to vehicle and erlotinib treatment groups after
ensuring similar levels of tumor burden with micro-CT. Micro-CT imaging and quantification of
tumor burden was performed as previously described (299). Erlotinib was purchased from
Selleckchem (Houston, TX). For in vivo experiments, erlotinib was dissolved into a slurry in
0.5% methylcellulose. The mice received 50 mg/kg erlotinib or vehicle via oral gavage 6 days a
week for 3 weeks.

3.3.9 Histology and immunohistochemistry

Tissues were fixed and subsequent histology and immunohistochemistry was performed as
previously described (301). For immunohistochemistry, the primary antibodies were used at the
following concentrations: Twist1 at 1:200, vimentin and E-cadherin at 1:400; cleaved caspase 3

3.4 RESULTS

3.4.1 Genetic or pharmacologic inhibition of TWIST1 results in growth inhibition and
apoptosis in EGFR mutant NSCLC

We previously observed that TWIST1 expression is required for tumorigenesis in oncogene-
driven NSCLC as inhibition of TWIST1, in oncogene driver-defined NSCLC cell lines, results in
activation of latent senescence and/or apoptotic programs (232,234,299). To more
comprehensively test the role of TWIST1 in EGFR mutant lung cancers, we infected a panel of
EGFR mutant lines with shRNAs targeting TWIST1 or with scrambled control shRNA.
Silencing of TWIST1 results in growth inhibition in the majority of lines screened (Figure 23). We have previously identified and characterized a novel TWIST1 inhibitor, harmine that had antitumor activity in oncogene driver-defined NSCLCs, inhibited multiple TWIST1-dependent functions, and induced degradation of TWIST1 (232). Similar to our previous findings in a limited number of EGFR mutant cell lines, harmine markedly inhibited growth across the large panel of EGFR mutant NSCLC cell lines, including EGFR TKI resistant lines, similar to the effects seen following silencing of TWIST1 (Figure 23). While we have previously observed that genetic and pharmacological inhibition of TWIST1 primarily results in oncogene-induced senescence (OIS) (232,234,299), there was a subset of cell lines that appeared more dependent on TWIST1 expression for survival and underwent apoptosis following inhibition of TWIST1 (232,234). We identified a subset of EGFR mutant cell lines (H1975 and PC9) that underwent apoptosis following knockdown of TWIST1 and harmine treatment (Figure 24A-B). PC9 cells have an EGFR TKI sensitizing EGFR exon 19 deletion (ΔE746-A750) and H1975 cells have both EGFR TKI sensitizing L858R mutation and an acquired resistance T790M mutation, suggesting that targeting TWIST1 may be an effective therapeutic target for EGFR mutant disease in both the EGFR TKI naïve and EGFR TKI acquired resistance setting. Of note, genetic and pharmacologic inhibition of TWIST1 (Figure 23-24) was also effective in the setting of T790M independent resistance such as in the EGFR TKI resistant cell line H1650 (137).
Figure 23: TWIST1 is required for EGFR mutant NSCLC
LEFT: Cell-Titer Glo assays demonstrating that knockdown of TWIST1 results in growth inhibition in a panel of EGFR mutant NSCLC cell lines. Cells were infected with shScram or shRNA targeting TWIST1 (shTWIST1 #1, #2) for 6 days. Viability data was normalized to shScram control. Data represent mean ± SD (n=4 technical replicates). Differences were statistically significant for each cell line for shScram versus shTWIST1#1 or shTWIST1#2, except for H1650 shScram versus shTWIST1#2, H3255 shScram versus shTWIST1#1, and 11-18 shScram versus shTWIST1#1/2, p < .01, 2-tailed Student’s t-test. RIGHT: MTS assays demonstrating that harmine has activity in a panel of EGFR mutant NSCLC cells. Cells were treated with harmine for 72 hours. Data represent mean ± SD (n=4 technical replicates).
Figure 24: Inhibition of TWIST1 induces apoptosis in a subset of EGFR mutant NSCLC cell lines
(A) Western blot demonstrating that knockdown of TWIST1 induces apoptosis in PC9 cells with EGFR TKI sensitizing EGFR exon 19 deletion (ΔE746-A750) and H1975 cells with both EGFR TKI sensitizing L858R mutation and an acquired resistance T790M mutation. Cells were infected with shScram and shRNA targeting TWIST1 (shTWIST1 #1-3) for 72 hours (PC9) or 6 days (H1975) and harvested for Western blot analysis. (B) UPPER: Western blots demonstrating that harmine treatment results in PARP cleavage in PC9 and H1975 cells. Cells were treated with harmine for 48 hours and harvested for Western blot analysis. LOWER: Active Caspase 3-7 staining demonstrating induction of apoptosis in PC9 and H1975 following 48 hours of harmine treatment. Data represents mean ± SD (n=3 biological replicates). **, p<.01, 2-tailed Student’s t-test.
3.4.2 TWIST1 is necessary and sufficient for EGFR TKI resistance in a subset of EGFR mutant NSCLC cell lines

Recent evidence has suggested that EMT-TFs mediate resistance to EGFR targeted therapy in lung cancer (162,164,298,302). TWIST1 has been implicated in chemoresistance in lung cancer and other cancer types (247,254,303,304). Given the requirement of TWIST1 for EGFR mutant NSCLC and its role in suppressing OIS and apoptosis in NSCLC, we investigated whether enforced TWIST1 expression would be sufficient to cause resistance to EGFR TKIs, using a panel of doxycycline inducible TWIST1 overexpressing EGFR mutant NSCLC cell lines. TWIST1 overexpression in these lines was sufficient to cause resistance to both 1st and 3rd generation EGFR TKIs (Figure 25A-B). Additionally, we observed that TWIST1-mediated resistance was associated with suppression of EGFR TKI-induced apoptosis in cells with and without the T790M EGFR gatekeeper mutation (Figure 26).

To investigate the requirement of TWIST1 for erlotinib resistance, we first assessed relative expression of TWIST1 in a panel of EGFR mutant TKI sensitive and resistant cell lines. We identified an EGFR mutant cell line, H1650 that had increased levels of TWIST1 mRNA and protein (Figure 27A). Interestingly, this cell line demonstrates de-novo resistance to EGFR TKIs (137). We found that genetic silencing of TWIST1 increases sensitivity of this cell line to erlotinib (Figure 27B). We observed a similar increase of sensitivity to erlotinib when used in combination with our small molecule TWIST1 inhibitor, harmine (Figure 27C). This increase in erlotinib sensitivity corresponded to increased apoptosis and BIM expression with decreased TWIST1 expression following harmine and erlotinib co-treatment (Figure 27C). We also investigated the role of TWIST1 in mediating resistance in an EGFR mutant NSCLC cell line (HCC827R2) with acquired resistance to erlotinib (139). Although TWIST1 was not increased in
the resistant cell line compared to the parental cell line, we observed that this cell line maintained a requirement for TWIST1 expression and that targeting TWIST1 in these cells increased sensitivity to erlotinib (Figure 28). These observations indicate that inhibiting TWIST1 may be a viable target in erlotinib resistance settings in which TWIST1 is expressed.
Figure 25: TWIST1 overexpression is sufficient to mediate resistance to EGFR TKIs

(A) UPPER: MTS or Cell-Titer Glo assays demonstrating that TWIST1 overexpression results in decreased response to erlotinib. H3255 TRE3G-TWIST1 (UPPER LEFT), 11-18 TRE3G-TWIST1 (UPPER RIGHT), and PC9 TRE3G-TWIST1 (LOWER) were pre-treated with doxycycline for 72 hours and then treated with doxycycline and erlotinib for 72 hours. Data represent mean ± SD (n=4 technical replicates). *, P<.05, **, P<.01, 2-way ANOVA, followed by Tukey’s Test.

(B) MTS assay demonstrate that TWIST1 overexpression decreases response to osimertinib. H1975 TRE3G-TWIST1 were pre-treated with doxycycline for 72 hours prior to a 72-hour treatment with osimertinib. Data represent mean ± SD (n=4 technical replicates). *, P<.05, **, P<.01, 2-way ANOVA, followed by Tukey’s Test.
Figure 26: TWIST1 overexpression suppresses EGFR TKI-induced apoptosis in EGFR mutant NSCLC cell lines

(A) Western blot demonstrating that TWIST1 overexpression decreases erlotinib-induced apoptosis as measured by PARP cleavage. PC9 TRE3G-TWIST1 cells were pre-treated with doxycycline (1000ng/ml) for 72 hours prior to a 48-hour treatment with erlotinib. (B) Western blot demonstrating that TWIST1 overexpression decreases osimertinib-induced apoptosis as measured by PARP cleavage. H1975 TRE3G-TWIST1 cells were pre-treated with doxycycline (50g/ml) for 72 hours prior to a 48-hour treatment with osimertinib.
Figure 27: Inhibition of TWIST1 is sufficient to overcome EGFR TKI resistance

A) Quantitative RT-PCR demonstrating baseline TWIST1 mRNA (LEFT) and protein (RIGHT) levels in a panel of erlotinib sensitive and resistant EGFR mutant NSCLC cells. RT-PCR was normalized to Hcc2935 TWIST1 mRNA levels. Data represent mean ±SD (n=3 technical replicates). (B) LEFT: Western blot demonstrating shRNA targeting TWIST1 decreases TWIST1 levels. The erlotinib resistant cell line, H1650 was infected with the indicated shRNA and harvested six days following infection for Western analysis. RIGHT: MTS assay demonstrating that knockdown of TWIST1 in H1650 cells can re-sensitize cells to erlotinib. H1650 cells which harbor both EGFR and PTEN mutations, were infected with the indicated shRNAs for 48 hours and subsequently treated with erlotinib for 72
hours. Data represent mean ±SD (n=4 technical replicates). *, P<.05, **, P<.01, 2-way ANOVA, followed by Tukey’s Test. (C) LEFT: Western blot demonstrating that the combination of harmine and erlotinib results in increased apoptosis as measured by PARP cleavage as well as BIM expression, and decreased TWIST1 expression. H1650 cells were treated with the indicated doses of harmine and erlotinib for 48 hours and harvested for Western analysis. RIGHT: MTS assay demonstrating that harmine treatment increases H1650 cell sensitivity to erlotinib. Cells were treated with the indicated doses of harmine and erlotinib for 48 hours. Data represent mean ±SD (n=4 technical replicates). *, P<.05, **, P<.01, 2-way ANOVA, followed by Tukey’s Test.
Figure 28: Inhibition of TWIST1 can overcome acquired resistance to erlotinib
(A) MTS assay demonstrating that Hcc827R2 cells, that harbor both an EGFR mutation and MET amplification are resistant to erlotinib. Cells were treated at the indicated doses of erlotinib for 72 hours. Data represent mean ± SD (n=4 technical replicates). (B) LEFT: MTS assay demonstrating that knockdown of TWIST1 in Hcc827R2 cells can resensitize cells to erlotinib. Hcc827R2 cells were infected with the indicated shRNAs for 48hrs. and subsequently treated with erlotinib for 72hrs. Data represent mean ±SD (n=4 technical replicates). RIGHT: MTS assay demonstrating that harmine treatment can partially resensitize Hcc827R2 cells to erlotinib. Hcc827R2 cells were treated for 48 hours with the indicated doses of harmine and erlotinib. Data represent mean ±SD (n=4 technical replicates). Data represent mean ± SD (n=4 technical replicates). 2-tailed Student’s t-test. *, P<.05, **, P<.01.
3.4.3 TWIST1 suppresses BIM expression

Previous studies have established that response to oncogene targeted therapies requires BIM expression and loss of BIM expression is associated with EGFR TKI resistance in patients (139,186,190,191,305). BIM expression is regulated both transcriptionally and post-translationally (306). We investigated whether TWIST1 could regulate BIM expression in EGFR mutant NSCLC cell lines. We found that knockdown of TWIST1 resulted in increased BCL2L11 (BIM gene) mRNA and protein expression of BIM (Figure 29A). In the cell lines in which TWIST1 was sufficient to mediate erlotinib resistance, we demonstrated that TWIST1 overexpression resulted in suppression of mRNA and protein expression of BIM (Figure 29B-C). To evaluate whether TWIST1 decreased BIM expression through a post-translational mechanism, we performed a pulse-chase experiment and demonstrated that TWIST1 did not decrease BIM half-life, suggesting that TWIST1 negative regulation of BIM expression is primarily at the mRNA level (Figure 30). To explore whether TWIST1 was directly repressing the transcription of BCL2L11, we performed TWIST1 ChIP on the promoter region and intron 1 which contained multiple E-box binding sites (CANNTG), the putative consensus binding site for TWIST1. We also performed TWIST1 ChIP on a putative TWIST1 binding site contained within the BCL2L11 genomic region in intron 12 previously identified on a global TWIST1 ChIP analysis (285). We identified that TWIST1 bound to one site upstream of the transcriptional start site (BS1) and a site in intron 12 (BS5) (Figure 29D). Interestingly, in the regions flanking the E-boxes found at the BS1 and BS5 sites, there are predicted binding sites for nuclear factor-1 (NF-1), while these predicted sites are not found at the other E-box sites investigated. Although no previous studies have implicated NF-1 in TWIST1 target gene regulation, NF-1 has been implicated in tumorigenesis through its ability to regulate chromatin structure and DNA
accessibility (307). TWIST1 binding specifically to these sites may be influenced by the presence of other transcription factors, such as NF-1. Overall, these studies establish BIM as a novel target gene of TWIST1.

While others have previously established the requirement of BIM for response to EGFR TKIs (186,190,191,305), we confirmed that in H1975 cells that BIM expression was required for response to osimertinib (Figure 29E). As BIM is required for EGFR TKI-induced apoptosis (186,190), we examined whether inhibition of anti-apoptotic BCL2 family members with the BCL-2/BCL-XL inhibitor (ABT-737) would be effective in TWIST1 overexpressing EGFR mutant NSCLC. We observed that BCL2/BCLXL inhibitor (ABT-737) was able to overcome TWIST1-mediated resistance to osimertinib in H1975 TWIST1 overexpression cells (TWIST1-ON) but did not affect osimertinib sensitivity in the absence of TWIST1 (TWIST-OFF) (Figure 29F). These data suggest that TWIST1-mediated resistance may be overcome through use of BH3 mimetics and that these therapies may be more effective in TWIST1 overexpressing EGFR mutant NSCLC cells.
Figure 29: TWIST1 suppresses BIM expression by directly suppressing its transcription
A) LEFT: Quantitative RT-PCR (qRT-PCR) demonstrating increased *BCL2L11* mRNA levels following knockdown of TWIST1. PC9 cells were infected with the indicated shRNA for 24 hours. Data represent mean ±SD (n=3 technical replicates). RIGHT: Western blot demonstrating that knockdown of TWIST1 increased BIM protein levels. PC9 cells were infected with the indicated shRNA for 72 hours. (B) qRT-PCR demonstrating that TWIST1 overexpression decreased *BCL2L11* mRNA levels. PC9 TRE3G-TWIST1 cells and H1975 TRE3G-TWIST1 were treated with doxycycline for 24 hours. Data represent mean ±SD (n=3 technical replicates). (C) Western blot demonstrating that TWIST1 overexpression decreased BIM protein levels. PC9 TRE3G-TWIST1 cells and H1975 TRE3G-TWIST1 were treated with doxycycline for 72 hours. (D) ChIP assay demonstrating TWIST1 binding to promoter and intronic regions of *BCL2L11*. UPPER: Model demonstrating E-box sites within the *BCL2L11* promoter, Intron 1, and Intron 12 that were interrogated for TWIST1 binding. LOWER: qRT-PCR demonstrating that TWIST1 is enriched at multiple sites within the *BCL2L11* promoter and intronic regions. Data represent mean ±SD (n=3 technical replicates). *, P<.05, **, P<.01. 2-tailed Student’s t-test. (E) LEFT: Western blot demonstrating that shRNA targeting BIM decreased BIM expression. RIGHT: MTS assay demonstrating decreased response to osimertinib following knockdown of BIM in H1975 cells. H1975 cells that stably express shScram or shBIM were treated with osimertinib for 72 hours. Data represent mean ±SD (n=4 technical replicates). *, P<.05, **, P<.01, 2-way ANOVA, followed by Tukey’s Test. (F) MTS assay demonstrating that TWIST1-mediated resistance to osimertinib can be overcome with ABT-737. H1975 TRE3G-TWIST1 cells were pre-treated with doxycycline for 72 hours and then co-treated with osimertinib and ABT-737 (1µM) ± doxycycline for 72 hours. Data represent mean ±SD (n=4 technical replicates). **, P<.01, 2-way ANOVA, followed by Tukey’s Test.
Figure 30: TWIST1 overexpression does not decrease BIM protein half-life
TWIST1 overexpression in PC9 TRE3G-TWIST1 cells does not markedly alter BIM protein half-life. PC9 TRE3G-TWIST1 cells were treated for 72 hours with doxycycline (500ng/ml). Cells were then treated with cyclohexamide (50 mg/ml) and harvested at the indicated time points. Media without doxycycline was used as a control. Protein levels were determined using Image J densitometry and BIM protein half-life for –DOX and + DOX groups was estimated using linear regression analysis.

3.4.4 Creation and characterization of an autochthonous EGFR mutant Twist1 overexpression lung tumor mouse model

We previously demonstrated that Twist1 could cooperate with mutant Kras for lung tumorigenesis and that genetic or pharmacologic inhibition of Twist1 in this model inhibited growth of these lung tumors (232,234,299). To investigate whether EMT and Twist1 could impart erlotinib resistance to EGFR mutant NSCLCs in vivo we made use of transgenic EGFR\textsuperscript{L858R} and Twist1 inducible mouse models (299,300). Both of these strains are well established doxycycline inducible lung specific transgenic mouse models: CCSP-rtTA/tetO-EGFR\textsuperscript{L858R} (CE), expressing human EGFR\textsuperscript{L858R} and CCSP-rtTA/Twist1-tetO7-luc (CT), expressing mouse Twist1. We crossed these two lines to create triple transgenic mice, CCSP-
Cohorts of CE and CET mice, aged 4-8 weeks, were administered doxycycline in the drinking water to turn on the transgenes. After 4 weeks, a point by which CE mice were reported to develop lung tumors (300), mice were sacrificed and necropsies performed. Upon comparison of H&E lung sections from CE and CET mice by a veterinary pathologist, both genotypes resulted in similarly diffuse adenocarcinoma growth in both lungs, as had been previously published for the CE model (300), but CET tumors were more anaplastic as the tumors had larger, more irregularly shaped nuclei (Figure 31B). We had previously shown that Twist1 expression accelerates mutant Kras tumorigenesis (299), but after 4 weeks on doxycycline, tumor burden was similar between CE and CET mice as shown by pathologic assessment of lung tumor burden (0 meaning no hyperplasia and 5 meaning >75% of the lung was affected) and microCT (Figure 31B-C). Thus, TWIST1 expression did not appear to have a primary effect on tumor proliferation rate, but rather resulted in a more aggressive or anaplastic appearance in the CET tumors.

To further characterize the novel CET mouse model, we looked at levels of epithelial and mesenchymal markers. We immunostained lung sections from both CE and CET mice with antibodies for E-cadherin, an epithelial marker, and vimentin, a mesenchymal marker. There was no distinguishable difference in levels of either marker between CE and CET mice (Figure 31D). We also did not observe any increased metastasis in the CET mice. In other contexts, Twist1 has been shown to impact the proliferation rate of tumor cells as well as apoptosis levels (234,308). We next examined the levels of proliferation through immunohistochemistry with an antibody for Ki-67 and apoptosis with an antibody for cleaved caspase 3. The overexpression of Twist1 in CET mice in fact modestly decreased proliferation rates, as measured by Ki-67 IHC, in
comparison to CE mice (Figure 31E). There was no significant effect on apoptosis with Twist1 expression (Figure 31F).
Figure 31: Generation and characterization of a novel Twist1 overexpressing, mutant EGFR autochthonous lung tumor mouse model

(A) Crosses (CE×CT) to produce CCSP-rtTA/EGFR<sup>L858R</sup>/Twist1-tetO7-luc (CET) mice. (B) UPPER: H&E images from lung tissue of CE and CET mice. CET histology was more anaplastic with larger, more irregular nuclei. 

C. 4 weeks on DOX

CE

CET

D. E-cadherin

Vimentin

Twist1

E. CE Untreated CET Untreated

Ki67

F. CE Untreated CET Untreated

Cleaved caspase 3

Figure 31: Generation and characterization of a novel Twist1 overexpressing, mutant EGFR autochthonous lung tumor mouse model

(A) Crosses (CE×CT) to produce CCSP-rtTA/EGFR<sup>L858R</sup>/Twist1-tetO7-luc (CET) mice. (B) UPPER: H&E images from lung tissue of CE and CET mice. CET histology was more anaplastic with larger, more irregular nuclei.
Lesions in both genotypes are more diffuse rather than discrete tumors. Black bars equal 500 and 50 μm. LOWER: Comparison of tumor burden, as percent of lung affected, between CE and CET untreated mice. Mice were on doxycycline for 4 weeks then sacrificed. (C) CT images from CE (upper) and CET (lower) mice on doxycycline for 4 weeks. As evidenced from the images, varying levels of tumor burden can be seen within a genotype, however the level is comparable between genotypes. CT images are non-invasive and based on density; the denser areas, like bone, appear white, while the air space is black. The mice are lying on their stomach with noses pointed forward. (D) Similar levels of E-cadherin and vimentin staining in CE and CET mice, with CET mice expressing Twist. (E) Decreased proliferation in CET mice compared to CE mice as determined by Ki-67 staining. Differences were statistically significant using Student t-test, ***, P<0.0005. (F) Similar levels of apoptosis in CE and CET mice using cleaved caspase 3 IHC. For C-E, n=4 mice per genotype. 2-tailed Student’s t-test, P = NS.
3.4.5 *Twist1 expression induces erlotinib resistance in vivo*

After characterizing the novel CET mouse model in the absence of drug treatment, we investigated whether Twist1 expression could induce resistance to the EGFR TKI erlotinib *in vivo*. As previously described, upon administration of erlotinib to CE mice, most lung tumors regress, with a distribution of objective responses including disease stabilization, partial response, and complete response (300). In order to compare CE and CET mice tumor responses and overall survival, all mice were put on doxycycline, to turn on transgene expression and allowed to develop tumors for 3 weeks. Both CE and CET mice had similar levels of tumor burden prior to the start of treatment. At that time point, treatment day 0, all mice were scanned by microCT and this scan was used as the baseline. The mice were treated for 3 weeks with erlotinib and scanned by microCT each week (*Figure 32A*). When baseline scans were compared to scans from after 3 weeks of erlotinib treatment, tumor regression was clearly visible in CE mice, while CET mice showed an increase in tumor burden (*Figure 32B*). All scans were assessed and tumor burden graded on a scale of 0 (no tumor visible) to 5 (lungs completely filled with tumor). Based on the tumor burden change from the beginning to the end of treatment, a majority of CE mice demonstrated no disease progression with erlotinib, with no progression including complete and partial responses as well as stable disease. Conversely, over half of the CET mice had tumor progression over the three weeks of treatment (*Figure 32C*). When examining erlotinib treatment responses based on degree of lung tumor regression, two-thirds of CE mice showed lung tumor regression, while only a quarter of CET mouse lung tumors regressed (*Figure 32C*). After the 3 weeks of treatment, mice were monitored for weight loss, lethargy and other signs indicating a need for euthanasia. CET mice median overall survival time from the beginning of treatment was 6.8 weeks, while CE mice lived a median of 8.7 weeks.
(Figure 32D). Importantly, we have demonstrated that Twist1 expression does not lead to an increased tumor burden in the EGFR mutant background so an increased tumor burden cannot explain this decrease in overall survival (Figure 32D). These data support that expression of Twist1 in CET mice induces resistance to erlotinib as shown by increased lung tumor burden and decreased overall survival time following treatment with erlotinib.

To confirm the tumor burden differences seen by microCT, a cohort of CE and CET mice were treated with erlotinib for 1 week followed by euthanasia for macroscopic and histologic tumor assessment. While partial and complete responses were seen in CE mice, only partial and no responses occurred in the CET mice (Figure 33A). Tumor burden as assessed on H&E slides by a veterinary pathologist between CE and CET mice treated with erlotinib demonstrated an early trend towards CET mice having greater tumor burden at 1 week (Figure 33A).

We then examined the mechanism of Twist1-mediated resistance. Since Twist1 is one of the key mediators of EMT, the tumors in the CET mice could be undergoing this phenotypic change. However, staining for E-cadherin and vimentin showed no change with Twist1 expression, with or without erlotinib treatment (Figure 33B). Additionally, there was no significant difference between proliferation levels in CE and CET mice following erlotinib treatment (Figure 33C). Interestingly, when the amount of apoptosis was assessed through staining for cleaved caspase 3, the levels of apoptosis were decreased in CET erlotinib treated lung tumors compared to CE erlotinib treated lung tumors (Figure 33C). These data suggest that while EMT status and the level of proliferation is unchanged following erlotinib treatment, Twist1 expression inhibits apoptosis in EGFR mutant lung tumors following erlotinib treatment.
Figure 32: Twist1 overexpression in vivo is sufficient to cause erlotinib resistance

(A) Treatment schema for CE and CET mice erlotinib treatment. Mice were started on doxycycline, inducing EGFR_{L858R} and Twist1 transgene expression, at 8 weeks of age and allowed to develop tumors for 3 weeks prior to erlotinib treatment. Mice were scanned at the beginning of treatment, week 11, and each week thereafter until the end of treatment. Mice are treated with 50 mg/kg erlotinib by oral gavage 6 days a week for 3 weeks (weeks 11-14). (B) Representative CT images from baseline and after 3 weeks of erlotinib treatment for CE and CET mice. CE mice show a decrease in tumor burden at the end of treatment compared to day 0. CET mice show a drastic increase in tumor burden despite 3 weeks of treatment. (C) Tumor burden, as visualized by CT image, was graded on a scale of 0 (no tumor) to 5 (lungs filled with tumor) at day 0 and the end of treatment. No progression was considered a complete or partial response as well as stable disease. Only 1 CE mouse demonstrated disease progression, while over half of the CET mice progressed despite erlotinib treatment. Regression was a decrease in tumor burden grade at 3 weeks compared to baseline. Two-thirds of CE mice regressed, while only one quarter of CET mice showed regression. (D) Kaplan-Meier overall survival from beginning of treatment. Median survival for CE mice was 8.7 weeks, for CET mice was 6.8 weeks. Difference in survival was statistically significant using the Mantel Cox test, P=0.0073.
Figure 33: Characterization of Twist1-mediated erlotinib resistance in vivo
A) LEFT: H&E images showing comparison of responses seen in CE and CET mice after 7 days of erlotinib treatment. Black bars equal 500 (top) and 50 (bottom) μm. RIGHT: Pathology scores indicating tumor burden as percent of total lung affected. (B) Similar levels of E-cadherin and vimentin staining in CE and CET mice with and without erlotinib treatment, with CET mice expressing Twist1. (C) LEFT: Representative images of Ki-67 and cleaved caspase 3 staining and quantification (RIGHT) of staining showing a decrease in proliferation to similar levels with erlotinib treatment in both CE and CET mice and a decrease in apoptosis in CET compared to CE mice following erlotinib treatment. Differences were statistically significant using Student t-test, * p<0.05, ** p<0.005, *** p<0.0005.
3.5 **DISCUSSION**

We have previously demonstrated that TWIST1 expression is required for oncogene-driven tumorigenesis and that loss of TWIST1 expression results in activation of latent senescence and/or apoptotic programs. Here, we demonstrated that both genetic silencing and pharmacological inhibition of TWIST1 results in growth inhibition in a large panel of EGFR mutant cell lines. Additionally, we identified that in a subset of EGFR mutant cell lines inhibition of TWIST1 results in induction of apoptosis. Of note, targeting TWIST1 resulted in growth inhibition in cells with EGFR TKI sensitizing mutations and acquired resistance T790M mutations, suggesting that targeting TWIST1 may be a viable option in EGFR mutant NSCLC both in the treatment naïve and acquired resistance settings.

Recently, others have demonstrated that EMT-TFs, specifically ZEB1 and SLUG (SNAI2), can contribute to resistance to EGFR TKIs (163,166,298). Hwang et. al have recently shown that TWIST1 overexpression is sufficient to cause EGFR TKI resistance in a single erlotinib sensitive cell line in long term assays and that VGF regulates TWIST1 (302). Here, we significantly expand upon these studies by demonstrating that TWIST1 overexpression is sufficient to cause resistance to EGFR TKIs, in multiple EGFR mutant cell lines with and without T790M mutations. We also establish that Twist1 overexpression promotes erlotinib resistance *in vivo*, using a mouse model of autochthonous EGFR mutant Twist1 overexpressing lung cancer. In both EGFR mutant NSCLC cell lines and our mouse model of EGFR mutant lung cancer, Twist1 overexpression was associated with suppression of EGFR TKI-induced apoptosis.

Importantly, as the third-generation EGFR TKI, osimertinib, has now been adopted in the first-line setting (82), the frequency of T790M mutations will likely significantly decrease in the
acquired resistance setting (82,130). Previously uncommon mechanisms of resistance have already been observed at increased frequency after osimertinib including MET and HER2 amplifications, KRAS mutations, additional second site EGFR mutations, EMT and SCLC transformation (83,130,132,136,143,309-312). Of note, there are no other FDA approved targeted agents following progression on osimertinib (130). Thus, there is clearly a need for the development of novel targeted agents to prevent and overcome EGFR TKI resistance.

Our study is the first to establish that TWIST1 expression is required for resistance in EGFR mutant cells that demonstrate de-novo or acquired resistance to EGFR TKIs. Importantly, our study demonstrates that therapeutic targeting of an EMT-TF, is able to restore sensitivity to erlotinib in EGFR mutant NSCLC cells that are resistant to EGFR TKIs. Our findings suggest that use of small molecule compounds that inhibit TWIST1 may be a viable option to overcome de-novo and acquired resistance to EGFR TKIs in lung cancer. Harmine is an active β-carbolin alkaloid found in the herb Peganum harmala used in traditional medicine in Central Asia and the Middle East (271). However, in mouse model systems and in humans, the efficacy of harmine may be limited due to neurotoxic side effects, such as tremors (271,313). We have identified analogues of harmine that are potentially more potent inhibitors of TWIST1 without the neurotoxicity associated with harmine and are currently performing further preclinical evaluation of these compounds.

Others have previously demonstrated that BIM expression is required for response to EGFR TKIs (186,190,191,305). Additionally, BIM polymorphisms which result in decreased expression of functional BIM protein, are associated with resistance to EGFR TKIs (192,247,314). Here, we establish that TWIST1 suppresses BIM expression through direct binding at both the promoter and intronic regions. Future studies while be aimed at determining
the mechanism(s) by which TWIST1 suppresses BIM expression. Specifically, we will be investigating if TWIST1 binding at the \textit{BCL2L11} promoter results in recruitment of histone deacetylases and/or co-repressors. Additionally, given that there are predicted binding sites for specific transcription factors, such as NF-1, found specifically at the E-box sites in which TWIST1 binds, we will also be investigating if binding of other transcription factors and/or cofactors influences TWIST1 binding to specific E-boxes within the \textit{BCL2L11} promoter.

Overall, these data suggest that one of the mechanisms by which TWIST1 mediates EGFR TKI resistance is through inhibition of EGFR TKI-induced apoptosis by suppressing BIM expression. Interestingly, we demonstrated that TWIST1-mediated resistance can be overcome with use of BCL2/BCLxL inhibitors. BCL2/BCLxL inhibitors, such as ABT-263 are in clinical trials, and our data suggest that use of these inhibitors may provide rapid means to overcome TWIST1-mediated resistance in the clinic. While we established that one mechanism by which TWIST1 can mediate resistance is through suppression of apoptosis, TWIST1 has been previously shown to suppress senescence in both oncogene-driven NSCLC and breast cancer (234,248,299). We are currently exploring whether TWIST1-mediated suppression of senescence is another mechanism by which TWIST1 promotes EGFR TKI resistance. Of note, a recent study demonstrated that TWIST1 can mediate resistance to 3rd generation EGFR TKIs through upregulation of the EMT-TF, ZEB1 (160). This study established that ZEB1 can also directly suppress \textit{BCL2L11} transcription (160). This study and our current study suggests that there are potentially multiple mechanisms by which TWIST1 can promote EGFR TKI resistance and multiple mechanisms by which TWIST1 can suppress BIM expression.

In summary, we demonstrated that genetic and pharmacological inhibition of TWIST1 results in growth inhibition in \textit{EGFR} mutant NSCLC. In a subset of cell lines, including cell lines
with acquired resistance $T790M$ mutations, inhibition of TWIST1 is associated with the induction of apoptosis. Additionally, we established that TWIST1 is both sufficient and, in some lines, required for EGFR TKI resistance in $EGFR$ mutant NSCLC both $in$ $vitro$ and $in$ $vivo$. We demonstrated that one of the mechanisms by which TWIST1 mediates resistance is through suppression of apoptosis via suppression of BIM expression. We also demonstrated that use of a TWIST1 inhibitor, harmine, was able to overcome both $de$-$novo$ and acquired resistance to EGFR TKIs. Of note, targeting TWIST1 may be associated with minimal side effect because it is rarely expressed post-natally (200,201). Our data suggests that targeting TWIST1 may be option to overcome EGFR TKI resistance in $EGFR$ mutant NSCLCs both in the $de$-$novo$ and acquired resistance settings.
4.0 TWIST1 IS A KEY MEDIATOR OF HGF-MET DRIVEN RESISTANCE TO TARGETED THERAPIES IN EGFR MUTANT AND MET-DRIVEN LUNG CANCER

4.1 ABSTRACT

The c-Met (MET) receptor and its ligand, hepatocyte growth factor (HGF) are frequently altered in non-small cell lung cancer (NSCLC). Aberrations in the MET/HGF pathway have emerged as a targetable oncogenic driver, as patients with MET amplification and/or mutations have marked responses to the MET tyrosine kinase inhibitor (TKI), crizotinib. However, long-term efficacy of MET TKIs is limited as acquired resistance is inevitable and almost half of patients with MET alterations fail to respond to MET TKIs. MET amplification and HGF overexpression have also been identified as mechanisms of resistance to MET and EGFR TKIs in MET altered and EGFR mutant NSCLC, respectively. However, the mechanism(s) by which the HGF-MET pathway causes resistance are poorly understood. We previously established that the EMT-transcription factor, TWIST1, is required for EGFR mutant and MET-driven NSCLC. Here, we investigated the requirement of TWIST1 in HGF-mediated resistance to MET and EGFR TKIs and the role of TWIST1 in de-novo and acquired resistance to MET TKIs. We found that HGF treatment induced EMT in NSCLC cell lines and increased TWIST1 protein expression through a post-translational mechanism. We demonstrated that targeting TWIST1 pharmacologically with the TWIST1 inhibitor, harmine, overcame HGF-mediated resistance to
both MET and EGFR TKIs in MET- and EGFR-driven NSCLC. This suggests that TWIST1 is required for HGF-mediated resistance to targeted therapies. We also found that TWIST1 overexpression was sufficient to cause resistance to MET TKIs. In MET-driven NSCLC cell lines that express TWIST1 and are resistant to targeted therapies, we demonstrated that harmine treatment resensitized cells to MET TKIs. To investigate the role of Twist1 overexpression in Hgf-driven lung cancer, we utilized a CCSP-Hgf (CH) mouse model that constitutively overexpresses Hgf in the lung and develops crizotinib sensitive tumors following treatment with the tobacco carcinogen, nicotine-derived nitrosamine ketone (NNK). We demonstrated that Hgf and Twist1 overexpressing CTH (CCSP-rtTA/Twist1-tetO-luc/CCSP-Hgf) mice developed significantly larger tumors in response to NNK as compared to CH mice. These studies suggest that targeting TWIST1 may be an effective therapeutic strategy to overcome HGF-MET-driven resistance in EGFR mutant NSCLC as well as MET TKI resistance in MET-driven NSCLC.

Contributors to study: Yochum, ZA1-2, Chatterjee, S1, Huang EH1, Maurer, DM1, Attar, MA1, Dacic, S3, Stabile, LP2, Burns, TF1-2

1Department of Medicine, Division of Hematology-Oncology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
2Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA
3Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
4.2 INTRODUCTION

The receptor tyrosine kinase c-MET (MET) and its only known ligand, hepatocyte growth factor (HGF) have been implicated in tumorigenesis as MET/HGF signaling can promote epithelial-mesenchymal transition (EMT), proliferation, invasion, motility, and angiogenesis (102). Currently, the treatment paradigm around non-small cell lung cancer (NSCLC) revolves around classifying patient into subgroups based on histology and known or putative molecular drivers. Aberrations in the MET/HGF pathway, specifically *MET* amplifications and *MET* mutations, have emerged as a targetable molecular driver. The most common *MET* mutations in NSCLC are *MET* exon 14 skipping mutations, which lead to increased stability of MET by impairing ubiquitination and proteasomal degradation (111,117). Approximately 8-14% of NSCLC patients harbor *MET* amplifications/mutations and patients with these *MET* alterations have demonstrated marked responses to MET tyrosine kinase inhibitors such as crizotinib or capmatinib (107,112-114,117-120). However, long-term clinical efficacy of MET TKIs remains limited in NSCLC due the frequency of *de-novo* resistance (~50%) and the inevitability of acquired resistance (112,113,117,121). Additionally, mechanisms of resistance to MET TKIs in *MET* altered NSCLC remain poorly understood.

*MET* amplification and overexpression of the MET ligand, HGF have been associated with poor patient prognosis and decreased survival in NSCLC (104-106). Additionally, both aberrations have been identified as drivers of resistance to EGFR and MET TKIs in EGFR- and MET-driven NSCLC, respectively. *MET* amplification drives resistance in approximately 5-20% of patients with *EGFR* mutant NSCLC resistant to 1\(^{st}\) generation EGFR TKIs, such as gefinitib or erlotinib (75,142). Additionally, *MET* amplification can also mediate resistance to osimertinib, the 3\(^{rd}\) generation EGFR TKI which has activity against the *T790M* mutation and is currently the
first-line therapy for \textit{EGFR} mutant patients (143,144). HGF overexpression has also been identified as a mediator of resistance to both MET and EGFR TKIs in NSCLC. HGF overexpression has been observed in patients with \textit{de-novo} and acquired resistance to EGFR TKIs (149,151). Additionally, in MET-driven gastric cancer and NSCLC, HGF overexpression leads to resistance to multiple MET inhibitors, including MET TKIs and MET targeted monoclonal antibodies (315). Studies have revealed that both \textit{MET} amplification and HGF overexpression may mediate resistance by activating bypass signaling, specifically reactivating PI3K and MAPK signaling (147). However, the specific downstream mediators of MET/HGF-driven resistance remain poorly elucidated.

The EMT-transcription factor, \textit{TWIST1}, is overexpressed in approximately 40\% of NSCLC and is associated with a more aggressive tumor phenotype, increased risk of metastasis, and worsened patient prognosis (198,233,316). We have previously demonstrated that \textit{TWIST1} expression is required for oncogene-driven NSCLC, including tumors with \textit{EGFR} mutations and \textit{MET} amplification/mutations (232,234). Genetic and pharmacological inhibition of \textit{TWIST1} in both EGFR- and MET-driven NSCLC results in oncogene-induced senescence (OIS) and in a subset of cells, apoptosis (232,234). Additionally, in Chapter 3, we have demonstrated that \textit{TWIST1} is both sufficient and required for EGFR TKIs resistance. In the current study, we explored the role of \textit{TWIST1} in HGF-driven resistance to both MET and EGFR TKIs in \textit{MET} altered and \textit{EGFR} mutant NSCLC, respectively, and in \textit{de-novo} and acquired resistance to MET TKIs in \textit{MET} altered NSCLC. We demonstrated that HGF treatment resulted in increased \textit{TWIST1} expression by increasing \textit{TWIST1} protein stability. Additionally, pharmacologic inhibition of \textit{TWIST1} was able to overcome HGF-mediated resistance to MET and EGFR TKIs. We demonstrated that \textit{TWIST1} overexpression was sufficient to cause decreased sensitivity to
the MET TKI, crizotinib. Additionally, targeting TWIST1 with our novel TWIST1 inhibitor, harmine, increased crizotinib sensitivity in MET-driven NSCLC cell lines. Of note, harmine had single agent activity in a patient-derived xenograft mouse model of EGFR mutant MET amplified NSCLC. In our transgenic mouse model of Hgf-driven NSCLC, we demonstrated that in response to the tobacco carcinogen, nicotine-derived nitrosamine ketone, mice that expressed Twist1 and Hgf developed larger tumors when compared to mice that expressed Hgf alone. Our studies demonstrate that TWIST1 is a potential therapeutic target to overcome resistance to MET and EGFR TKIs, in the presence and absence of HGF overexpression.

4.3 METHODS

4.3.1 Cell lines and reagents

H23, H1648, Hcc827, H596, H1993, H1437 and embryonic kidney cell line HEK 293T were acquired from the American Type Culture Collection (ATCC) and were cultured in the recommended ATCC media. 11-18 cells were obtained from Dr. Christine Lovly (Vanderbilt University) and cultured in the recommended media. The identity of the aforementioned cell lines was verified by autosomal STR (short tandem repeat) profiling done at University of Arizona Genetics Core (UAGC). Cell lines were tested for mycoplasma every six months using MycoAlert Detection Kit (Lonza). Recombinant Human HGF (294-HGN-005/CF 5 μg) was purchased from R&D Systems (Minneapolis, MN). Harmine (286044-1G) and cyclohexamide (C4859) was purchased from Sigma-Aldrich (St. Louis, MS). Crizotinib (S1068) was purchased from Selleck Chemicals (Houston, TX). 4-(Methylnitrosoamino)-1-(3-pyridyl)-1-butanone
(NNK) (M325750) was purchased from Toronto Research Chemicals (Toronto, ON) and was dissolved in 0.9% saline.

### 4.3.2 Cell proliferation assays

For all viability experiments, cells were seeded at an appropriate density in 96 well plates and incubated for 24 hours. Cells were subsequently treated with a range of doses of the appropriate inhibitor for the indicated timepoints. Viability was determined using the CellTiter96® Aqueous One Solution Cell Proliferation Assay kit (Promega) or Cell-Titer Glo 2.0 Assay (Promega) according to manufacturer’s protocol. Data was analyzed as previously described in Chapter 2.3.2.

### 4.3.3 Western blot and antibodies

Following appropriate treatment, cells were harvested and lysed and subsequent protein was quantified and western blotting was performed as previously described (234). All information on antibodies is included in Table 3 (Appendix A). Western blot experiments were performed at least twice unless otherwise stated.

### 4.3.4 Lentiviral shRNA and cDNA overexpression

293T cells were seeded at a density of 4 x 10^6 in 25-cm² flasks. Following a 24-hour incubation period, cells were transfected to generate lentivirus using a four-plasmid system according to the
TRC Library Production and Performance protocols, RNAi Consortium, Broad Institute (264) and as previously described (234). A complete list of the constructs used is in Supplementary Tables 4-6 (Appendix A) and sequences of these constructs and primers used are available upon request.

4.3.5 Pulse-Chase experiments

For harmine pulse-chase experiments, H23 cells were treated with HGF (50 µg/ml) or vehicle for 48 hours. Cells were then treated with cyclohexamide (50 µg/ml) and harvested at the indicated time points. Data analysis was carried out as previously described in Chapter 2.3.11.

4.3.6 Xenograft experiments

All mice were maintained in pathogen-free animal facilities and experiments were conducted under an approved Institutional Animal Care and Use Committee protocol at the University of Pittsburgh (Pittsburgh, PA). For the patient-derived xenograft (PDX) experiments, we used a EGFR mutant MET amplified PDX established from the lung mass (MSK-LX29) of a patient with EGFR mutant (L858R mutation) MET amplified lung cancer (317). Tissue implantation, harmine treatment, and tumor measurement/analysis were carried out as previously described in Chapter 2.3.15.
4.3.7 Transgenic Mice

All mice were maintained in pathogen-free animal facilities and experiments were conducted under an approved Institutional Animal Care and Use Committee protocol at the University of Pittsburgh (Pittsburgh, PA). Constitutive Hgf and inducible Twist1 transgenic mice in the FVB/N inbred background were of the genotype: CTH (CCSP-rtTA/Twist1-tetO-luc/CCSP-Hgf). All the mice were weaned at 3–4 weeks of age and then placed on doxycycline containing chow or control chow at 6 weeks of age. At week 8, all mice received NNK i.p. injections twice per week (3mg per i.p. injection) for 5 weeks (6mg/week). Following NNK treatment, mice were observed for 17 weeks and then harvested for tumor analysis. Lungs tumors were analyzed by formalin inflation of the lungs and gross examination using a dissection microscope and Motic Image software to count and measure surface tumors.

4.4 RESULTS

4.4.1 Pharmacologic inhibition of TWIST1 overcomes HGF-mediated resistance to MET and EGFR TKIs in EGFR mutant and MET amplified NSCLC

HGF overexpression has been linked to EMT in cancer and resistance to EGFR and MET TKIs in EGFR- and MET-driven NSCLC, respectively (149,151,315,318-320). Additionally, HGF levels may be a key determinate of sensitivity or resistance to EGFR TKIs in treatment naïve EGFR mutant patients, as HGF is frequently overexpressed in patients with de-novo resistance to EGFR TKIs (149,151). Upregulation of TWIST1 has been associated with HGF-mediated EMT
(321,322). In breast cancer and melanoma, HGF increases TWIST1 expression and activity, potentially through increased AKT and ERK phosphorylation of TWIST1 (321,322). HGF treatment has also been linked to increased TWIST1 mRNA expression (323). However, the mechanisms and downstream mediators of HGF-driven resistance to targeted therapies in NSCLC remain poorly understood. In the current study, we first examined whether HGF could induce EMT and increase TWIST1 expression in NSCLC. We found that HGF treatment in NSCLC cell lines leads to EMT and induces TWIST1 expression (Figure 34A-B). We demonstrated that HGF treatment markedly increases the protein half-life of TWIST1 (Figure 34C), suggesting that HGF increases TWIST1 expression via a post-translational mechanism(s).

Given that HGF increased TWIST1 expression in NSCLC cell lines, we explored whether targeting TWIST1 can overcome HGF-mediated resistance to TKIs in MET amplified and EGFR mutant NSCLC cell lines. As seen in other studies (149,151,315), HGF treatment led to resistance to both EGFR TKI and MET TKIs in EGFR- and MET-driven NSCLC, respectively (Figure 35A-B). Interestingly, treatment with harmine was able to overcome HGF-mediated TKI resistance in both EGFR mutant and MET amplified NSCLC (Figure 35A-B). These studies suggest targeting TWIST1 pharmacologically may be a viable option to overcome HGF-driven resistance to MET and EGFR TKIs in NSCLC.
Figure 34: HGF treatment increases TWIST1 protein stability

(A-B) Induction of TWIST1 and markers of EMT (decreasing claudin or E-cadherin, increasing vimentin or β-catenin) in a KRAS mutant (A) and EGFR mutant (B) NSCLC cell lines after HGF treatment. (C) HGF treatment increases the half-life of TWIST1 protein. Protein concentration was quantified using densitometry and protein half-lives were determined using linear regression analysis.

Figure 35: Pharmacologic inhibition of TWIST1 overcomes HGF-mediated resistance to MET and EGFR TKIs in EGFR mutant and MET amplified NSCLC

(A-B) MTS assay demonstrating that in EGFR mutant, Hcc827 (A), and MET amplified, H1993 (B), NSCLC cell lines that harmine overcomes HGF-mediated resistance to EGFR and MET targeted therapy. Cells were co-treated with the indicated doses of harmine, HGF (50ng/ml), erlotinib (100nM), and/or crizotinib (100nM) for 72 hours, and then harvested for MTS analysis. Data represent mean ±SD (n=4 technical replicates). **, p<.01, 2-tailed Student’s t-test
4.4.2 TWIST1 mediates resistance to MET TKIs in MET altered NSCLC

In Chapter 3, we demonstrated that TWIST1 is both sufficient and required for resistance in EGFR mutant NSCLC. While we demonstrated in this study that TWIST1 expression is required for HGF-mediated resistance to TKIs in EGFR- and MET-driven NSCLC (Figure 35), we also explored the role of TWIST1 in MET TKIs resistance in the absence of HGF overexpression. We found that TWIST1 overexpression decreased crizotinib sensitivity in a MET amplified NSCLC cell line (Figure 36A). Additionally, we demonstrated that harmine treatment increases crizotinib sensitivity in both MET amplified and mutant crizotinib resistant NSCLC cell lines that express TWIST1 (Figure 36B-C). We also explored the in vivo efficacy of harmine in a patient-derived xenograft (PDX) mouse model of EGFR mutant MET amplified NSCLC. In this PDX model, harmine significantly inhibited tumor growth as a single agent (Figure 37), which suggests that targeting TWIST1 may be viable therapeutic option in patients with EGFR mutations that develop MET amplification as a mechanism of acquired resistance to EGFR TKIs. Additionally, these studies also suggest that targeting TWIST1 may be a viable strategy to overcome MET TKI resistance in MET altered NSCLC.
Figure 36: TWIST1 modulates sensitivity to crizotinib in MET altered NSCLC

(A) Cell-Titer Glo (CTG) assay demonstrating that TWIST1 overexpression decreases response to crizotinib in MET amplified H1648 cells. H1648 cells were infected with a TWIST1 overexpressing vector or a control vector. 72 hours following lentiviral infection, H1648 cells were treated with crizotinib for 24 hours and then harvested for CTG analysis.

(B-C) MTS assay demonstrating that harmine increases sensitivity to crizotinib in MET mutant (B) and MET amplified (C) NSCLC cell lines. MET altered NSCLC cells were treated for the indicated doses of harmine and crizotinib for 48 hours or 72 hours and then harvested for MTS analysis. Data represent mean ±SD (n=4 technical replicates). **, p<.01, 2-tailed Student’s t-test

Figure 37: Harmine has activity in a PDX mouse model of EGFR mutant MET amplified lung cancer

Tumor growth is decreased after 24 days of harmine treatment in a EGFR mutant MET amplified PDX model (MSK-LX29). Tumor size was monitored twice a week until tumors were approximately 2000 mm³. N = 7 mice in vehicle arm, and n=5 mice in harmine arm. Data represent mean ±SEM. **, p<.01, 2-tailed Student’s t-test.
4.4.3 Twist1 cooperates with Hgf to promote tumorigenesis in a mouse model of Hgf-driven lung cancer

We have previously demonstrated that Twist1 cooperates with mutant Kras in vivo to accelerate tumorigenesis (233). Twist1 expression in our transgenic mouse models of Kras mutant NSCLC functions to suppress OIS and promote the transformation of lung adenomas to adenocarcinomas (233). In the current study, we next examined whether Twist1 cooperates with Hgf in our carcinogen-induced model of Hgf-driven lung cancer (324,325). CCSP-Hgf (CH) mice that constitutively overexpress Hgf in the lung, develop an increased number of tumors in response to the tobacco carcinogen, Nicotine-derived nitrosamine ketone (NNK) (324,325). Interestingly, in the CH model, NNK-induced tumors are sensitive to the MET TKI, crizotinib (324,325). To elucidate the role of TWIST1 in Hgf-driven tumorigenesis, we generated CTH (CCSP-rtTA/Twist1-tetO-luc/CCSP-Hgf) mice that both constitutively overexpress Hgf and doxycycline inducibly overexpress Twist1 in the lung by crossing our previously characterized CH and CCSP-rtTA/Twist1-tetO-luc (CT) mice (233,324,325) (Figure 38A). Following exposure to NNK, the number of tumors in the CHT animals was not significantly different in the presence or absence of Twist1 expression. However, we observed a 57% increase in tumor size in the presence of doxycycline (Twist ON) in the CTH animals when compared to the CHT animals that did not receive doxycycline (Twist OFF) (Figure 38B). These data suggest that Twist1 expression may cooperate with Hgf to promote tumorigenesis in the setting of carcinogen-induced lung cancer.
Figure 38: Twist1 overexpression leads to increased tumor size in a mouse model of Hgf-driven lung cancer

(A) Schema representing the creation of CCSP-rtTA/Twist1-tetO-luc/CCSP-Hgf (CHT) by crossing CCSP-Hgf (CH) mice with CCSP-rtTA/Twist1-tetO-luc (CT). CHT mice constitutively overexpress HGF and doxycycline inducibly express Twist1. (B) TWIST1 overexpression leads to increased tumor size in a NNK-induced CCSP-rtTA/Twist1-tetO-luc/CCSP-Hgf (CTH) lung cancer model in the presence of doxycycline. Tumor size was log2 transformed. A single linear mixed effects was fitted to estimate group differences in tumor size, with a random intercept to accommodate multiple tumors per animal. On average tumor size in the CHT+NNK+DOX group was 57% greater than for CHT+NNK (95% CI 19%-108% greater), p=0.0015.

4.5 DISCUSSION

Our study is the first to demonstrate that HGF treatment leads to increased TWIST1 expression in NSCLC. We also demonstrate that HGF likely increases TWIST1 expression through a post-translational mechanism, as HGF treatment significantly increases TWIST1 protein half-life. Previous studies have demonstrated that TWIST1 can be regulated post-translationally by ERK and AKT phosphorylation. The major regulators of TWIST1 protein half-life are mitogen activated kinases (MAPKs). Phosphorylation of TWIST1 on serine 68 (S68) of TWIST1 by MAPKs such p38, JNK, and ERK1/2 leads to increased protein stability by inhibiting its ubiquitination and proteasomal degradation (203). Interestingly, we have evidence that TWIST1
can increase ERK phosphorylation (data not shown), suggesting that there may be a positive feedback loop between ERK1/2 and TWIST1. We have observed an increase ERK phosphorylation 72 hours following TWIST1 overexpression. Currently, we are investigating the kinetics of this potential feedback loop between ERK and TWIST1. Additionally, AKT2 phosphorylation of TWIST1 is required for TWIST1-mediated metastasis in breast cancer (222). Previous studies have demonstrated that HGF/MET signaling leads to increased ERK and AKT activity (147). Future experiments will be aimed at determining if ERK and/or AKT phosphorylation of TWIST1 is required for HGF-mediated induction of TWIST1. Additionally, if ERK and/or AKT phosphorylation of TWIST1 is required for HGF induction of TWIST1, we will determine if treatment with ERK and/or AKT inhibitors is able to prevent TWIST1 induction following HGF-treatment. We also demonstrated that harmine treatment can overcome HGF-mediated resistance to EGFR and MET TKIs in EGFR mutant and MET amplified NSCLC, respectively. Currently, we are following up the aforementioned harmine experiments with genetic approaches to inhibit TWIST1 to ensure that TWIST1 inhibition by harmine is the main mechanism by which harmine overcomes HGF-mediated TKI resistance.

Our study also demonstrated that TWIST1 expression is sufficient to cause resistance to MET TKIs and that targeting TWIST1 with harmine increases crizotinib sensitivity in MET altered NSCLC cell lines. In Chapter 3, we demonstrated that TWIST1 direct suppression of BCL2L11 (gene encoding BIM) transcription is critically important for TWIST1-mediated resistance EGFR TKIs in EGFR mutant NSCLC. Currently, we are exploring if TWIST1-suppression of apoptosis plays a role in TWIST1-mediated resistance to MET TKIs in the presence and absence of HGF. We are also examining if TWIST1 negatively regulates BIM expression in MET altered NSCLC. TWIST1 negative regulation of BIM in MET-driven NSCLC
also has implications in HGF-mediated resistance to MET and EGFR TKIs, as HGF suppression of BIM has been previously shown to be required for HGF-mediated resistance to targeted therapies in melanoma (326). If TWIST1 suppresses BIM-mediated apoptosis in response to MET TKIs, we will determine if use of BCL-2/BCL-xL inhibitors, such as navitoclax which is currently in clinical trials, is able to overcome TWIST1-mediated MET TKI resistance. Developing pharmacological strategies to overcome TWIST1-mediated resistance has important implications for not only patients with MET-driven NSCLC resistant to MET TKIs but also EGFR mutant patients with MET amplification as a mechanism of acquired resistance to EGFR TKIs, such as osimertinib.

In our mouse model of Hgf-driven tobacco carcinogen-induced lung cancer, we demonstrated that Twist1 expression leads to increased tumor size, suggesting that Twist1 may cooperate with Hgf in vivo to promote tumorigenesis. We are currently examining the mechanisms by which Twist1 promotes Hgf-mediated tumorigenesis and increases tumor size. Given that we previously demonstrated that Twist1 suppresses oncogene-induced senescence (OIS) in transgenic models of Kras mutant lung cancer, we are specifically investigating if Twist1 suppresses failsafe programs of OIS and/or apoptosis in our mouse model of Hgf-driven lung cancer. Importantly, CCSP-Hgf (CH) mice that constitutively overexpress Hgf in the lung develop tumors that are sensitive to the MET TKI, crizotinib (147,324,325). Utilizing our CHT mice that constitutively overexpress Hgf and doxycycline inducibly overexpression Twist1, we are investigating whether Twist1 overexpression leads to crizotinib resistance. Additionally, if Twist1 expression is sufficient to mediate crizotinib resistance in this model, we will explore if targeting TWIST1 with harmine is able to overcome Twist1-mediated crizotinib resistance.
In summary, we demonstrated that HGF treatment in NSCLC cells led to EMT and increased TWIST1 expression. TWIST1 induction following HGF treatment most likely occurs through a post-translational mechanism, as HGF significantly increased TWIST1 protein half-life. Targeting TWIST1 with harmine was able to overcome HGF-mediated resistance to MET and EGFR TKIs in MET amplified and EGFR mutant NSCLC cell lines. TWIST1 overexpression was also sufficient to decrease crizotinib sensitivity in a MET amplified NSCLC cell line. Additionally, harmine treatment increased crizotinib sensitivity in MET altered crizotinib resistant NSCLC cells that express TWIST1 and had single agent activity in a PDX mouse model of EGFR mutant MET amplified NSCLC. In our mouse model of Hgf-driven lung cancer, we demonstrated that Twist1 expression led to increased tumor size. Overall, our results suggest that TWIST1 is a potential therapeutic target to overcome EGFR and MET TKI resistance in the presence and absence of HGF overexpression.
5.0 TWIST1 MEDIATES RESISTANCE TO TRAIL-BASED THERAPIES THROUGH DIRECT UPREGULATION OF C-FLIP

5.1 ABSTRACT

TNF-relates apoptosis inducing ligand (TRAIL) is a death ligand that binds death receptor 4 (DR4) and death receptor 5 (DR5) and activates extrinsic apoptosis. TRAIL is a promising therapeutic option as it can selectively induce apoptosis in cancer cells, while sparing normal cells. However, TRAIL has limited clinical efficacy due to the frequency of de-novo resistance and acquired resistance. Interestingly, a novel TRAIL-inducing small molecule TIC10/ONC201 has efficacy in solid tumors, however, mechanisms of resistance to TIC10/ONC201 have already been identified. In non-small cell lung cancer (NSCLC), epithelial-mesenchymal transition (EMT) has been associated with resistance to TRAIL. We have previously demonstrated that the EMT-transcription factor TWIST1 is required for oncogene-driven NSCLC, suppresses both oncogene-induced senescence (OIS) and apoptosis, and mediates resistance to targeted therapies in NSCLC. In this study, we investigated the role of TWIST1 in mediating resistance to TRAIL-based therapies. We found that TWIST1 overexpression suppressed both intrinsic- and extrinsic-mediated apoptosis in NSCLC cells. By genetically inhibiting TWIST1 and overexpressing TWIST1, we demonstrated that TWIST1 positively regulates expression of cFLIP, a negative regulator of DR4/5 signaling, and negatively regulates expression of BID, a pro-apoptotic protein.
that mediates crosstalk between intrinsic and extrinsic apoptosis. TWIST1 induced cFLIP expression through a direct transcriptional mechanism as we found that TWIST1 directly bound to the CFLAR (gene encoding cFLIP) promoter in ChIP assays and induced luciferase expression in a CFLAR promoter reporter construct. We also demonstrated that TWIST1 overexpression was sufficient to cause resistance to both recombinant TRAIL and TIC10. TWIST1 expression was required for TRAIL resistance as knockdown of TWIST1 in a TRAIL-resistance NSCLC cell line resulted in increased sensitivity to TRAIL. These studies demonstrate TWIST1 mediates resistance to TRAIL-based therapies by upregulating of its novel target gene, cFLIP.

**Contributors to study:** Zachary A. Yochum\(^1\,^2\), Susheel K. Khetarpal \(^2\), Timothy F. Burns\(^1\,^2\)

\(^1\)Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA
\(^2\)Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.

Manuscript in preparation.

### 5.2 INTRODUCTION

TNF-relates apoptosis inducing ligand (TRAIL) is a death ligand that induces extrinsic apoptosis by activating death receptor 4 (DR4) and death receptor 5 (DR5) signaling (173). Binding of TRAIL to DR4/5 results in receptor trimerization and recruitment of Fas associated via death domain (FADD) (173). Procaspace-8 subsequently binds to FADD, forming a death
receptor-FADD-caspase-8 complex referred to as the death inducing signaling complex (DISC) (173). At the DISC, procaspase-8 is cleaved into its active form, which induces apoptosis by activating executioner caspases-3/7 (173). Additionally, caspase-8 can activate intrinsic apoptosis by cleaving BID, a pro-apoptotic BCL-2 protein that translocates to the mitochondria. At the mitochondria, BID can induce apoptosis by directly activating BAX/BAK or inhibiting anti-apoptotic BCL-2 proteins.

Preclinical studies have demonstrated TRAIL can selectively induce apoptosis in cancer cells, while sparing normal cells (327). Despite promising preclinical evidence for the potential efficacy of recombinant TRAIL and TRAIL receptor agonists, these TRAIL-based therapies have largely failed clinically (328). De-novo and acquire resistance to TRAIL-based therapies have limited their clinical efficacy in solid tumors (329). Several mechanisms of resistance to TRAIL-based therapies have been identified and typically involve modulation of proteins within the extrinsic apoptotic pathway (168,327,329). One mechanism is upregulation of FLICE-inhibitor protein (cFLIP), which blocks caspase-8 activation at the DISC (330). Alternatively, cancers can decrease caspase-8 expression (331). Aberrations in DR4/5 can also cause resistance to TRAIL. Cancers frequently decrease DR4/5 transport to the plasma membrane or harbor mutations in DR4/5 that result in impaired caspase-8 activation at the DISC (178,327,332). Interestingly, Type II cells require BID cleavage by caspase-8 in order to undergo apoptosis. In Type II cells, resistance to TRAIL can be mediated by increasing expression of anti-apoptotic proteins such as BCL-2, MCL-1, and BCL-xL (327,329,333). New TRAIL-based therapies have shown activity in cancers resistant to recombinant TRAIL (328,334). Of note, TIC10/ONC201, a first-in-class small molecule that induces TRAIL and DR5 expression, has marked activity in vivo and in vitro activity in solid tumors, including lung cancer (334). TIC10 inhibits both ERK
and AKT, which results in FOXO3A translocation to the nucleus and increased TRAIL and DR5 transcription (334). The activity of TIC10 requires TRAIL/DR5 signaling (334).

Patients with non-small cell lung cancer (NSCLC) are currently classified based on histology and molecular driver. Some subsets of patients with targetable molecular drivers like those patients with *EGFR* mutation or *ALK* translocations demonstrate marked clinical benefit from therapies targeting these molecular drivers (10). However, most patients do not have a targetable oncogenic molecular driver and the most frequent driver, mutant *KRAS*, is not targetable (10). There is a significant need for novel agents to durably treat oncogene-driven NSCLC.

While there is a subset of non-small cell lung cancer (NSCLC) that are sensitive to TRAIL and TRAIL-based therapies, most NSCLC are resistant to these therapies (335,336). Interestingly, epithelial-mesenchymal transition (EMT) has been associated with TRAIL resistance in NSCLC (337). Our group and others have previously demonstrated that the EMT-transcription factor, TWIST1, is required for oncogene-driven NSCLC and can confer chemoresistance and resistance to targeted therapies in NSCLC (160,198,232,234). In the current study, we investigated the role of TWIST1 in mediating resistance to recombinant TRAIL and TRAIL-based therapies. We found that apoptosis is required for growth inhibition following genetic inhibition of *TWIST1*. TWIST1 suppresses apoptosis through transcriptional regulation of both intrinsic and extrinsic pathway members. Interestingly, TWIST1 modulates multiple proteins within extrinsic apoptotic pathway, including cFLIP. TWIST1 regulates cFLIP expression by increasing transcriptional activity at the *CFLAR* (gene encoding cFLIP) promoter and directly binding to multiple E-box binding sites with the *CFLAR* promoter. Additionally, overexpression of TWIST1 leads to TRAIL resistance, while TWIST1 inhibition increases
TRAIL sensitivity. TWIST1 also suppresses apoptosis in response to the novel TRAIL-inducing therapy, TIC10/ONC201.

5.3 METHODS

5.3.1 Cell lines and reagents

PC9, H460, Calu-6, H23 and embryonic kidney cell line HEK 293T were acquired from the American Type Culture Collection (ATCC) and were cultured in the recommended ATCC media. The identity of the aforementioned cell lines was verified by autosomal STR (short tandem repeat) profiling done at University of Arizona Genetics Core (UAGC). Cell lines were tested for mycoplasma every six months using MycoAlert Detection Kit (Lonza). Recombinant TRAIL was purchased from PeproTech (Rocky Hill, NJ). Harmine was purchased from Sigma-Aldrich (St. Louis, MS). TIC10/ONC201 was obtained from Oncoceutics (Philadelphia, PA).

5.3.2 Cell proliferation assays

For all viability experiments, cells were seeded at an appropriate density in 96 well plates and incubated for 24 hours. Cells were subsequently treated with a range of doses of the appropriate inhibitor for the indicated timepoints. Viability was determined using the CellTiter96® Aqueous One Solution Cell Proliferation Assay kit (Promega) or Cell-Titer Glo 2.0 Assay (Promega) according to manufacturer’s protocol. Data was analyzed as previously described in Chapter 2.3.2.
5.3.3 Western blot and antibodies

Following appropriate treatment, cells were harvested and lysed and subsequent protein was quantified and western blotting was performed as previously described (234). All information on antibodies is included in Table 3 (Appendix A). Western blot experiments were performed at least twice unless otherwise stated.

5.3.1 Luciferase reporter assay

Luciferase promoter reporter assays were performed as previously described (265). Cell extracts were prepared 48 hours after transfection in passive lysis buffer, and the reporter activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Full length, PR4, PR5 CFLAR constructs were a gift from Wafik El-Diery (Addgene plasmid #16016, 19129, and 19130). R281 and R201 fragments were amplified from full length CFLAR construct. R281, R201, and pGL3 were digested with Kpn and HindIII. Subsequently, R281 and R201 were cloned into pPGL3 using T4 DNA ligase. R281 and R201 pGL3 constructs were all sequence verified.

5.3.2 Chromatin immunoprecipitation

PC9 TRE3G-TWIST1 cells were seeded in 15cm dishes and incubated for 24 hours. Cells were treated with 1000ng/ml of doxycycline. Following 24 hours of doxycycline treatment, cells were harvested and Chromatin Immunoprecipitation (ChIP) was performed using SimpleChIP
Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to manufacturer’s recommendations. ChIP primers that were used are included in Table 8 (Appendix A). For ChIP, 2µg of ChIP-grade TWIST1 antibody (Abcam, Ab5087) and 2µg Mouse IgG, Whole Molecule Control (Thermo Scientific, 31903) were used.

5.3.3 Lentiviral shRNA and cDNA overexpression

293T cells were seeded at a density of 4 X 10^6 in 25-cm² flasks. Following a 24 hour incubation period, cells were transfected to generate lentivirus using a four-plasmid system according to the TRC Library Production and Performance protocols, RNAi Consortium, Broad Institute (264) and as previously described (234). A complete list of the constructs used is in Supplementary Tables 4-6 (Appendix A) and sequences of these constructs and primers used are available upon request. A pCR3-cFLIPS plasmid was obtained from Dr. Dr. Shi-Yong Sun (Emory University) and the insert was cloned into the pDONOR plasmid. Using gateway cloning cFLIPS was then cloned into pLENTI6 destination plasmid.

5.4 RESULTS

5.4.1 Apoptosis following loss of TWIST1 expression requires both the intrinsic and extrinsic apoptotic pathways

We have previously demonstrated that TWIST1 expression is required for oncogene-driven NSCLC including those tumors with KRAS mutations, EGFR mutations, and MET
mutations/amplifications (232-234). Loss of TWIST1 expression results in growth inhibition, typically due to induction of oncogene induced senescence (OIS) (232-234). However, there are a subset of NSCLC cell lines that may be more dependent on TWIST1 expression for survival and undergo apoptosis following loss of TWIST1 expression (Figures 12, 24 and 39). We investigated the mechanisms by which TWIST1 suppresses apoptosis in NSCLC. We first demonstrated that apoptosis is required for growth inhibition following genetic inhibition of \textit{TWIST1} as use of a pan-caspase inhibitor rescues growth inhibition following TWIST1 knockdown (Figure 40). In order to better understand the requirement of the intrinsic apoptotic pathways following loss of TWIST1 expression, we overexpressed BCL-2, an inhibitor of intrinsic apoptosis, or genetically silenced \textit{BCL2L11}, a pro-apoptotic gene involved in promoting intrinsic apoptosis that we demonstrated in Chapter 3.4.3 is negatively regulated by TWIST1. We demonstrated that BCL-2 overexpression or BIM knockdown partially suppressed apoptosis and growth inhibition following genetic inhibition of \textit{TWIST1} in Calu-6 cells, a \textit{KRAS} mutant NSCLC cell line that undergoes apoptosis following knockdown of TWIST1 (Figure 41 and Figure 42A-B). In addition, knockdown of BIM decreased the cytotoxicity of harmine, a TWIST1 inhibitor (Figure 42C). To explore the role of the extrinsic pathway, we overexpressed cFLIPs, an inhibitor of extrinsic apoptosis, in Calu-6 cells. We demonstrated that cFLIPs overexpression partially rescued apoptosis and growth inhibition, following genetic inhibition of \textit{TWIST1} (Figure 41C). The rescue observed with cFLIPs overexpression was less robust than that seen with BCL-2 overexpression, which suggests that the intrinsic pathway is the dominant pathway in Calu-6 cells. Alternatively, Calu-6 cells may be type II cells in which death receptor activity is not sufficient to activate executioner caspases, but rather activates intrinsic apoptosis.
by cleaving the pro-apoptotic protein BID. Overall, these data suggest that TWIST1 suppresses both intrinsic and extrinsic-mediated apoptosis.

**Figure 39: Silencing of TWIST leads to apoptosis in NSCLC cell lines**

UPPER: Silencing of TWIST with two different shRNAs (shTWIST1#1 and shTWIST1#3) resulted in growth inhibition of KRAS mutant (H23 and Calu-6) NSCLC cell lines, as shown by representative triplicates of crystal violet staining. LOWER: Western blot demonstrating an increase in cleaved PARP, a marker of apoptosis, 4 days following shRNA infection.
Figure 40: Growth inhibition following genetic inhibition of TWIST1 requires apoptosis
Cell-Titer Glo proliferation assay demonstrating that growth inhibition following TWIST1 knockdown can be prevented by treatment with Q-VD-oph, a pan caspase inhibitor. Cells were pre-treated with Q-VD-oph at the indicated µM concentrations (DMSO was used as control) for 3 hours and were subsequently infected with the indicated shRNA for 4 days (Calu-6) or 5 days (H23). Data represent mean ±SD (n=4 technical replicates). **, p< .01, 2-tailed Student’s t-test
Figure 41: Overexpression of c-FLIPs or BCL-2 partially rescues apoptosis and growth inhibition following silencing of TWIST1.

(A) Cell-Titer Glo proliferation assay demonstrating that overexpressing c-FLIPs or Bcl-2 can partially rescue growth inhibition following silencing of TWIST1. Calu-6 cells that stably overexpress c-FLIPs, Bcl-2, or empty vector were infected with the indicated shRNA for 96 hours. Data represent mean ±SD (n=4 technical replicates). **, p<.01, 2-tailed Student’s t-test

(B) Western blot demonstrating that overexpressing of c-FLIPs or Bcl-2 can partially prevent PARP cleavage following silencing of TWIST1. Calu-6 cells that stably overexpress c-FLIPs or Bcl-2 were infected with the indicated shRNA for 72 hours and then harvested for Western blot analysis (cells transduced with empty vector, pLENTI6, were used as control).

(C) Overexpression of Bcl-2 or c-FLIPs results in partial rescue of long-term growth inhibition following silencing of TWIST1, as shown by duplicates of crystal violet staining 24 days following plating (28 days following TWIST1 knockdown).
Figure 42: Knockdown of BIM partially rescues growth inhibition following pharmacologic and genetic inhibition of TWIST1

(A) Western blot demonstrating BIM knockdown following infection with two distinct shRNA targeting BIM. (B) LEFT: Western blot demonstrating that knockdown of BIM can partially prevent PARP cleavage following silencing of TWIST1. Calu-6 cells that stably express shScram or shBIM were infected with the indicated shRNA for 72 hours and then harvested for Western blot analysis. RIGHT: Cell-Titer Glo (CTG) proliferation assay demonstrating that knockdown can partially rescue growth inhibition following silencing of TWIST1. Calu-6 cells that stably express shScram or shBIM#1/2 were infected with the indicated shRNA for 96 hours. Data represent mean ± SD (n=4 technical replicates). 2-tailed Student’s t-test. **, p<.01

(C) LEFT: Western blot demonstrating that harmine treatment increases BIM expression. Calu-6 cells were treated with the indicated doses of harmine for 48 hours and then harvested for Western blot analysis. RIGHT: CTG proliferation assay demonstrating that BIM knockdown can partially rescue harmine-induced growth inhibition. Calu-6 cells stably expressing shBIM#1/2 or shScram were treated with harmine at the indicated µM concentrations (DMSO was used as control) for 96 hours. Data represent mean ± SD (n=4 technical replicates). 2-tailed Student’s t-test. **, p<.01
5.4.2 TWIST1 directly upregulates cFLIP

We have previously demonstrated that TWIST1 can modulate the intrinsic apoptotic protein, BIM (Figure 29). Given evidence that extrinsic pathway may be important for apoptosis following loss of TWIST1 expression (Figure 41), we explored whether TWIST1 modulates apoptotic proteins within the extrinsic pathway. Knockdown of TWIST1 in Calu-6 cells results in cleavage of caspase-3, -9, and -8 confirming that apoptosis following loss of TWIST1 involves both intrinsic and extrinsic apoptosis (Figure 43A). Additionally, TWIST1 knockdown resulted in increased levels of BID and decreased levels of both the short and long isoforms of cFLIP (cFLIPs and cFLIPL) (Figure 43A). Conversely, overexpression of TWIST1 results in increased levels of cFLIPs, cFLIPL and decreased levels of BID, suggesting that TWIST1 may regulate both apoptotic proteins (Figure 43B).

cFLIP can be regulated on the transcriptional and post-translational levels (338). Transcription factors like NF-kB and androgen receptor have been shown to transcriptionally induce cFLIP and decrease sensitivity to TRAIL (338-340). Interestingly, other oncogenic transcription factors like cMYC have been shown to suppress cFLIP expression and confer sensitivity to TRAIL (338,341). We investigated the mechanism(s) by which TWIST1 regulates cFLIP expression in NSCLC cells. Initially, we explored whether TWIST1 could modulate CFLAR (gene encoding cFLIP) promoter activity, using a luciferase reporter construct containing the CFLAR promoter (341). We demonstrated that overexpression of TWIST1 increased CFLAR promoter activity, resulting in 3-fold increase in luciferase activity (Figure 44A). Of note, there are multiple E-box binding sites, the canonical binding site of TWIST1, within the CFLAR
promoter. By removing regions of the putative CFLAR promoter, we created multiple luciferase promoter constructs that allowed for interrogation of the role of specific E-boxes in TWIST1-mediated transactivation of the CFLAR promoter (Figure 44A). Using these modified constructs, we demonstrated that TWIST1 transactivation was not affected by removal of the 5 E-boxes within a 676 base pair (bp) upstream region (-1179 to -503) in the CFLAR promoter (Figure 44A). However, TWIST1-mediated transactivation was markedly reduced in the PR4 and R281 constructs, suggesting that TWIST1 transactivation of the CFLAR promoter requires an E-box approximately 500 bp upstream of the transcriptional start site (TSS) and an E-box approximately 280 bp downstream of the TSS (Figure 44A).

Additionally, we and others have previously shown that TWIST1 homo- versus heterodimerization can influence the ability of TWIST to regulate target genes (248,265). We demonstrated that both the TWIST1-TWIST1 homodimer and TWIST1-E2A heterodimer were able to transactivate the CFLAR promoter (Figure 44B). Of note, the TWIST1-E2A heterodimers did demonstrate greater induction of luciferase activity than the TWIST1-TWIST1 homodimer (5-fold), suggesting that the TWIST1-E2A heterodimer may more effectively upregulate cFLIP (Figure 44B), which is consistent with our findings for other TWIST1 responsive promoters (Figure 19B). In order to determine if TWIST1 is directly regulating CFLAR transcription, we performed TWIST1-ChIP on multiple regions of the CFLAR promoter. We demonstrated that TWIST1 binds to two regions of the CFLAR promoter, a double E-box approximately 1000 bp upstream of the TSS (Primer#2) and the E-box approximately 500 bp upstream of the TSS (Primer#4) (Figure 45). Given the aforementioned luciferase reporter data, TWIST1 binding to the E-box in Primer#2 may not be required for TWIST1-mediated transactivation of the CFLAR promoter, given that removal of this double E-box did not affect
luciferase activity. TWIST1 binding to the E-box in Primer#4 seems to be required to be TWIST1-mediated transactivation, as its removal results in suppressed luciferase activity. Of note, TWIST1 did not directly bind to E-box downstream of the TSS (Primer#5) in our ChIP experiment, which was required TWIST1-mediated transactivation of the CFLAR promoter in our luciferase experiments. One potential explanation for the lack of TWIST1 binding to this downstream E-box may be that TWIST1 directly upregulates other EMT-transcription factors which can subsequently bind to this downstream E-box and regulate CFLAR expression. This phenomenon has been observed with other TWIST-regulated genes. For example, TWIST1-suppression of E-cadherin requires TWIST1 direct upregulation of the EMT-transcription factor, SNAI2 (236). However, TWIST1 upregulation of SNAI2 is unlikely to be important in CFLAR regulation, as overexpression of SNAI2 does not modulate CFLAR promoter activity (data not shown).

Another potential reason for the lack of binding of TWIST1 to this aforementioned downstream E-box (Primer#5) may be that the CFLAR promoter construct utilized may not recapitulate the chromatin structure of the endogenous CFLAR gene, as transiently transfected DNA does not recapitulate the chromatin structure of endogenous genes (342). Additionally, there are predicted binding sites for Retinoic X Receptor (RXR) and Aryl hydrocarbon receptor (AhR) exclusively found at sites flanking the E-boxes that TWIST1 binds (Primer#2 and Primer#4). Interestingly, RXR has previously been identified as a candidate co-factor for TWIST1 (343). TWIST1 binding specifically to these sites may be influenced by the presence of these other transcription factors.
Figure 43: Modulation of TWIST1 expression results in altered expression of extrinsic apoptotic pathway members

(A) Western blot demonstrating that genetic silencing of TWIST1 results in an increase in BID levels as well as cleaved PARP and caspase-3, -8, -9 and a decrease in cFLIP expression in KRAS mutant Calu-6 NSCLC cells, 4 days following shRNA infection. (B) Western blot demonstrating induction of cFLIPS and cFLIP_L and repression of BID levels following exogenous TWIST1 protein expression in Calu-6 TRE3G-TWIST1 and H460 TRE3G-TWIST1 cells 72 hours (Calu-6) or 48 hours (H460) after treatment with the indicated doses of doxycycline.
Figure 44: The TWIST1 homodimer and heterodimer transactivates the CFLAR promoter
(A) UPPER: A schematic representation of c-FLIP promoter constructs utilized in the current study. “E” marks denote the canonical E-box sequences (CANNTG) to which TWIST1 can potentially bind. LOWER: Luciferase assay showing increased CFLAR promoter activity in 293T cells transiently overexpressing TWIST1 compared to the reporter activity of the vector alone. 293T cells were co-transfected with 0.24 µg of pGL4-cFLIP-Luc reporter plasmid, 0.48 µg of either W118 empty plasmid or TWIST1 and 0.08 µg pRL-TK. All values are normalized to the luciferase activity of pGL4-cFLIP-Luc alone that corresponds to 1.
(B) Luciferase assay showing increased induction of CFLAR promoter activity in cells transiently overexpressing either TWIST1 alone, TWIST-TWIST homodimer, TWIST-E12 heterodimer, or TWIST-E47 heterodimer compared to the reporter activity with the vector alone (fold induction = 1) after 48 hours. 293T cells were co-transfected with 0.40 µg of pGL4-cFLIP-Luc reporter plasmid, 0.40 µg of either W118 empty plasmid, TWIST, TWIST-TWIST, TWIST-E12, or TWIST-E47 expression plasmids and 0.01 µg pRL-TK after 48 hours. All luciferase values were normalized to the corresponding renilla luciferase value in each well.
5.4.3 TWIST1 mediates resistance to TRAIL-based therapies

Upregulation of cFLIP has been linked to TRAIL resistance (338). Additionally, previous studies have demonstrated that EMT may mediate resistance to TRAIL-based therapies (337). Given that TWIST1 can induce EMT and upregulate cFLIP, we investigated whether TWIST1 can mediate resistance to TRAIL. In order to this we created doxycycline inducible TWIST1 overexpressing H460 KRAS mutant NSCLC cells, which is a cell line sensitive to TRAIL. In this cell line, enforced expression of TWIST1 was sufficient to cause resistance to TRAIL (Figure 46A). Additionally, in Calu-6 cells, a TRAIL resistant NSCLC cell line, we demonstrated that
knockdown of TWIST1 increased TRAIL sensitivity (Figure 46B). These data suggested that TWIST1 is both sufficient and required for TRAIL resistance in a subset of NSCLC cell lines. Next, we explored whether TWIST1 mediates resistance to the novel TRAIL-inducing small molecule, TIC10. Previous studies have demonstrated that TIC10 has marked antitumor activity in solid tumors, including NSCLC (334,335). Additionally, previous studies have demonstrated that TIC10 cytotoxicity is primarily through induction of extrinsic apoptosis and that cFLIP overexpression can mediate resistance to TIC10 (344). Here, we investigated whether TWIST1 overexpression modulates response to TIC10 by generating doxycycline inducible TWIST1 overexpressing PC9 and H460 NSCLC cells, which are TIC10 sensitive NSCLC lines. We demonstrated that TWIST1 overexpression leads to suppression of TIC10-induced apoptosis in both H460 and PC9 NSCLC cell lines (Figure 46C). These data suggesting that TWIST1 can mediate resistance recombinant TRAIL and other TRAIL-based agents.
Figure 46: TWIST1 mediates resistance to TRAIL-based therapies

(A) Cell-Titer Glo (CTG) proliferation assay demonstrating decreased TRAIL sensitivity following TWIST1 overexpression. H460 doxycycline inducible TWIST1 cells were treated with doxycycline for 48 hours prior to TRAIL treatment and treated with TRAIL for 24 hours. Data represent mean ±SD (n=4 technical replicates). **, p<.01, 2-tailed Student’s t-test

(B) CTG proliferation assay demonstrating increased TRAIL sensitivity following TWIST1 knockdown. Calu-6 cells were infected with the indicated shRNA for 48 hours and the treated with TRAIL for 48 hours. Data represent mean ±SD (n=4 technical replicates). **, p<.01, 2-tailed Student’s t-test

(C) Western blot demonstrating TWIST1 overexpression suppresses TIC10-induced apoptosis in PC9 and H460 cells. PC9 and H460 doxycycline inducible TWIST1 cells were treated with doxycycline for 72 hours and subsequently treated with TIC10 for 24 hours.
5.5 DISCUSSION

We have previously shown that TWIST1 is required for oncogene-driven NSCLC and primarily functions to suppress OIS and apoptosis in NSCLC (232-234). In Chapter 3, we demonstrated that TWIST1 mediates resistance to EGFR tyrosine kinase inhibitors (TKIs) in \textit{EGFR} mutant NSCLC by suppressing BIM-mediated apoptosis. Here, we demonstrated that growth inhibition following TWIST1 inhibition requires both intrinsic and extrinsic apoptosis. We establish that TWIST1 negative regulation of extrinsic apoptosis leads to resistance to both recombinant TRAIL and the novel TRAIL-inducing small molecule, TIC10. Our studies suggest that TWIST1 may be a viable therapeutic target to overcome both \textit{de-novo} and acquired resistance to TRAIL-based therapies in NSCLC.

Our study is the first to demonstrate that the EMT-transcription factor (EMT-TF), TWIST1, mediates resistance to TRAIL and TIC10. Previous studies have implicated EMT in TRAIL resistance, however, the mechanism(s) by which an EMT phenotype promotes TRAIL resistance remain poorly elucidated (337,345). Our study suggests that EMT-TFs may mediate resistance to TRAIL-based therapies by suppressing extrinsic apoptotic signaling. Numerous studies have demonstrated that TWIST1 is a potent inducer of EMT (198), however, TWIST1-mediated TRAIL resistance may occur independently of EMT, as TWIST1 expression does not lead to an EMT phenotype in all NSCLC utilized in the current study. While we established that TWIST1 overexpression is sufficient for TRAIL and TIC10 resistance in NSCLC cell lines, we are currently exploring the role of TWIST1 in mediating resistance to TRAIL and TIC10 \textit{in vivo}, using xenograft mouse models. Our studies also suggest that TWIST1 is a potential therapeutic target to overcome resistance to TRAIL-based therapies, as we demonstrated that knockdown of TWIST1 can resensitive TRAIL-resistant NSCLC cells to TRAIL. In Chapter 3, we
demonstrated resistance to EGFR TKIs can be overcome with our novel small molecule inhibitor of TWIST1, harmine. We are currently explored whether harmine treatment is able to overcome TRAIL and TIC10 resistance both in NSCLC cell lines and in vivo using cell line and patient-derived xenograft mouse models.

Our study identified CFLAR (gene encoding cFLIP) as a novel target gene of TWIST1. Given that cFLIP has been previously identified as a mediator of resistance to TRAIL (181,330), it is likely that TWIST1 upregulation of cFLIP is a mechanism by which TWIST1 mediates resistance to TRAIL/TIC10. However, future studies will be aimed at determining if TWIST1 upregulation of cFLIP is the only mediator of TWIST1-mediated resistance or if TWIST1 regulation of other apoptotic proteins is important for TWIST1-mediated TRAIL resistance. Previous studies have demonstrated that downregulation of the pro-apoptotic proteins BIM or BID can cause resistance to TRAIL (346-348). Given that we have found that TWIST1 negatively regulates both proteins, future studies we be aimed at determine if TWIST1 regulation of either protein is important for TWIST1-mediated TRAIL resistance. Additionally, we are exploring the mechanism(s) by which TWIST1 negatively regulates BID expression. Previous studies have demonstrated that BID is regulated at both the transcriptional and post-translational levels (349). BID phosphorylation and ubiquitination play an important role in its post-translation stability (349,350). Few studies have investigated BID transcriptional regulation. However, BID has been identified as a p53 target gene that is important for p53-mediated apoptosis in response to chemotherapy (349,351). Given that we observed decreased BID protein levels with TWIST1 overexpression and conversely, increased expression with silencing of TWIST1 in p53 mutant NSCLC cell lines, it likely that that TWIST1 regulation of BID is p53 independent. Alternatively, BID can be transcriptionally repressed by the transcription factor,
promyelocytic leukemia zinc finger (PLZF) protein (352). Currently, we are exploring if TWIST1 directly or indirectly regulates BID transcription and/or regulates BID expression by modulating its post-translational modification.

Initial studies investigating mechanisms of resistance to TIC10 have revealed that overexpression of cFLIP or BCL-2 leads to TIC10 resistance (344). Interestingly, a recent study demonstrated that TIC10 activity in vivo requires NK cells, as depletion of NK cells completely abrogated the antitumor activity of TIC10 (353). This study demonstrated that TIC10 increased NK cell TRAIL secretion, activation, and accumulation in tumors (353). While TWIST1 has not been implicated in NK cell biology, previous studies have demonstrated that TWIST1 can suppress NF-κB signaling and suppress inflammation (198). Additionally, recent studies have demonstrated that an EMT phenotype is associated with an immunosuppressive tumor microenvironment (354-356). In our ongoing experiments investigating the role of TWIST1 in TIC10 resistance in vivo, we will investigate whether TWIST1 modulates NK cell activity and accumulation as a potential mechanism of resistance.

In summary, we demonstrated that TWIST1 suppresses both intrinsic and extrinsic apoptosis in NSCLC. We established that TWIST1 negatively regulates extrinsic apoptosis through upregulation of its novel target gene, CFLAR. Additionally, we demonstrated that TWIST1 expression is both sufficient and required for resistance to TRAIL-based therapies, such as recombinant TRAIL and TIC10. Given that most NSCLC is resistant to TRAIL and TWIST1 is frequently overexpressed in NSCLC, targeting TWIST1 with small molecules such as novel TWIST1 inhibitor, harmine, represents a therapeutic option to overcome resistance to TRAIL-based therapies in NSCLC.
Lung cancer remains the leading cause of cancer-related deaths in the United States and worldwide (2). There have been advances in the treatment of subsets of lung cancer patients, specifically those patients with non-small cell lung cancer (NSCLC). The current treatment paradigm in NSCLC revolves around classifying patients into subgroups based on histology and oncogenic drivers. The subgroups of NSCLC patients with targetable oncogenic drivers such as those patients with EGFR mutations or ALK translocations have benefitted significantly from the use of tyrosine kinase inhibitors (TKIs) targeting these oncogenes. However, the long-term efficacy of TKIs remains limited due to the fact that almost all patients that initially response to TKIs, inevitably develop acquired resistance. Additionally, a proportion of patients with targetable oncogenic drivers demonstrate de-novo resistance. Of note, there are no FDA approved targeted therapies for the 25% of NSCLC patients with the most frequent oncogenic driver, mutant KRAS. There is a clear clinical need to develop therapeutic strategies to durably target oncogene-driven NSCLC.

Epithelial-mesenchymal transition (EMT) has been associated with de-novo and acquired resistance to both chemotherapy and targeted therapies in NSCLC (160,186,278,357,358). However, the mechanisms by which EMT may promote therapeutic resistance remain poorly understood and currently no therapeutic strategies exist to overcome resistance associated with EMT. We have previously demonstrated that the EMT-transcription factor, TWIST1, is required
for oncogene-driven NSCLC both in vitro and in vivo. In this collection of studies, we identified and characterized a first-in-class small molecule inhibitor of TWIST1 and demonstrated that TWIST1 mediates resistance to targeted agents in NSCLC.

The first portion of our work focused on identifying potential small molecule inhibitors of TWIST1. Using a chemical-bioinformatic screen, we identified multiple potential inhibitors of TWIST1. Further characterization of the top hits from our screen, revealed that the harmala alkaloid, harmine, inhibited multiple TWIST1 functions including dissemination and suppression of mammary epithelial cell branching in 3D culture. We demonstrated that harmine promoted degradation of TWIST1 in NSCLC cells. Importantly, harmine had activity in oncogene-driven NSCLC cell lines including those with EGFR mutations, MET alterations, and KRAS mutations. Additionally, harmine had marked antitumor activity in both a patient-derived xenograft and transgenic mouse model of KRAS mutant NSCLC. Previous work has demonstrated that developing inhibitors of transcription factors is challenging (267). Our work is one of the first studies identifying and characterizing a small molecule inhibitor of an EMT-transcription factor.

Future studies will focus on the identifying the mechanism(s) by which harmine promotes TWIST1 degradation. Through our ongoing studies, we have demonstrated that harmine treatment increases TWIST1 ubiquitination and proteasomal degradation (data not shown). We are currently exploring if harmine promotes degradation of TWIST1 through upregulation of F-box proteins, specifically the F-box and leucine-rich repeat protein 14 (FBXL-14) which has been previously demonstrated to polyubiquitinate TWIST1 (224). Additionally, harmine has neurotoxicity in humans (269). The 7-methoxy moiety on harmine is associated with its neurotoxicity and we demonstrated that this structural moiety is not required for harmine
cytotoxicity in NSCLC (268-270). We are currently attempting to identify analogues of TWIST1 that potently inhibit TWIST1 without the neurotoxicity associated with harmine.

Targeting TWIST1 is an exciting therapeutic option for oncogene-driven NSCLC. As previously mentioned TWIST1 is frequently overexpressed in NSCLC (233). Given that TWIST1 is required for KRAS mutant NSCLC, targeting TWIST1 may be a viable strategy to treat the 25% patients with KRAS-driven NSCLC, which currently has no approved targeted therapies (233,234). Additionally, TWIST1 is overexpressed in NSCLC with squamous histology (233). There are few efficacious therapies for patients with metastatic squamous NSCLC. Future studies aimed at characterizing the role of TWIST1 in squamous NSCLC tumorigenesis may provide insight into the potential efficacy of targeting TWIST1 in this subset of NSCLC patients. Furthermore, we have data suggesting that TWIST1 is enriched in lung brain metastases compared to matched primary lung tumors (personal communication). As brain metastases occur in 40% of lung cancer patients and often recur following radiation, targeting TWIST1 may also be effective for lung cancer patients with central nervous system involvement.

Targeting TWIST1 may also a therapeutic option in other tumor types as it frequently overexpressed in solid tumors, such as breast, colon, and prostate cancer (198,213). In solid tumors, such as breast cancer, TWIST1 is an important mediator of cancer cell invasion, metastasis, and cancer cell stemness (198,213,359,360). Targeting TWIST1 in these settings represents a novel therapeutic strategy to prevent metastasis and/or eliminate cancer stem cells. Additionally, TWIST1 is amplified in approximately 20% patients with rhabdomyosarcoma (211,212,241). TWIST1 has been implicated in rhabdomyosarcoma tumorigenesis by preventing differentiation of myogenic precursors and promoting cell survival (241). Pharmacologic
inhibition of TWIST1 may have important clinical implications in the treatment of TWIST1-driven sarcomas.

TWIST1 overexpression is also associated with chemoresistance in solid tumors (198,213). For example, in breast cancer, TWIST1 mediates chemoresistance and resistance to endocrine therapy (252,361). Being able to directly target an EMT-transcription factor such as TWIST1 has vast therapeutic implications given that EMT is associated with de-novo and acquired resistance to chemotherapies, targeted therapies, and immunotherapies (160,161,295,362,363).

In the second portion of our work we focused on investigating the role of TWIST1 in therapeutic resistance to targeted therapies in NSCLC. In Chapter 3, we demonstrated that TWIST1 was both sufficient and required for resistance to both 1st and 3rd generation EGFR TKIs in EGFR mutant NSCLC. We also demonstrated in a mouse model of EGFR mutant lung cancer that Twist1 expression led to erlotinib resistance. TWIST1 promoted resistance by suppressing EGFR TKI-induced apoptosis, specifically by repressing transcription of its novel pro-apoptotic target gene, BCL2L11 (gene encoding BIM). Consistent with our data that TWIST1 suppresses apoptosis following EGFR TKI treatment, use of a BCL-2/BCL-xL inhibitor was able to overcome TWIST1-mediated resistance in vitro. Currently, we are investigating whether TWIST1 mediates resistance to EGRK TKIs through other mechanisms such as suppressing senescence or growth arrest in response to EGFR TKIs. Future studies will be aimed at determining if targeting TWIST1 with harmine or use of BCL-2/BCL-xL inhibitors can overcome Twist1-mediated resistance in our mouse model of EGFR mutant lung cancer.

An important unanswered question is whether TWIST1 is overexpressed in NSCLC patients with de-novo or acquired resistance to EGFR TKIs. We are currently assembling the
necessary tissues to try to answer this question. We also aim to determine if TWIST1 overexpression in EGFR TKI resistant patients occurs in patients with an EMT phenotype. Given that the frequency of $T790M$ resistance mutations will likely decreased following first-line osimertinib treatment, EGFR-independent mechanisms of acquired resistance will likely increase in frequency. Initial studies have already demonstrated that previously uncommon mechanisms of resistance, such as EMT, $MET$ amplification, and histological transformation are more frequently observed in the osimertinib resistant population (83,130,132,136,143,309-312). The increase in frequency of EGFR-independent resistance mechanisms to osimertinib suggests that TWIST1 may be a more frequent mediator of resistance in the setting of osimertinib resistance. Specifically validating TWIST1 as a mechanism of de-novo and/or acquired resistance to osimertinib will provide the clinical rational for targeting TWIST1 directly or indirectly as a means to overcome or prevent osimertinib resistance.

In a parallel study to our work investigating the role of TWIST1 in resistance to EGFR inhibitors, we examined the role of TWIST1 in mediating de-novo and acquired resistance to MET TKIs as well as acquired resistance to EGFR and MET TKIs in the setting of HGF overexpression. We demonstrated that TWIST1 overexpression led to MET TKI resistance in MET-driven NSCLC cells. Targeting TWIST1 with harmine increased MET TKI sensitivity in MET altered cell lines. Given that we demonstrated that TWIST1 mediates resistance to EGFR TKIs by suppressing BIM-mediated apoptosis, we are currently determining if TWIST1 suppression of BIM is a mechanism by which TWIST1 mediates resistance to MET TKIs. Additionally, in our mouse model of Hgf-driven lung cancer, we are exploring if Twist1 overexpression in vivo is sufficient to cause MET TKI resistance. Future studies will also be aimed at validating TWIST1 as a mediator of resistance to MET TKIs in patients with $MET$
amplified and *MET* mutant NSCLC. Given that mechanisms of resistance MET TKIs in MET-driven NSCLC are poorly described, validating TWIST1 as a mechanism of resistance to MET TKIs in patients will provide the rationale for targeting TWIST1 as a means to overcome MET TKI resistance in MET-driven NSCLC.

Additionally, in our initial studies investigating the role of TWIST1 in HGF-mediated resistance to TKIs, we demonstrated that HGF induces both EMT and TWIST1 expression in NSCLC cells. TWIST1 expression appears to be required for HGF-mediated resistance to MET and EGFR TKIs in MET- and EGFR-driven NSCLC as targeting TWIST1 with harmine overcame HGF-mediated resistance. Currently, we are exploring the mechanism(s) by which HGF induces TWIST1 expression in lung cancer. Additionally, we aim to determine if TWIST1 is upregulated in EGFR TKI resistant patients with *MET* amplification or HGF overexpression (tumor and/or blood). As previously mentioned, HGF is an important mediator of *de-novo* resistance to EGFR TKIs (149,151), while *MET* amplification is a well-validated mechanisms of resistance to 1st generation EGFR TKIs and importantly osimertinib (142,311). Our studies suggest that targeting TWIST1 in these patients may be a viable therapeutic strategy to combat MET-mediated resistance to EGFR TKIs. Importantly, we demonstrated that TWIST1-mediated EGFR TKI resistance can be overcome with a BCL-2/BCL-xL inhibitor. Targeting TWIST1-mediated resistance indirectly through use of navitoclax, a BCL-2/BCL-xL inhibitor, may represent another strategy to overcome TWIST1-mediated resistance to EGFR TKIs in the setting of *MET* amplification or HGF overexpression.

In Chapter 5, we demonstrate that apoptosis following loss of TWIST1 expression requires both the intrinsic and extrinsic apoptotic pathways. Investigation into the mechanisms by which TWIST1 suppresses extrinsic apoptosis revealed that TWIST1 modulates multiple
proteins in the extrinsic apoptotic pathway, specifically cFLIP and BID. We demonstrated that 
CFLAR (gene encoding cFLIP) is a direct target gene of TWIST1, as TWIST1 binds to the 
CFLAR promoter and increases CFLAR promoter activity. Of note, we are currently investigating 
the mechanisms by which TWIST1 regulates BID expression. Additionally, we demonstrated 
that TWIST1 suppression of extrinsic apoptosis signaling has therapeutic significance, as 
TWIST1 expression can mediate resistance to both recombinant TRAIL and the TRAIL-
inducing small molecule, TIC10. Currently, we are examining if TWIST1 regulation of other 
apoptotic proteins, specifically BID, is required for TWIST1-mediated resistance to TRAIL-
based therapies. Future studies will be aimed at determining if TWIST1 overexpression leads to 
TRAIL and TIC10 resistance in vivo and if targeting TWIST1 with harmine can overcome 
TWIST1-mediated resistance TRAIL and TIC10. Additionally, given that TRAIL has been 
implicated in T-cell and NK mediated killing of tumor cells (337,364), future studies will aim to 
determine if TWIST1 can mediate resistance to immunotherapies by negatively regulating death 
receptor signaling in cancer cells. Interestingly, we have evidence that TIC10 can degrade 
TWIST1 (data not shown). Given that TIC10 inhibits both AKT and ERK (334), both of which 
regulate TWIST1 stability and activity (203,222,246), we are exploring if TIC10 inhibition of 
AKT and ERK mediates TIC10-mediated degradation of TWIST1. Additionally, given that 
TWIST1 expression is required for survival of oncogene-driven NSCLC cells (232-234), we are 
also exploring if TIC10 degradation of TWIST1 is a mechanism by which TIC10 leads to cell 
death in NSCLC cells.

In summary, we have demonstrated that the EMT-transcription factor TWIST1 mediates 
resistance to both TKIs and TRAIL-based therapies in NSCLC. Our work provides insight into 
the mechanisms by which reactivation of TWIST1 expression in cancer leads to therapeutic
resistance. This collection of studies suggests that expression of the EMT-transcription factor, TWIST1, increases the apoptotic threshold in lung cancer cells by transcriptionally suppressing pro-apoptotic genes such as $BCL2L11$ and inducing anti-apoptotic genes such as $CFLAR$. Overcoming TWIST1-suppression of apoptosis through use of BCL-2 or BCL-2/BCL-xL inhibitors may be a viable therapeutic strategy to overcome resistance associated with TWIST1 reactivation in cancers. Additionally, direct targeting of TWIST1 with small molecules, such as our novel TWIST1 inhibitor, harmine, represent an exciting therapeutic option to treat oncogene-driven NSCLC both in the primary and resistant setting.
Table 1. List of primers used for SYBR Green qRT-PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer Sequence (5’→ 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18s Forward</td>
<td>AAC GAA CGA GAC TCT GGC AT</td>
</tr>
<tr>
<td>18s Reverse</td>
<td>CAA GCT TAT GAC CCG CAC TT</td>
</tr>
<tr>
<td>TWIST1 Forward</td>
<td>GCT TGA GGG TCT GAA TCT TGC T</td>
</tr>
<tr>
<td>TWIST1 Reverse</td>
<td>GTC CGC AGT CTT ACG AGG AG</td>
</tr>
<tr>
<td>TCF3 Forward</td>
<td>GCA GCC TAG ACA CGC AGC CC</td>
</tr>
<tr>
<td>TCF3 Reverse</td>
<td>GCA GCC TAG ACA CGC AGC CC</td>
</tr>
<tr>
<td>BCL2L11 Forward</td>
<td>GGC CCC TAC CTC CCT ACA</td>
</tr>
<tr>
<td>BCL2L11 Reverse</td>
<td>GGG GTT TGT GTT GAT TTG TCA</td>
</tr>
</tbody>
</table>
Table 2. List of Primers used for Taqman qRT-PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Catalogue#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eukaryotic 18S rRNA Endogenous Control</td>
<td>4333760T</td>
</tr>
<tr>
<td>Human TWIST1</td>
<td>4331182</td>
</tr>
</tbody>
</table>

Table 3. List of antibodies used for western blotting and immunohistochemistry

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Company</th>
<th>Product number</th>
</tr>
</thead>
<tbody>
<tr>
<td>p21</td>
<td>Calbiochem</td>
<td>OP64</td>
</tr>
<tr>
<td>p27</td>
<td>Santa Cruz</td>
<td>sc-1641</td>
</tr>
<tr>
<td>cleaved PARP</td>
<td>Cell Signaling</td>
<td>5625</td>
</tr>
<tr>
<td>BIM</td>
<td>Cell Signaling</td>
<td>2933</td>
</tr>
<tr>
<td>E-Cadherin</td>
<td>Cell Signaling</td>
<td>3195</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Cell Signaling</td>
<td>5741</td>
</tr>
<tr>
<td>E2A</td>
<td>Santa Cruz</td>
<td>sc-763</td>
</tr>
<tr>
<td>TWIST1</td>
<td>Abcam</td>
<td>ab50887</td>
</tr>
<tr>
<td>TWIST1 (used for immunohistochemistry)</td>
<td>Santa Cruz</td>
<td>sc- 81417</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Santa Cruz</td>
<td>sc-25778</td>
</tr>
<tr>
<td>Actin</td>
<td>Millipore</td>
<td>MAB1501</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>Cell Signaling</td>
<td>2870P</td>
</tr>
<tr>
<td>FLIP</td>
<td>Cell Signaling</td>
<td>8510</td>
</tr>
<tr>
<td>BID</td>
<td>Cell Signaling</td>
<td>2002S</td>
</tr>
<tr>
<td>Cleaved Caspase-3</td>
<td>Cell Signaling</td>
<td>9661</td>
</tr>
<tr>
<td>Cleaved Caspase-9</td>
<td>Cell Signaling</td>
<td>7237S</td>
</tr>
<tr>
<td>Caspase-8</td>
<td>Cell Signaling</td>
<td>9496S</td>
</tr>
<tr>
<td>Claudin</td>
<td>Cell Signaling</td>
<td>4933P</td>
</tr>
<tr>
<td>B-catenin</td>
<td>Cell Signaling</td>
<td>8480</td>
</tr>
<tr>
<td>Ki-67</td>
<td>Leica Biosystems</td>
<td>ACK02</td>
</tr>
<tr>
<td>Anti-Rabbit IgG HRP linked Secondary Ab</td>
<td>GE Healthcare, UK</td>
<td>NA934V</td>
</tr>
<tr>
<td>Anti-Mouse IgG HRP linked Secondary Ab</td>
<td>GE Healthcare, UK</td>
<td>NA931V</td>
</tr>
<tr>
<td>PowerVision Poly-HRP anti-rabbit IgG</td>
<td>Leica Biosystems</td>
<td>PV6118</td>
</tr>
</tbody>
</table>
Table 4. Sequences for TWIST1/BCL2L11/TCF3 shRNA (5’-3’) in pKLO.1

<table>
<thead>
<tr>
<th>shRNA Target</th>
<th>Clone ID</th>
<th>Target sequence</th>
<th>shRNA sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>shTWIST1-1</td>
<td>TRCN0000020539</td>
<td>GCATTCTGA TAGAAGTCT GAA</td>
<td>CCGGGCATTCTGTAGA AGTCTGAACCTGAGTTCA GACTTCTATCAGAATGCT TTT</td>
</tr>
<tr>
<td>shTWIST1-2</td>
<td>TRCN0000020543</td>
<td>GCTGGAATC CAAGATGGG GAG</td>
<td>CCGGGCTGAATCCAG AGTGGCAAG CTCGAGCTTGGCATCTTTG GAGTCCAGCTTTT</td>
</tr>
<tr>
<td>shTWIST1-3</td>
<td>TRCN0000020543</td>
<td>GCTGGACTC CAAGATGGG GAG</td>
<td>CCGGGCTGAATCCAG AGTGGCAAG CTCGAGCTTGGCATCTTTG GAGTCCAGCTTTT</td>
</tr>
<tr>
<td>shBIM-1</td>
<td>TRCN0000355973</td>
<td>TACGACTGT TACGTTACA TTA</td>
<td>CCGGTAAGGTTATCTTACG ACTGTTACTCGAGTAACA GTCGTAAGATAACCATTT TTT</td>
</tr>
<tr>
<td>shBIM-2</td>
<td>TRCN0000001051</td>
<td>ATGGTTATC TTACGACTG TTA</td>
<td>CCGGATAGGGTTATCTTACG ACTGTTACTCGAGTAACA GTCGTAAGATAACCATTT TTT</td>
</tr>
<tr>
<td>shBIM-5</td>
<td>TRCN0000001054</td>
<td>AGCCGAAGA CCACACCAG AAT</td>
<td>CCGGAGCCGAAGACCAC CCACGAATCTCGAGATTC GTGGGTGGTCTTTCGGCTT TTT</td>
</tr>
<tr>
<td>shTCF3-1</td>
<td>TRCN0000274216</td>
<td>AGGGCCTGC AGAGTAGA TAG</td>
<td>CCGGACGGCCTGCAGAG TAAGATAG CTGAGCTTACTTTACTCT GCAGGCCGTTTTT</td>
</tr>
<tr>
<td>shTCF3-2</td>
<td>TRCN0000274218</td>
<td>CCCGGATCA CTCAAGCAA TAA</td>
<td>CCGGCCCCGGATCAGTCA AGCATAAATCTCGAGATTA TTTGCTTGAGTGATCCGGGT TTTT</td>
</tr>
<tr>
<td>shTCF3-4</td>
<td>TRCN0000017535</td>
<td>CAGCCTCTC TTATCCAC ATT</td>
<td>CCGGACGGCCTCTTTCATT CCGATAGACGTAGTGATCCGGGT TTTT</td>
</tr>
<tr>
<td>shScram</td>
<td>Addgene (plasmid 1864) obtained from Dr. David Sabatini (365)</td>
<td>CAGCCTCTC TTATCCAC ATT</td>
<td>CTCAGGTTAAAGTCGCC TCGTCGAGCGAGGCTT ACTAAACCTTAGG</td>
</tr>
</tbody>
</table>
Table 5. ORFs obtained from Johns Hopkins University HiT Center

<table>
<thead>
<tr>
<th>ORF</th>
<th>CLONE ID</th>
<th>Catalogue#</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCL2</td>
<td>IOH10622</td>
<td>pENTR</td>
</tr>
<tr>
<td>TWIST1</td>
<td>IOH22915</td>
<td>pENTR</td>
</tr>
</tbody>
</table>

Table 6. Source of plasmids utilized

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>pLenti6/V5-DEST Gateway Vector (Invitrogen)</td>
<td>NA</td>
</tr>
<tr>
<td>pLVX-Tet3G (Clontech)</td>
<td>NA</td>
</tr>
<tr>
<td>pLVX-TRE3G-IRES (Clontech)</td>
<td>NA</td>
</tr>
<tr>
<td>pLenti CMV Puro DEST (w118-1) (Addgene (plasmid 17452))</td>
<td>(366)</td>
</tr>
<tr>
<td>pLenti CMV/TO NEO (Addgene (plasmid 17482))</td>
<td>(366)</td>
</tr>
<tr>
<td>pGL4-YBX1-Luc</td>
<td>(265)</td>
</tr>
<tr>
<td>pGL4-SNAI2-Luc</td>
<td>(265)</td>
</tr>
<tr>
<td>pGL3-FLIP1500 (Addgene plasmid 16016)</td>
<td>341</td>
</tr>
<tr>
<td>pGL3-FLIP pr5 (Addgene plasmid 19130)</td>
<td>341</td>
</tr>
<tr>
<td>pGL3-FLIP pr4 (Addgene plasmid 19129)</td>
<td>341</td>
</tr>
<tr>
<td>pRL-RT</td>
<td>NA</td>
</tr>
<tr>
<td>pLenti CMV Pur W118 Twist1</td>
<td>(234)</td>
</tr>
<tr>
<td>pLenti CMV Pur W118 Twist1-Twist1-Addgene</td>
<td>234</td>
</tr>
<tr>
<td>pLenti CMV Pur W118 Twist1-E12</td>
<td>(265)</td>
</tr>
<tr>
<td>pLenti CMV Pur W118 Twist1-E47</td>
<td>(232)</td>
</tr>
</tbody>
</table>
Table 7: ChIP Primers for BCL2L11 Promoter

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer Sequence (5’→ 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BS1 Forward</td>
<td>AAA CTG TGG TGC CGA GTG AAA G</td>
</tr>
<tr>
<td>BS1 Reverse</td>
<td>GTC CGT GCG TTT CCT TGC AGA G</td>
</tr>
<tr>
<td>BS2 Forward</td>
<td>TGT CCC ACT GAC GTT ACA GAA G</td>
</tr>
<tr>
<td>BS2 Reverse</td>
<td>GAA ACT CTG TAA AGG GAC CAC CCT A</td>
</tr>
<tr>
<td>BS3 Forward</td>
<td>GGG TCC TAG CCA AAT GCA GTG</td>
</tr>
<tr>
<td>BS3 Reverse</td>
<td>CTA AGA GAC AGA GGC CGT GG</td>
</tr>
<tr>
<td>BS4 Forward</td>
<td>AGC TGA GGA CCT GCT CGT AG</td>
</tr>
<tr>
<td>BS4 Reverse</td>
<td>GAA ACA CCC TCA CAC TGC GC</td>
</tr>
<tr>
<td>BS5 Forward</td>
<td>TCA CAG TCA GGT TGT CCA G</td>
</tr>
<tr>
<td>BS5 Reverse</td>
<td>CAT GCC CAG GTC ACA GTT AGC C</td>
</tr>
</tbody>
</table>
Table 8: ChIP Primers for *CFLAR* Promoter

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer Sequence (5’→ 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1 Forward</td>
<td>GCT GAA CAA AGG GAG AGG TTT GG</td>
</tr>
<tr>
<td>#1 Reverse</td>
<td>GAC TAA CAG CAG GAC GGC ATG AA</td>
</tr>
<tr>
<td>#2 Forward</td>
<td>TTC TTC ACC TTT CCT GTG AG</td>
</tr>
<tr>
<td>#2 Reverse</td>
<td>CCA CCA TGC CCG ACT AAT TT</td>
</tr>
<tr>
<td>#3 Forward</td>
<td>AGA CCA GCC TTG CCA ACA TG</td>
</tr>
<tr>
<td>#3 Reverse</td>
<td>CAA ACC ATC CAG CCC TCA GC</td>
</tr>
<tr>
<td>#4 Forward</td>
<td>TGT GTT CAC GTT TGC TAT GAC TCC</td>
</tr>
<tr>
<td>#4 Reverse</td>
<td>CAA AGT GCT GGG ATT ACA GGC G</td>
</tr>
<tr>
<td>#5 Forward</td>
<td>AAA GGG ACT CCC GGA GCT AG</td>
</tr>
<tr>
<td>#5 Reverse</td>
<td>GCT TCT CTC CTA CAC CTC CTC C</td>
</tr>
</tbody>
</table>


304. Zhuo WL, Wang Y, Zhuo XL, Zhang YS, Chen ZT. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to


